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Quotation 
“When one idea is drawn from another, we say that there has been an association. Some 
are even of the opinion that the whole human mental process derives from this 
succession of stimuli, sometimes unconscious, sometimes only pretending to be 
unconscious, which achieves original combinations, new relationships of thoughts 
interlinked by the species and together forming what might be called a commerce, an 
industry of ideas, because man, apart from all the other things he is, has been, or will be, 
performs an industrial and commercial function, first as producer, then as retailer, and 
finally as consumer, but even this order can be shuffled and rearranged. I am speaking 
only of ideas and nothing else. So, then, we can consider ideas as corporate entities, 
independent or in partnership, perhaps publicly held, but never with limited liability, 
never anonymous, for a name is something we all possess.” 
José Saramago, Year of the Death of Ricardo Reis, 1984 
___ 
 “Quando uma ideia puxou outra, dizemos que houve associação delas, não falta mesmo 
quem seja de opinião que todo o processo mental humano decorre dessa sucessiva 
estimulação, muitas vezes inconsciente, outras nem tanto, outras compulsiva, outras 
agindo em fingimento de que o é para poder ser adjunção diferente, inversa quando 
calha, enfim, relações que são muitas, mas entre si ligadas pela espécie que juntas 
constituem e parte do que latamente se denominará comércio e indústria dos 
pensamentos, por isso o homem, entre o mais que seja, tenha sido ou venha a ser, é lugar 
industrial e comercial, produtor primeiro, retalhista depois, consumidor finalmente, e 
também baralhada e reordenada esta ordem, de ideias falo, de aí não, então lhe 
chamaríamos, com propriedade, ideias associadas, com ou sem companhia, ou em 
comandita, acaso sociedade cooperativa, nunca de responsabilidade limitada, jamais 
anónima, porque, nome, todos o temos.” 
José Saramago, O Ano da morte de Ricardo Reis, 1984 
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Abstract 
Cervical cancer is the second most common cancer in women worldwide. For decades, 
most developed countries have applied organized cytology screening programs using 
the Papanicolau (PAP) test to identify abnormal cases. Despite a high specificity of 95-
98%, Pap test sensitivity is reported to vary greatly from 74 to 96% with constant 
testing needed to achieve the highest values. Semi-automated cytology screening 
platforms, immunocytochemistry panels and other methodologies such as human 
papilloma virus (HPV) testing has been developed to help reduce false negative rates. 
More recently, HPV testing, thus far used for triage of abnormal cytology cases and test 
of cure, have been recommended for primary screening. However HPV testing only 
informs on the presence of the virus not adding on the abnormal transformation of the 
cells. Its suitability for screening of younger women (<30 years) whom present the 
highest rates of transient viral infection is also questionable.  The potential of Raman 
spectroscopy has also been acknowledged with its ability of detecting spectral changes 
in malignant and pre-malignant cells extensively reported. In this project the potential of 
Raman spectroscopy for cytological diagnosis of samples from a cervical cancer 
screening population was assessed. Routinely used ThinPrep® glass slides were used as 
spectroscopy substrates in order to minimize costs and simplify sample processing. 
Raman spectra were recorded from single cell nuclei and subjected to multivariate 
statistical analysis. Different approaches were tested to minimize the glass contribution 
to the sample spectra and a non-negative least squares method was found to provide the 
best results. Normal and abnormal ThinPrep® samples were discriminated based on 
their biochemical fingerprint using Principal Component Analysis (PCA). Principal 
Component Analysis – Linear Discriminant Analysis (PCA-LDA) was further 
employed to build classification models using both Cervical Intraepithelial Neoplasia 
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(CIN) and Squamous Intraepithelial Lesion (SIL) terminology. Results showed that 
Raman spectroscopy can be successfully applied to the study of routine cervical 
cytology samples from a cervical screening programme and normal and abnormal 
samples could be discriminated with high sensitivity and specificity rates (>95%) when 
tested with leave one patient out cross validation. In addition, the results suggested that 
HPV infection and previous disease history might be inferred from negative samples 
and might influence the performance of classifiers. In summary this study has shown 
Raman spectroscopy has potential as a screening tool for Thinprep® cervical cytology 
samples.   
ix 
 
Table of Contents 
CHAPTER 1 Introduction: The cervix, cancer and diagnosis challenges ............... 1 
1.1 The Cervix .......................................................................................................... 2 1.1.1 Embryology ................................................................................................ 2 1.1.2 Anatomy & Histology ................................................................................ 2 1.1.3 Function ...................................................................................................... 4 
1.2 Cancer ................................................................................................................. 6 1.2.1 What is cancer? .......................................................................................... 6 1.2.2 Carcinogenesis ........................................................................................... 7 
1.3 Cervical cancer ................................................................................................... 8 1.3.1 Statistics: Worldwide, Europe and Ireland ............................................. 8 1.3.2 Histological Types ..................................................................................... 9 1.3.3 Aetiology – Human Papillomavirus (HPV) ............................................ 12 1.3.4 Grading ..................................................................................................... 15 1.3.5 Symptoms ................................................................................................. 17 1.3.6 Risk factors ............................................................................................... 17 
1.4 Current diagnostic methods and technologies for cervical cancer ................... 21 1.4.1 Papanicolau (Pap) test ............................................................................ 21 1.4.2 HPV Testing .............................................................................................. 27 1.4.3 Colposcopy ............................................................................................... 30 1.4.4 Histopathology ......................................................................................... 34 
x 
 
1.5 Guidelines for cervical cancer screening programmes ..................................... 41 1.5.1 Republic of Ireland .................................................................................. 41 1.5.2 UK - England and Northern Ireland ....................................................... 43 1.5.3 USA ............................................................................................................ 43 
1.6 Biomarkers ....................................................................................................... 44 1.6.1 Biomarkers in cervical cancer ................................................................ 45 
1.7 Optical Spectroscopy ........................................................................................ 54 1.7.1 Raman Spectroscopy ............................................................................... 55 
1.8 Overall aims of the present study ..................................................................... 60 
CHAPTER 2 Current Advances in the Application of Raman Spectroscopy for 
Molecular Diagnosis of Cervical Cancer..................................................................... 62 
2.1 Raman spectroscopy for biomedical applications ............................................ 64 2.2 Raman spectroscopy in cervical cancer research ........................................ 65 2.2.1 In vivo - spectra recorded from the patient .......................................... 71 2.2.2 Ex vivo – spectra recorded from excised patient tissue ....................... 74 2.2.3 FFPP sections – spectra recorded from histological sections .............. 76 2.2.4 In vitro – spectra recorded from cell lines ............................................. 77 2.2.5 Cytology – spectra recorded from exfoliated patient cells .................. 79 2.2.6 Cervical Fluids .......................................................................................... 80 2.2.7 Treatment response ................................................................................ 81 2.2.8 Improving data analysis & recording..................................................... 82 
xi 
 
CHAPTER 3 Materials and Methods ....................................................................... 85 
3.1 Samples ............................................................................................................ 86 3.1.1 Sample reception and database construction ....................................... 86 3.1.2 Hydrogen peroxide (H2O2) Treatment .................................................. 87 
3.2 Raman spectroscopy ......................................................................................... 88 3.2.1 Calibration Procedures ........................................................................... 88 3.2.2 Measurements’ Settings .......................................................................... 89 
3.3 Statistical Techniques ....................................................................................... 90 3.3.1 Pre-processing Procedures ..................................................................... 90 3.3.2 Glass correction methods ....................................................................... 90 3.3.3 Principal Component Analysis (PCA) .................................................... 91 3.3.4 Principal component analysis – linear discriminant analysis (PCA-LDA) 93 3.3.5 Leave one patient out cross validation (LOPOCV) ................................ 93 
3.4 Immunocytochemistry (ICC) ........................................................................... 94 3.4.1 CINTec® PLUS kit dual staining ............................................................. 94 
3.5 Pap stain ........................................................................................................... 96 
3.6 Light Microscopy ............................................................................................. 97 
CHAPTER 4 Evaluation of substrate correction methods for Raman spectra 
recorded from Thinprep® cervical cytology samples ................................................ 98 
4.1 Uncorrected spectra for glass substrate .......................................................... 101 
4.2 [1200-1800 cm-1] Spectral Range ................................................................... 108 
xii 
 
4.3 Glass subtraction (iterative glass correction) ................................................. 117 
4.4 Non-negative least squares (NNLS) ............................................................... 127 
4.5 Discussion ...................................................................................................... 137 
CHAPTER 5 The influence of clinical features on the Raman spectroscopic 
profiles………. ............................................................................................................. 143 
5.1 Age ................................................................................................................. 144 
5.2 Menstrual cycle .............................................................................................. 150 5.2.1 Negative Samples ................................................................................... 152 5.2.2 CIN 1, 2 and 3 Samples .......................................................................... 153 
5.3 HPV status ...................................................................................................... 160 
5.3.1 CIN 1 samples according to HPV test .................................................... 161 5.3.2 CIN 2 and CIN 3 samples according to HPV test ................................. 165 
5.3.3 All CIN samples according to HPV test result........................................ 169 
5.4 Previous disease history ................................................................................. 173 5.4.1 Negative and CIN 1 samples ................................................................. 173 5.4.2 CIN 2 and CIN 3 Samples ....................................................................... 180 
5.5 Discussion ...................................................................................................... 186 
5.5.1 Age .......................................................................................................... 186 
5.5.2 Menstrual Cycle ...................................................................................... 188 
5.5.3 HPV status ............................................................................................... 190 
5.5.4 Previous disease history .......................................................................... 193 
CHAPTER 6 Evaluation of SIL Vs CIN Classification models ............................ 197 
xiii 
 
6.1 The performance of SIL classification ........................................................... 199 
6.2 Influence of Clinical features on the SIL classification ................................. 204 
6.2.1 Menstrual Cycle phase ............................................................................ 204 
6.2.2 HPV status ............................................................................................... 206 
6.2.3 Previous disease history .......................................................................... 208 
6.3 Discussion ...................................................................................................... 211 
CHAPTER 7 Evaluation of both CIN and SIL classification models on an 
independent test set ..................................................................................................... 214 7.1 Mean Spectral Analysis of the Test Samples ............................................... 215 7.2 Testing the PCA-LDA disease classification models................................... 222 7.3 Discussion ...................................................................................................... 230 
CHAPTER 8 Investigation of p16 and Ki-67 staining profiles in Thinprep® 
cervical cytology samples following Raman spectroscopic analysis ....................... 234 
8.1 ICC Optimization ........................................................................................... 235 
8.2 CINtec PLUSTM ICC staining of the samples included in this study ............. 238 
8.3 Pap staining of the samples included in this study ......................................... 243 
8.4 Discussion ...................................................................................................... 244 
CHAPTER 9 Conclusions and future work ........................................................... 248 
9.1 Conclusion ...................................................................................................... 249 
9.2 Future directions ............................................................................................. 257 
References…… ............................................................................................................ 261 
Appendices….. ............................................................................................................. 294 
xiv 
 
List of Publications ...................................................................................................... 326 
 
  
xv 
 
List of Figures 
Figure 1.1 Schematic representation of the female genital tract and of the ecto and 
endocervical epithelia adapted from (A.D.A.M. 2016) and (Mescher 2013). ________ 3 
Figure 1.2 Schematic representation of the stratified squamous epithelium of the 
ectocervix with representation of the different cell types present; adapted from (Frazer 
2004). _______________________________________________________________ 4 
Figure 1.3 Schematic of the carcinogenesis process: Initiation, Promotion and 
Progression (Almeida et al. 2010). _________________________________________ 7 
Figure 1.4 Schematic presentation of the HPV genome, showing the arrangement of the 
early E or non-structural genes, the capsid genes (L1 and L2) and the URR (Cooper et 
al. 2013). ____________________________________________________________ 13 
Figure 1.5 Representation of the integration of HPV DNA into the host cell DNA 
(Woodman et al. 2007). _________________________________________________ 15 
Figure 1.6 Representation of the progression from normal cervical epithelium to 
invasive carcinoma adapted from (Lowy et al. 2006). SIL (red) and CIN (blue) reporting 
systems are indicated as well as the grade of dysplasia associated with each 
classification. _________________________________________________________ 16 
Figure 1.7 Representation of the cervical smear collection, with indication of the 
transformation zone location (The Johns Hopkins University 2012). _____________ 21 
Figure 1.8 Schematic representation of the conventional method adapted from (Rovers 
Medical Devices B.V. 2006). ____________________________________________ 22 
Figure 1.9 Schematic representation of the ThinPrep® method (West Coast Pathology 
Laboratories 2011). ____________________________________________________ 23 
Figure 1.10 Schematic representation of the SurePath® method (Becton Dickson 2016).
 ____________________________________________________________________ 23 
xvi 
 
Figure 1.11 Bright-field image of a Pap stained negative ThinPrep® cervical smear 
showing superficial cells with orange stained cytoplasm and intermediate cells with blue 
stained cytoplasm. _____________________________________________________ 25 
Figure 1.12 Automated slide screening systems. A - The FocalPoint™ GS Imaging 
system, (a) - FocalPoint™ Slide Profiler, (b) - Guided Screener Workstation, (c) – a 
screenshot of the screening window (IARC 2012a). B – The ThinPrep™ Imaging 
system, (a) - Image Processor, (b) - Review Scope, (c) – an example of the field of view 
with the guiding marker showing stained cervical cells (Franco et al. 2003). _______ 27 
Figure 1.13 Colposcopic examination scheme (National Screening Unit 2016). ____ 30 
Figure 1.14 The DSI. A - The DySIS™ instrumentation, B – example of application of 
the DySIS™ to map the acetowhitening level (DySISmedical Ltd. 2001). _________ 32 
Figure 1.15 The LUMA™ Cervical Imaging System. A - LUMA™ console (Scranton 
Gillette Communications. 2014), B – Image of the cervix utilising LUMA™ Cervical 
Imaging System to identifying high grade dysplasia (in blue), adapted from (Poliakoff 
2012). ______________________________________________________________ 33 
Figure 1.16 Biopsy of the cervix a) punch biopsy, b) cone biopsy adapted from (Penn 
Medicine 2008). ______________________________________________________ 35 
Figure 1.17 CervicalCheck Screening Process adapted from (The National Cancer 
Screening Service 2009). The actions taken by different partners are indicated by 
different colours with the programme office in black, smear-taker in green, cytology 
laboratory in red, colposcopy clinic in blue and histology laboratory in purple.  ASC-
US: atypical squamous cells of undetermined significance; ASC-H: atypical squamous 
cells of undetermined significance, cannot exclude high grade; AGUS: atypical 
glandular cells of undetermined significance; AGC: atypical glandular cells AGH: 
atypical glandular cells, favour neoplastic process. ___________________________ 42 
xvii 
 
Figure 1.18 Energy level diagram for Rayleigh, Stokes and anti-Stokes scattering 
(Ostrowska 2011). _____________________________________________________ 55 
Figure 1.19 Schematic showing the process involved in Raman spectra collection. 
When the sample is illuminated by an incident monochromatic light, the majority of the 
scattered light is of the same wavelength - elastically scattered (green arrow). A notch 
filter is therefore used to block the elastically scattered light which would otherwise 
overwhelm the weak signal of the Raman or inelastically scattered light (orange arrow). 
The Raman scattered light may be dispersed according to wavelength through a grating 
and detected by a CCD (charge-coupled device) detector. A Raman spectrum is finally 
shown upon software analysis. ___________________________________________ 58 
Figure 1.20 Raman spectrum of cervical cancer CaSki cell line. The variation of Raman 
shift wavelength is expressed in wavenumbers (cm-1) and can be observed along the X-
axis whilst the intensity is represented along the Y-axis. The fingerprint and the high 
wavenumber (HW) regions of the spectrum are indicated by the arrows. __________ 59 
Figure 3.1 Xplora (Horiba Jobin Yvon) confocal microscope. __________________ 88 
Figure 3.2 Negative ThinPrep® cervical cytology sample as presented upon Raman 
microscopy. __________________________________________________________ 89 
Figure 3.3 CINTec® PLUS detection mechanism. The individual antigens are first 
detected by the primary antibodies which are then bound by the secondary antibodies. 
Secondary antibodies are HRP and AP polymer conjugated which allows them to be 
revealed by reaction with hydrogen peroxidase & DAB and naphthol phosphate & fast 
red, respectively. The HRP reaction results in a brown precipitate which allows the 
detection of p16 in the cell cytoplasm whilst the AP reaction results in a red precipitate 
which allows the detection of Ki67 in the nucleus. ___________________________ 95 
xviii 
 
Figure 3.4 Pap stained negative Thinprep slide showing parabasal (black arrowheads), 
intermediate (solid _____________________________________________________ 96 
Figure 4.1 Mean Raman spectra of the ThinPrep® glass substrate recorded from all 
sampling groups. ; negative (green,) CIN  1  (magenta,) CIN 2 (red) and CIN 3 (black.)
 ___________________________________________________________________ 100 
Figure 4.2 Mean Raman spectrum and SD (shadowing) obtained for each sampling 
group. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 
samples in red and CIN3 samples in black. Arrows indicate the areas where the glass 
substrate contribution is visible. Highest contribution of glass spectral features can be 
seen in the average spectra of CIN 1 samples. ______________________________ 100 
Figure 4.3 (A) PCA scatter plot for all sampling groups; Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 
samples in black. (B) PC loadings for PC1, 2 and 3 which explain respectively 76.1%, 
9.49% and 3.97% of the variance within the dataset. _________________________ 103 
Figure 4.4 PCA scatter plot for pairwise comparison of all sampling groups (right) and 
relevant PC loadings (left); Negative samples are represented in green, CIN 1 samples 
in magenta, CIN2 samples in red and CIN3 samples in black. __________________ 106 
Figure 4.5 Mean Raman spectrum and SD (shadowing) obtained for each sampling 
group on the 1200 to 1800cm-1 spectral range. Negative samples are represented in 
green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. The 
ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main 
difference between the mean spectra. _____________________________________ 108 
Figure 4.6 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 
(red) and CINI 3 (black) cervical cytology samples. SD is also indicated for each 
sampling group. Mann Whitney test showed CIN 1, 2 and 3 ratios to be significantly 
xix 
 
different from that of negative samples with **p=0.0031 and ****p<<0.0001. Ratio 
differences between CIN samples were also significant with ****p<0.0001, 
***p=0.0008 and *p= 0.0420. __________________________________________ 109 
Figure 4.7 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 
samples in black. (B) PC loadings for PC1 and 2 which explain respectively 65.7% and 
17.16% of the variance within the dataset. _________________________________ 110 
Figure 4.8 PCA scatter plot for pairwise combination of all sampling groups (right) and 
relevant PC loadings (left) in the 12001800 cm-1 spectral range. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 
samples in black. _____________________________________________________ 116 
Figure 4.9 Mean spectra for each sampling group before (continuous line) and after 
iterative correction (IT) (dotted line).  SD is represented by shadowing. Negative 
samples are indicated in green, CIN 1 samples in magenta, CIN 2 in red and CIN 3 in 
black. ______________________________________________________________ 118 
Figure 4.10 Mean Raman spectrum and SD (shadowing) obtained for each sampling 
group after FC correction. Negative samples are represented in green, CIN 1 samples in 
magenta, CIN2 samples in red and CIN3 samples in black. The ratio of 1318:1339cm-1 
indicated by the circles on the spectra seems to be the main difference between the 
mean spectra. Other visible differences between the spectra are indicated by the black 
arrows and the blue arrow heads. ________________________________________ 119 
Figure 4.11 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 
(red) and CINI 3 (black) cervical cytology samples. SD is also indicated for each 
sampling group. Mann Whitney test showed CIN 1, 2 and 3 ratios to be significantly 
different from that of negative samples with ****p<<0.0001, p=0.0069 and p=0.0020 
xx 
 
respectively. Ratio differences between CIN  samples were not statistically significant.
 ___________________________________________________________________ 120 
Figure 4.12 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 
samples in black. (B) PC loadings for PC1 and 3 which explain respectively 92.01% 
and 0.30% of the variance within the dataset. _______________________________ 121 
Figure 4.13 PCA scatter plot for pairwise combination of all sampling groups (right) 
and relevant PC loadings (left) after iterative glass correction. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 
samples in black. _____________________________________________________ 125 
Figure 4.14 Mean Raman spectrum and SD(shadowing) obtained for each sampling 
group after NNLS correction. Negative samples are represented in green, CIN 1 samples 
in magenta, CIN2 samples in red and CIN3 samples in black. The ratio of 
1318:1339cm-1 indicated by the circles on the spectra seems to be the main difference 
between the mean spectra. Another visible difference between the spectra is the peak 
~1093cm-1 indicated by the black arrows. _________________________________ 127 
Figure 4.15 Mean spectra for each sampling group before (continuous line) and after 
correction (dotted line). SD is represented by shadowing. Negative samples are 
indicated in green, CIN 1 samples in magenta, CIN 2 in red and CIN 3 in black. ___ 129 
Figure 4.16 1339:1318 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 
(red) and CIN 3 (black) cervical cytology samples. SD is indicated for each sampling 
group. Mann Whitney test showed CIN 1, 2 and 3 ratios to be significantly different 
from that of negative samples with **p=0.0042 and ****p<<0.0001. Ratio differences 
between CIN 1 and 2 samples were not statistically significant whilst CIN 3 ratios 
displayed a ****p<0.0001 and p=0.0011 against CIN 1 and 2 respectively. _______ 130 
xxi 
 
Figure 4.17 Mean Raman intensity at the 1093 cm-1 peak for negative (green), CIN 1 
(magenta), CIN 2 (red) and CINI 3 (black) cervical cytology samples. SD is indicated 
for each sampling group. Mann Whitney test showed all intensity differences to be 
statistically significant with ****p< 0.0001 and **P=0.0094. __________________ 131 
Figure 4.18 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. 
Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in 
red and CIN3 samples in black. (B) PC loadings for PC1 and 2 which explain 
respectively 99.54% and 0.15% of the variance within the dataset. ______________ 132 
Figure 4.19 PCA scatter plot for pairwise combination of all  CIN sample groups (right) 
and relevant PC loadings (left) after NNLS glass correction. CIN 1 samples in magenta, 
CIN2 samples in red and CIN3 samples in black. ___________________________ 135 
Figure 5.1 Sample database according to patient’s age by decades; [20-29] years are 
represented in green, [30-39] in blue, [40-49] in red and [50-60+] in black. _______ 145 
Figure 5.2 Mean spectra for each sampling group according to patient’s age interval. 
Standard deviation is represented by shadowing. Samples where patient is between [20-
29] years old are indicated in green, [30-39 ]in magenta, [40-49] in red and [50-60+] in 
black. ______________________________________________________________ 146 
Figure 5.3 3-D PCA scatterplot of all samples according to age and disease 
classification. Negative samples are represented in green, CIN 1 samples in magenta, 
CIN 2 samples in red and CIN 3 samples in black. Each sample is also represented 
according to the patient age interval with [20-29] represented by a circle, [30-39] 
represented by a square, [40-49] represented by an inverted triangle and [50-60+] 
represented by an upright triangle. _______________________________________ 147 
Figure 5.4 Sample database according to menstrual cycle phases. Only samples with 
known menstrual date could be included. __________________________________ 151 
xxii 
 
Figure 5.5 3-D PCA scatterplot of negative samples according to their menstrual cycle 
phase. Samples in the proliferative phase, from day 5 to 13, are represented by a light 
green circle whereas samples in the secretory phase, from day 14 to 28, are represented 
by a dark green square. PC1, PC2 and PC3 represent 45.56%, 21.09% and 13.66% of 
the explained variance within the dataset.__________________________________ 152 
Figure 5.6 (A) 2-D PCA scatterplot of CIN 1, 2 and 3 samples according to their 
menstrual cycle phase. Samples in the proliferative phase, from day 5 to 13, are 
represented by a circle whereas samples in the secretory phase, from day 14 to 28, are 
represented by a square. CIN 1 samples are represented in magenta, CIN 2 in red and 
CIN 3 in black. PC2 and PC4 represent 0.23% and 0.07% of the explained variance 
within the dataset. (B) PC2 loading. ______________________________________ 154 
Figure 5.7 (A) 2-D PCA scatterplot of CIN 1 samples according to HPV. HPV negative 
samples are represented in green, HPV positive for 12 other high-risk types in magenta, 
HPV 18 in blue, HPV 16 and 18 in orange and HPV 16 in red. PC1 and PC2 account for 
99.53% and 0.21% of the variability within the dataset respectively. (B) PC2 loading.
 ___________________________________________________________________ 162 
Figure 5.8 (A) 3-D PCA scatterplot of Negative and CIN 1 HPV negative and positive 
samples. Negative samples are represented in  green,  CIN 1 HPV negative samples in 
magenta and CIN 1 HPV positive samples in red. PC1, PC2 and PC3 account for 
99.56%, 0.18% and 0.08% of the variability within the dataset respectively. (B) PC2 
and PC3 loadings. ____________________________________________________ 164 
Figure 5.9 3-D PCA scatterplot of CIN 2 samples according to HPV. HPV negative 
samples are represented in green, HPV positive for 12 other high-risk types in magenta, 
HPV 16 in red, HPV 16 and 12 other high-risk types in orange and HPV 16, 18 and 12 
xxiii 
 
other high-risk types in blue. PC1, PC2 and PC3 account respectively for 99.77, 0.11 
and 0.03% of the variability within the dataset. _____________________________ 166 
Figure 5.10 3-D PCA scatterplot of CIN 3 samples according to HPV. HPV negative 
samples are represented in green, HPV positive for 12 other high-risk types in magenta, 
HPV 16 in red, HPV 16 and 12 other high-risk types in orange and HPV 18 in blue. 
PC1, PC2 and PC3 account respectively for 99.66%, 0.17% and 0.06% of the variability 
within the dataset. ____________________________________________________ 167 
Figure 5.11 3-D PCA scatterplot of CIN 2 and 3 samples according to HPV. CIN 2 
samples are represented in red and CIN 3 are represented in black. HPV negative 
samples are represented by a circle, HPV positive for 12 other high-risk types by a 
square, for HPV16 by an upright triangle, for HPV 16 and 12 other high-risk types, for 
HPV 18 by an asterisk mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 
other high-risk types by a cross. PC1, PC2 and PC3 account respectively for 99.67%, 
0.15% and 0.06% of the variability within the dataset. _______________________ 167 
Figure 5.12 2-D PCA scatterplot of all sampling groups according to HPV test result. 
Negative samples are represented in green, CIN 1 samples in magenta, CIN 2 samples 
in red and CIN 3 samples in black. Furthermore, HPV negative samples are represented 
by a circle, HPV positive for 12 other high-risk types by a square, for HPV16 by an 
upright triangle, for HPV 16 and 12 other high-risk types, for HPV 18 by an asterisk 
mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 other high-risk types by a 
cross. PC2 and PC3 account respectively for 0.27% and 0.08% of the variability within 
the dataset. __________________________________________________________ 169 
Figure 5.13 (A) 3-D PCA scatterplot of CIN samples only according to the HPV test 
result. HPV negative samples are represented in green, HPV positive for 12 other high-
risk types in magenta, HPV 16 in red, HPV 16 and 12 other high-risk types in orange, 
xxiv 
 
HPV 18 in dark blue, HPV 16 and 18 by light blue and, HPV 16, 18 and 12 other high-
risk types in black. PC1, PC2 and PC3 account respectively for 99.47%, 0.27% and 
0.08% of the variability within the dataset. (B) PC2 loading which accounts for 0.27% 
of the variability within the dataset. ______________________________________ 170 
Figure 5.14 3-D PCA scatterplot of negative samples according to previous disease 
history. PC1 , PC2 and PC3 account respectively for 99.66%, 0.17% and 0.06% of the 
variability within the dataset. ___________________________________________ 174 
Figure 5.15 3-D PCA scatterplot of CIN 1 samples according to previous disease 
history. PC1 , PC2 and PC3 account respectively for 99.53%, 0.21% and 0.07% of the 
variability within the dataset. ___________________________________________ 178 
Figure 5.16 3-D PCA scatterplot of CIN 2 samples according to previous disease 
history. PC1 , PC2 and PC3 account respectively for 99.66%, 0.21% and 0.05% of the 
variability within the dataset. ___________________________________________ 181 
Figure 5.17 3-D PCA scatterplot of CIN 2 samples according to previous disease 
history. PC1 , PC2 and PC3 account respectively for 99.23%, 0.49% and 0.12% of the 
variability within the dataset. ___________________________________________ 183 
Figure 6.1 Mean Raman spectrum and SD (shadowing) obtained for each sampling 
group after NNLS correction. Negative samples are represented in green, SIL samples 
in magenta, and HSIL samples in black. The ratio of 1318:1339cm-1 indicated by the 
circles on the spectra seems to be the main difference between the mean spectra. Other 
visible differences are indicated by the arrow heads. _________________________ 199 
Figure 6.2 1339:1318 cm-1 peak ratios for negative (green), SIL (magenta) and HSIL 
(black) cervical cytology samples. SD is indicated for each sampling group. Mann 
Whitney test showed LSIL and HSIL ratios to be statistically significant from negative 
with **p=0.0042 and ****p<0.0001; and between them with ***p=0.0006. ______ 200 
xxv 
 
Figure 6.3 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. 
Negative samples are represented in green, LSIL samples in magenta and HSIL samples 
in black. (B) PC loadings for PC1 and 2 which explain respectively 76.81% and 7.55% 
of the variance within the dataset. ________________________________________ 201 
Figure 7.1 Mean Raman spectra of all samples composing the test set database plotted 
according to their cytology diagnosis. Negative samples are indicated in green, CIN 1 
samples in magenta, CIN 2 in red and CIN 3 in black. ________________________ 215 
Figure 7.2 Mean spectra of negative samples test set (dark green) against each 
classification group where negative model set samples are indicated in green, CIN 1 
samples in magenta, CIN 2 in red and CIN 3 in black ________________________ 216 
Figure 7.3 Mean spectra of CIN 1 samples test set (purple) against each classification 
group of the model set where negative samples are indicated in green, CIN 1 samples in 
magenta, CIN 2 in red and CIN 3 in black. _________________________________ 217 
Figure 7.4 Mean spectra of CIN 2 samples testing set (orange) against each 
classification group of the modeling set where negative samples are indicated in green, 
CIN 1 samples in magenta, CIN 2 in red and CIN 3 in black ___________________ 218 
Figure 7.5 Mean spectra of CIN 3 samples test set (grey) against each classification 
group of the model set where negative samples are indicated in green, CIN 1 samples in 
magenta, CIN 2 in red and CIN 3 in black _________________________________ 219 
Figure 7.6 Difference spectra plots between negative samples from model and test sets 
(green) and between negative and CIN 1 samples of model set (magenta). ________ 220 
Figure 7.7 Difference spectra plots between CIN 1 samples from model set and 
negative samples from test set. __________________________________________ 221 
xxvi 
 
Figure 7.8 A) 3-D PCA scatter plot of test set samples with negative samples indicated 
in green, CIN 1 samples in magenta, CIN 2 in red and CIN 3 in black. B) PC loadings.
 ___________________________________________________________________ 222 
Figure 7.9 Test sample database according to patient’s age by decades; [20-29] years 
are represented in green, [30-39] in blue, [40-49] in red and [50-60+] in black. ____ 224 
Figure 7.10 Test sample database according to menstrual cycle phases. Only samples 
with known menstrual date where considered. ______________________________ 228 
Figure 8.1 CINtec® PLUS immunostain of CIN III ThinPrep® samples after 
H2O2 treatment and Raman spectroscopy.  In A-I) Red Ki-67 nuclear staining (arrows) 
and brown p16IKNK4a cytoplasmic staining (arrowheads) can be observed at x200 
magnification under light microscopy, whereas no stain can be observed in the negative 
control slide A-II). B) is a positive control image of positive CINtec® PLUS 
immunostain from (Ventana® 2013). _____________________________________ 237 
Figure 8.2 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. 
Although brown stain, attributed to p16, can be observed (arrow heads) the 
morphological and nuclear detail is lost and the specificity of the stain to cytoplasm 
cannot be assessed. (A), (B) and (C) show the same sample at x100, x200 and x400 
magnifications with arrow heads indicating the possible positive brown stain for p16.
 ___________________________________________________________________ 240 
Figure 8.3 ThinPrep® cervical cytology sample stained with CINTecPLUSTM. (A) 
Shows the erratic single red stain, attributed to Ki-67, which can be observed in most 
samples. However, as no cytoplasm is present it is not possible to establish which type 
of cell it is or if the stain is specific. (B) is a x200 magnification of (A).__________ 240 
Figure 8.4 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. (A) is a 
x100 magnification image showing inconsistent red stain indicated by the black arrows 
xxvii 
 
and attributed to Ki-67, on cells without cytoplasm.  Red stain, indicated by red arrow 
heads, can also be observed in some cells of cellular aggregate at x100 magnification; 
however the morphological detail is lost and the specificity of the stain to the nucleus of 
the cells cannot be assessed. (B) Another sample with an aggregate of cells, at x400 
magnification, where a brownish stain can be observed; in addition, red stain is also 
observed as indicated by the two black arrows. The morphological detail however does 
not allow establishing if both stains are specific for cytoplasm and nucleus respectively.
 ___________________________________________________________________ 241 
Figure 8.5 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. 
Positive dual stain can be observed at x200 (A) and x400 magnification (B). The cell 
nucleus is stained red for Ki-67 whilst the cytoplasm stained brown for p16. ______ 242 
Figure 8.6 Pap stained ThinPrep® cervical cytology sample showing a cellular 
aggregate with poor cellular morphology and nuclear detail to allow definitive 
classification of the sample. (A) and (B) show the cellular aggregate at x200 and x400 
magnification respectively. Superficial cells can be observed in orange 
whileintermediate cells present a blue cytoplasm. ___________________________ 243 
 
xxviii 
 
List of tables 
Table 1.1 2015 Cervical cancer incidence and mortality forecasts for Europe, Ireland 
and the United Kingdom. ________________________________________________ 9 
Table 1.2 Tumors of the Cervix adapted from IARC screening group (IARC 2015) . _ 9 
Table 1.3 Cervical cancer grades adapted from (Sobin et al. 2009). ______________ 37 
Table 1.4 FIGO Staging for Cervical Cancer adapted from (Sobin et al. 2009). _____ 39 
Table 1.5 Summary of the cervical screening recommendations made by the American 
Cancer Society, the American Society for Colposcopy and Cervical Pathology and the 
American Society for Clinical Pathology, adapted from (Saslow et al. 2012). ______ 44 
Table 1.6  Most promising biomarkers for cervical cancer detection together with their 
clinical value and reported sample and assay type. ____________________________ 46 
Table 2.1 Raman spectroscopy studies concerning cervical cancer reported in the 
literature until November 2016 sorted by diagnosis (D), treatment response (R) and 
further conditions analysed. Sampling numbers and data analysis methodology are also 
indicated as maximum representation and discrimination feature (MRDF), sparse 
multinomial logistic regression (SMLR), principal component analysis (PCA), linear 
discriminant analysis (LDA), genetic algorithm-partial least squares-discriminant 
analysis (GA-PLS-DA), partial least squares-discriminant analysis (PLS-DA), Fisher’s 
discriminant analysis (FDA), principal component analysis logistic regression  (PCA-
LR) and spectral analysis when no multivariate statistical method was reported. ____ 66 
Table 3.1 Cellular components used for the NNLS model. _____________________ 91 
Table 4.1 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV. The model was obtained based on the Raman spectra for the full spectral 
range without glass correction. __________________________________________ 107 
xxix 
 
Table 4.2 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV. The model was obtained based on the Raman spectra for the 1200-1800cm-1 
range only. __________________________________________________________ 112 
Table 4.3 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV. The model was obtained based on the Raman spectra after iterative glass 
correction. __________________________________________________________ 126 
Table 4.4 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV. The model was obtained based on the Raman spectra after NNLS glass 
correction. __________________________________________________________ 136 
Table 5.1 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the negative samples by age group. __________________ 148 
Table 5.2 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the CIN 1 samples by age group. ___________________ 148 
Table 5.3 Sensitivity and specificity values obtained for PCA-LDA classification model 
with LOPOCV for the complete dataset by age group. _______________________ 149 
Table 5.4 Sample database, information regarding menstrual cycle day. _________ 150 
Table 5.5 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the menstrual cycle phase of negative samples. ________ 153 
Table 5.6 Sensitivity and specificity results for the PCA-LDA classification model with 
LOPOCV of CIN 1 samples according to their menstrual cycle phase. ___________ 155 
Table 5.7 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for menstrual cycle phase for negative and CIN 1 samples . _ 156 
Table 5.8 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV of negative samples according to their menstrual cycle phase and 
CIN 1 samples. ______________________________________________________ 157 
xxx 
 
Table 5.9 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for Negative - proliferative or secretory menstrual cycle phase, 
and CIN 1, 2 and 3 samples. ____________________________________________ 158 
Table 5.10 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the menstrual cycle phase of all samples considered in the 
study regardless of cytological classification. _______________________________ 159 
Table 5.11 HPV test results for CIN samples. ______________________________ 161 
Table 5.12 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for HPV positive or negative CIN 1 samples. _____________ 163 
Table 5.13 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for Negative and CIN 1 samples - HPV positive or negative. 165 
Table 5.14 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV of negative, CIN 1 HPV negative or positive, CIN 2 and 3. __ 168 
Table 5.15 Sensitivity and specificity values obtained for a PCA-LDA classification 
model with LOPOCV that would classify negative, CIN 1 HPV negative, CIN 1 HPV 
positive, CIN 2 and CIN 3 samples. ______________________________________ 171 
Table 5.16 Previous disease history for negative and CIN 1 samples.____________ 173 
Table 5.17 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for negative samples by previous disease history. ___________________ 174 
Table 5.18 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for negative samples classified into negative or positive previous disease 
history. _____________________________________________________________ 175 
Table 5.19 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV considering negative samples according to their previous disease 
history and CIN 1 samples. _____________________________________________ 176 
xxxi 
 
Table 5.20 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV considering negative samples previous disease history. _____ 177 
Table 5.21 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV considering negative samples previous disease history. ______________ 177 
Table 5.22 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 1 samples by previous disease history. _____________________ 178 
Table 5.23 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 1 samples by previous disease history. _____________________ 179 
Table 5.24 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV considering CIN 1 samples previous disease history. ________________ 180 
Table 5.25 Previous disease history for CIN 2 and 3 samples. _________________ 180 
Table 5.26 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 2 samples by previous disease history. _____________________ 181 
Table 5.27 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 2 samples positive or negative previous disease history. _______ 182 
Table 5.28 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 2 samples by previous disease history versus Negative, CIN 1 and 
CIN 3. _____________________________________________________________ 182 
Table 5.29 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 3 samples by previous disease history. _____________________ 183 
Table 5.30 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 3 samples positive or negative previous disease history. _______ 184 
Table 5.31 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV for CIN 3 samples positive or negative previous disease history versus 
Negative, CIN 1 and CIN 2. ____________________________________________ 184 
xxxii 
 
Table 6.1 Sensitivity and specificity values obtained for the SIL PCA-LDA 
classification model with LOPOCV.______________________________________ 203 
Table 6.2 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV of HSIL samples according to their menstrual cycle phase. __ 204 
Table 6.3 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV of negative, LSIL and HSIL samples, also classifying the latter 
according to their menstrual cycle phase. __________________________________ 205 
Table 6.4 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for negative samples according to proliferative or secretory 
menstrual cycle phase and LSIL and HSIL samples. _________________________ 206 
Table 6.5 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV of LSIL HPV negative or positive, and HSIL. ____________ 207 
Table 6.6 Sensitivity and specificity values obtained for a PCA-LDA classification 
model with LOPOCV that would classify negative, LSIL HPV negative, LSIL HPV 
positive, and HSL samples. _____________________________________________ 207 
Table 6.7 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the HSIL sample group by previous disease history 
background. _________________________________________________________ 208 
Table 6.8 Sensitivity and specificity values obtained for the PCA-LDA classification 
model with LOPOCV for the CIN 2 and 3 sample group by previous disease history. 209 
Table 6.9 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV considering negative samples previous disease history. ______________ 209 
Table 6.10 Sensitivity and specificity values obtained for the PCA-LDA model with 
LOPOCV considering negative samples previous disease history. ______________ 210 
xxxiii 
 
Table 7.1 Confusion matrix showing the result of the testing of the test set samples on 
the CIN PCA-LDA classification algorithm. _______________________________ 223 
Table 7.2 Confusion matrix showing the result of the testing of the test set samples on 
the SIL PCA-LDA classification algorithm. ________________________________ 223 
Table 7.3 Confusion matrix of negative test set samples when tested on the PCA-LDA 
model to predict negative samples according to their previous disease history. ____ 225 
Table 7.4 Negative test set database according to their previous disease history. ___ 225 
Table 7.5 Confusion matrix of negative and CIN 1 test set samples when tested on the 
PCA-LDA model to predict negative samples according to their previous disease history 
as well as CIN 1 disease. _______________________________________________ 226 
Table 7.6 Test set sample database, information regarding menstrual cycle day. ___ 227 
Table 7.7 Confusion matrix of negative and CIN 1 test set samples when tested on the 
PCA-LDA model to predict negative samples according to their menstrual cycle phase.
 ___________________________________________________________________ 228 
Table 7.8 Confusion matrix of negative and CIN 1 test set samples when tested on the 
PCA-LDA model to predict negative samples according to their menstrual cycle phase 
as well as CIN 1 disease. _______________________________________________ 229 
Table 7.9 Confusion matrix of all test set samples when tested on the PCA-LDA 
disease classification model PCA-LDA which also stratifies CIN 1 samples into HPV 
positive or negative. __________________________________________________ 229 
 
  
xxxiv 
 
Abbreviations 
µm micrometre 
AGC Atypical glandular cells 
AGM Atypical glandular cells, favour neoplastic process 
AGUS Atypical glandular cells of undetermined significance  
AIDS Acquired immune deficiency syndrome 
AP Alkaline phosphatase 
ASC-H Atypical glandular cells, cannot exclude HSIL 
ASCUS Atypical cells of undetermined significance 
BMI Body mass index 
bp base-pair 
CADM1  cell adhesion molecule 1  
CCD Charged couple device 
CCRT Concurrent chemoradiotherapy  
CDH1 cadherin 1 
CDKN2A Cyclin Dependent Kinase Inhibitor 2A 
CDKx Cyclin dependent kinase where x is a number 
CIN Cervical Intraepithelial Neoplasia  
DAB Diaminobenzidine 
DAPK1 death-associated protein kinase 1 
DAPK1 Death associated protein kinase 1 
dCV double cross validation 
DNA Deoxyribonucleic acid 
DRS Diffuse reflectance spectroscopy 
DSI Dynamic Spectral Imaging 
EA Eosin azure 
EMSC Extended Multiplicative Signal Correction 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 
EU European Union 
EUCAN  European cancer estimates administered by the International 
Agency for Research on Cancer 
Ex Early HPV gene,  with x=1 to 7 
xxxv 
 
FDA Food and Drug Administration Agency 
FFPP Formalin fixed, paraffin preserved 
FIGO International Federation of Gynaecology and Obstetrics  
GA-PLS-DA genetic algorithm-partial least squares-discriminant analysi 
H&E Haematoxylin & Eosin 
HC2®  Hybrid Capture 2® 
HIV Human immune deficiency virus 
HPK Primary human keratinocytes  
HPV Human Papilloma Virus 
hr- high risk (HPV type) 
HRP Horseradish peroxidase 
HSE Health Service Executive 
HSIL High-grade Squamous Intraepithelial Lesion 
HSV Herpes Simplex Virus 
HW High wavenumber 
IARC International Agency for Research on Cancer 
ICC Immunocytochemistry 
kDa kilodalton 
KMCA K-means cluster analysis 
LAST Lower Anogenital Squamous Terminology 
LBC Liquid based cytology 
LDA Linear discriminant analysis 
LEEP Loop electrosurgical excision procedure 
LLETZ Large loop excision of the transformation zone of the cervix 
LMP Last menstruation period 
LOPOCV Leave one patient out cross validation 
LOPOCVacc Accuracy of the Leave one patient out cross validation 
LSIL Low-grade Squamous Intraepithelial Lesion 
Lx Late HPV gene, with x=1 or 2 
MAL myelin and lymphocyte protein 
MCM2 Minichromosome Maintenance Complex Component 2 
MMMTs Malignant Mixed Mullerian tumors 
MRDF Maximum representation and discrimination feature 
xxxvi 
 
mRNA Messenger RNA 
MYBL2 MYB Proto-Oncogene Like 2 
NBCCEDP National Breast and Cervical Cancer Detection Program 
NHS National Health Service 
NICE National Institute for Health and Care Excelence 
NILM Negative for intraepithelial lesion and malignancy  
NIR Near Infrared 
NNLS Non-negative least squares 
NSS National Screening Service 
OG Orange G 
p(x) protein where x is a number 
Pap  Papanicolau 
PAX1 paired box 1 
PC Principal Component 
PCA Principal component analysis 
PCA-LR Principal Component Analysis Logistic Regression 
PCR Polymerase chain reaction 
PHK Primary Human Keratinocytes 
pRb retinoblastoma protein 
PRDM14 protease domain domain-containing 14 
PSL-DA Partial Least Squares Discriminant Analysis 
RARB Retinoic acid receptor 
Rb Retinoblastoma 
RNA Ribonucleic Acid 
RT Room Temperature 
SCC Squamous cell carcinoma 
SD Standard deviation 
SD_LOPOCVacc Standard deviation of the Leave one patient out cross validation 
accuracy  
SERS Surface-enhanced Raman spectroscopy 
SIL Squamous Intraepithelial Lesion 
SLIT2 Slit guidance ligand 2 
SMLR Sparse multinomial logistic regression 
xxxvii 
 
SOP Standard operating procedure 
STI Sexually transmitted infection 
TERT telomerase reverse transcriptase 
TOP2A Topoisomerase 2-alpha 
UK  United Kindgdom 
URR Upstream regulatory region 
USA  United States of America 
UV Ultraviolet 
WHO World Health Organization 
WIF1 Wnt-inhibitory factor 1 
 
 
1 
 
CHAPTER 1 INTRODUCTION: THE CERVIX, CANCER AND 
DIAGNOSIS CHALLENGES 
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1.1 The Cervix 
1.1.1 Embryology 
The cervix like the uterine fundus and upper vagina, develops from the embryonic 
paramesonephric ducts (Sahdev 2010).  
The process begins at the fifth week of gestation, when the Wolffian mesonephric and 
the Müllerian paramesonephric ducts are formed from the intermediate mesoderm. In 
the absence of testosterone and Müllerian inhibitory substance, the mesonephric ducts 
regress and the paramesonephric ducts continue to develop the female reproductive 
structures; this is completed by the fifth month of pregnancy when the vagina and a 
variable portion of the ectocervix become covered by squamous epithelium (Sahdev 
2010).   
1.1.2 Anatomy & Histology 
Macroscopically, the cervix is the lower extension of the uterus, presenting a fusiform 
shape of 2,5 to 3 cm in diameter and 3 to 5 cm in length. It can be divided into two 
parts, the interior portio vaginallis or ectocervix, which protrudes into the vagina and the 
supravaginal part or endocervix (Sahdev 2010). 
The endocervical canal measures 6 to 8 mm wide and contains ridges perpendicular to 
the long axis of the canal, the plicae palmateae (Mescher 2013).  It communicates with 
the uterine cavity through the internal os and, its opening at the portio vaginalis is 
known as the external os (Mescher 2013). 
Histologically, three different areas can be found in a normal human cervix as shown in 
Figure 1.1. The endocervix, the closest part to the uterus, is lined by a mucin-producing 
simple columnar epithelium. The ectocervix, the part next to the vagina, is lined with a 
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stratified squamous epithelium. And, the area where the endocervix joins the ectocervix 
which is known as the squamo-columnar junction, also called the transformation zone 
because it is the site where the simple columnar epithelium undergoes transition to 
stratified squamous epithelium (Mescher 2013; Sahdev 2010). 
 
Figure 1.1 Schematic representation of the female genital tract and of the ecto and endocervical epithelia 
adapted from (A.D.A.M. 2016) and (Mescher 2013). 
 
The stratified squamous epithelium of the ectocervix consists of layers of basal, 
parabasal, intermediate and superficial cells, as shown in Figure 1.2. 
The basal cells are the smallest, measuring about 10 μm diameter; they are immature 
cells with a round to elliptical shape and large spherical nucleus. Derived from the basal 
layers, the parabasal cells are similar in shape but somewhat larger, about 10 μm to 15 
μm in diameter (Koss et al. 2006). 
Intermediate cells, in comparison, are larger, measuring from 15 to 40 μm in diameter, 
and present a more elongated shape and a smaller nucleus (Koss et al. 2006).   
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Measuring from 40 μm to 60 μm in diameter, the superficial cells are the largest; they 
are mature cells with small, dense, pyknotic1 nuclei. During the maturation process, 
cells migrate from the basal layer to the surface (superficial layer), accumulate glycogen 
in the cytoplasm, and acquire a flattened shape. The epithelial layer of cells is composed 
of 15-20 cells with a thickness of 200-400 μm (Koss et al. 2006). 
 
Figure 1.2 Schematic representation of the stratified squamous epithelium of the ectocervix with 
representation of the different cell types present; adapted from (Frazer 2004). 
  1.1.3 Function 
The cervix has several important functions, most of them related with the female 
reproductive cycle. 
As it connects the body of the uterus to the vagina, it allows the menstrual flow of blood 
and debris, to come from the uterus into the vagina and out of the body. Similarly, it 
also directs sperm into the uterus during intercourse (Almeida et al. 2010). 
                                                 
1 Pyknosis –condensation of DNA causing shrinking of the nucleus. 
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Moreover, cervical secretions change cyclically, and play a significant role in 
fertilization and early pregnancy. At the end of ovulation, the mucous secretions are 
maximal, watery, and facilitate movement of the sperm through the uterus. In the luteal 
phase, high progesterone levels cause the mucous secretions to become viscous and 
hinder the passage of both sperm and microorganisms into the body of the uterus. 
During pregnancy, cervical glands proliferate and secrete abundant, highly viscous 
mucus which forms a plug in the endocervical canal to help keep the foetus inside the 
womb (Mescher 2013).  
Similarly, the cervical epithelium is also affected by the cyclical changes arising from 
the menstrual cycle. In the proliferative phase of the cycle, between day 5 and 13, 
oestrogen levels reach their peak leading to the complete maturation of the squamous 
epithelium which therefore presents a high proportion of superficial cells compared to 
intermediate and basal cells. Inversely, in the secretory phase, between day 14 and 28, it 
is progesterone that reaches its peak preventing the complete maturation of the 
epithelium that now presents more intermediate and immature cells. Once a woman 
stops ovulating, usually between the ages of 48 and 55 years of age, she is considered to 
be menopausal.  At this stage, levels of both oestrogen and progesterone drop 
dramatically and there is a gradual arrest of the squamous epithelial maturation, 
resulting in the gradual loss of superficial and intermediate cells with the squamous 
epithelium composed entirely of parabasal cells and classed as atrophic (Koss et al. 
2006; Jordan et al. 2006). 
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1.2 Cancer 
1.2.1 What is cancer? 
The proliferation, differentiation and survival of individual cells in multicellular 
organisms, as in the human body, are carefully regulated to meet the needs of the 
organism as a whole (Cooper et al. 2013). 
Cells from different parts of the body that look, function and ultimately are different, are 
in intrinsic collaboration resting, growing, dividing, differentiating or dying as needed 
for human body function (Alberts et al. 2014). 
Of the more than 1014 human cells, billions of them experience mutations2 every day; 
normally, the now abnormal cells would try to reverse these mutations, activating a 
correction mechanism and undergoing apoptosis3 when they fail. However when the 
mutation gives the cell a selective advantage that allows it to grow, survive and divide 
in a more vigorous and unregulated manner, this becomes a founder of growing mutant 
clones (Alberts et al. 2014). 
As a result, a tumor also known as neoplasm – from the Greek new growth – can 
develop from a single altered cell that begins to grow and proliferate abnormally 
(Cooper et al. 2013). A tumor can be either benign, if it remains confined to its site of 
origin, or malignant, if its cells have acquired the ability to invade surrounding tissue 
and spread (metastasise) throughout the body via circulatory or lymphatic systems 
(Cooper et al. 2013; Kumar et al. 2012). Only the malignant type is referred to as 
cancer. 
                                                 
2 Mutation – permanent alteration of the nucleotide sequence of the genome of an 
organism, virus, or extrachromosomal DNA or other genetic elements.  
3 Apoptosis – Mechanism of programmed cell death. 
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1.2.2 Carcinogenesis 
Carcinogenesis, oncogenesis, or tumorigenesis, is the dynamic process by which normal 
cells are transformed into cancer cells. It is characterized by a succession of changes at 
the genetic and cellular level that ultimately reprogramme a cell to undergo uncontrolled 
cell division, thus forming a malignant neoplasm (Kumar et al. 2012). 
Three distinct phases can be identified in this multistage process as illustrated in Figure 
1.3. First there is Initiation when the cells are exposed to a carcinogen4 which makes 
them more susceptible to Deoxyribose nucleic acid (DNA5) damage and possible 
malignant transformation. Then, there is Promotion when the mutant cells are induced 
by various chemicals and growth factors to undergo an unregulated accelerated growth. 
And finally, a Progression when these cells acquire a malignant phenotypic that 
promotes autonomous growth tendencies, increased chromosomal instability, 
invasiveness and metastatic competence (Almeida et al. 2010; Porth 2014). 
 
Figure 1.3 Schematic of the carcinogenesis process: Initiation, Promotion and Progression (Almeida et al. 
2010). 
                                                 
4 Carcinogen – Any substance or agent an agent that induces changes to a cell 
population which can cause cancer.  
5 DNA - Deoxyribonucleic acid is a nucleic acid containing the genetic instructions used 
in the development and functioning of all known living organisms with exception of 
RNA virus. 
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1.3 Cervical cancer 
1.3.1 Statistics: Worldwide, Europe and Ireland 
Cervical cancer is the fourth most common cancer in women worldwide, and the 
seventh overall, with an estimated 528,000 new cases in 2012 alone. The majority of 
cases arise in less developed regions where almost nine out of ten cervical cancer deaths 
occur (IARC 2012b). 
In 2012 there were an estimated 266,000 deaths from cervical cancer worldwide which 
accounts for 7.5% of all female cancer deaths (IARC 2012b).  
Across Europe, the overall incidence and mortality cases for 2012 were estimated at 
58348 and 24397 respectively as shown by EUCAN data (Ferlay et al. 2013; IARC 
2012a). 
Amongst the 28 member states of the European Union (EU) approximately 34,000 new 
cases and 13,000 deaths occur annually, and despite the significant progress made in 
reducing the burden of the disease, mortality rates are still high in many member states, 
particularly those that joined the EU after 2003 (Ferlay et al. 2013; IARC 2012a; von 
Karsa et al. 2015).  
In Ireland, the incidence rates of cervical cancer have been shown to rise from 1994 to 
2008. On average, 1300 women were diagnosed with cervical intraepithelial neoplasia 
(CIN) 3, 210 with invasive cervical cancer and 75 women died each year (O’Brien et al. 
2013).  According to GLOBOCAN 2012 data and taking into account the demographic 
effect, cervical cancer incidence in Ireland is predicted at 357 for 2012 and 372 for 
2015, whilst mortality is predicted at 101 for 2012 and 106 for 2015, as shown in Table 
1.1 which also contains European and United Kingdom (UK) projections. 
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Table 1.1 2015 Cervical cancer incidence and mortality forecasts for Europe, Ireland and the United Kingdom.  
Values obtained from GLOBOCAN 2012 (IARC) on 28th August 2015 and computed using age-specific rates 
and corresponding populations for 10 age-groups. Population forecasts were extracted from the United 
Nations, World Population prospects, the 2012 revision (IARC 2012b). 
 1.3.2 Histological Types 
According to the World Health Organization, tumors of the cervix are as summarized in 
Table 1.2 (IARC 2015). 
Table 1.2 Tumors of the Cervix adapted from IARC screening group (IARC 2015) . 
Epithelial tumours 
Squamous tumours and precursors 
   Squamous cell carcinoma, not otherwise specified 
      Keratinizing 
      Non-keratinizing 
      Verrucous 
      Warty 
      Papillary 
      Lymphoepithelioma-like 
      Squamotransitional 
   Early invasive (microinvasive) squamous cell 
carcima 
   Squamous intraepithelial neoplasia 
      Cervical intraepithelial neoplasia (CIN 3) 
      Squamous cell carcinoma in situ 
   Benign squamous cell lesions 
      Condyloma acuminatum 
      Squamous papilloma 
      Fibroepithelial polyp 
 Glandular tumours and precursors 
   Adenocarcinoma 
      Mucinous adenocarcinoma 
         Endocervical 
         Intestinal 
         Signet-ring cell 
         Minimal deviation 
 
2012 2015 
Europe Ireland United Kingdom Europe Ireland 
United 
Kingdom 
Incidence  
 67355 357 2659 68431 372 2675 
Mortality 28003 101 979 28863 106 1008 
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         Villoglandular 
      Endometrioid adenocarcinoma 
      Clear cell adenocarcinoma 
      Serous adenocarcinoma 
      Mesonephric adenocarcinoma 
   Early invasive adenocarcinoma 
   Adenocarcinoma in situ 
   Glandular dysplasia 
   Benign glandular lesions 
      Müllerian papilloma 
      Endocervical polyp 
  Other epithelial tumours 
   Adenosquamous carcinoma 
   Glassy cell carcinoma variant 
   Adenoid cystic carcinoma 
   Adenoid basal carcinoma 
   Neuroendocrine tumours 
      Carcinoid 
      Atypical carcinoid 
      Small cell carcinoma 
      Large cell neuroendocrine carcinoma 
   Undifferentiated carcinoma 
 Mesenchymal tumours and tumour-like 
conditions 
   Leiomyosarcoma 
   Endometrioid stromal sarcoma, low grade 
   Undifferentiated endocervical sarcoma 
   Sarcoma botryoides 
   Alveolar soft part sarcoma 
   Angiosarcoma 
   Malignant peripheral nerve sheath tumour 
   Leiomyoma 
   Genital Rhabdomyoma 
   Postoperative spindle cell nodule 
Mixed epithelial and mesenchymal tumours 
   Carcinosarcoma (malignant müllerian mixed 
tumour) 
   Adenosarcoma 
   Wilms tumour 
   Adenofibroma 
   Adenomyoma 
Melanocytic tumours 
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   Malignant melanoma 
   Blue naevus 
Miscellaneous tumours 
Tumours of germ cell type 
   Yolk sac tumour 
   Dermoid cyst 
   Mature cystic teratoma 
Lymphoid and haematopoetic 
   Malignant lymphoma (specify type) 
   Leukaemia (specify type) 
 
Between 85% and 95% of cervical cancers are squamous cell carcinomas (SCC). 
Developing almost exclusively at the squamo-columnar junction, most of them involve 
the ectocervix and may be visible on direct speculum examination as exophytic6, 
especially in younger women, when the junction lies outside the external os (Sahdev 
2010).  
Adenocarcinomas arise from the glandular epithelium and the endocervical glands of 
the endocervical canal, and comprise 5% of all cervical tumors. Because of their deep 
endocervical origin, adenocarcinomas are usually detected at a later stage than SCC, and 
often present large infiltrative lesions that lead to poor prognosis (Sahdev 2010). 
Malignant lymphomas of the female genital tract are rare and often a diagnostic 
challenge. In advanced disease status it is almost impossible to determine whether they 
are primary, originated from the genital tract and then spread to lymph nodes, or 
secondary if they originated from the lymphatic system; in either case, diffuse large B-
cell and follicular are the prevailing type among lymphomas (Sahdev 2010). 
                                                 
6 Exophytic – growing outward; in oncology, proliferating externally or on the surface 
epithelium of an organ in which the growth originated. 
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Even rarer than lymphomas, sarcomas of the cervix such as Malignant Mixed Müllerian 
tumors (MMMTs) and leiomyosarcomas, mainly occur in postmenopausal women, 
between the age of 50 and 70 years. Nevertheless, primary leiomyosarcomas of the 
cervix have only been reported as case reports, with the majority originating from the 
corpus uteri and involving the cervix (Sahdev 2010). 
Finally, neuroendocrine tumors represent less than 1% of cervical malignancies.  This 
type of tumor is extremely aggressive, and often diagnosed in an advanced stage thus 
holding poor prognosis; small cell carcinomas and carcinoids are the two most frequent 
subtypes diagnosed (Sahdev 2010). 
1.3.3 Aetiology – Human Papillomavirus (HPV) 
The association between HPV and cervical cancer is one of the strongest statistical 
relations ever identified in cancer epidemiological studies. Both biological and 
epidemiological retrospective and prospective studies have demonstrated an 
unequivocal association between HPV infection and higher risk of malignancy, from the 
early lesion states to invasive carcinoma (Franco et al. 2003; Boulet et al. 2007). 
Human papillomaviruses are sexually transmitted small circular double-stranded DNA 
viruses from the Papovaviridae family. Their genome, as represented in Figure 1.4, 
consists of 8000 base-pair (bp) long circular DNA molecules wrapped into a protein 
shell composed of L1 and L2 proteins; it has the capacity for coding these two late 
expression proteins as well as six other early proteins (E1 to E7) necessary for the 
replication of viral DNA and its assembly within infected cells. There is also an 
upstream regulatory region (URR) that, although not coding for any proteins, contains 
cis-elements required for regulation, expression and packaging the genome into the 
virus  (Muñoz et al. 2006). 
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Figure 1.4 Schematic presentation of the HPV genome, showing the arrangement of the early E or non-
structural genes, the capsid genes (L1 and L2) and the URR (Cooper et al. 2013). 
From more than 200 different HPV types identified, about 40 are known to infect the 
genital tract. These mucosal types are classified as “low-risk” or “high-risk” (HR-) 
based on their prevalence ratio in cervical cancer and its precursor lesions (Boulet et al. 
2007; Woodman et al. 2007). 
Low-risk HPV types, such as 6 and 11, are believed to induce benign lesions with 
minimum risk of malignant progression, whereas HR types have a higher oncogenic 
potential. Approximately, 99% of cervical cancers contain HR-HPV DNA, with 
HPV16, 18, 31, 33 and 45 being the most prevalent worldwide in that order (Boulet et 
al. 2007).   
The HPV life cycle is perfectly adapted to its natural tissue host, the epithelium; being 
strongly linked to epithelial differentiation (Muñoz et al. 2006; Pyeon et al. 2009).  
In the cervix, HPV is thought to access the basal cells through micro-abrasions in the 
epithelium and infect the dividing basal cells during wound healing (Pyeon et al. 2009).  
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Following entry, the early genes (E1 – E7) are expressed and the viral DNA replicates 
from the episomes7, afterwards in the upper layers of the epithelium the genome is 
replicated further and the late genes (L1 and L2) are expressed; they then encapsulate 
the viral genome from progeny virions in the nucleus and the newly shed virus can 
initiate a new infection (Woodman et al. 2007; Doorbar et al. 2015). 
Expressed in the lower epithelial layers, E6 and E7 are the critical proteins for HPV 
replication as their function inactivates the products of two important tumor suppressor 
genes – p53 and pRb, respectively. While E6 acts as repressor of p53 and therefore of 
apoptosis, mediating survival of severely damaged cells; E7 is a promoter of pRb and 
therefore of cell growth and replication. Referred to as oncoproteins as they induce 
proliferation, immortalization and malignant transformation of the infected cells; their 
joint function is complementary and synergistic inducing an even more marked 
malignant transformation (Boulet et al. 2007). 
Whereas the low-risk HPV genomes are preferentially maintained in episomes, high-
risk HPV types have a greater tendency for integration with the host DNA. This 
integration, represented in Figure 1.5, usually occurs by the E2 region downstream of 
the E6 and E7 genes which leads to an increase in their expression due to the loss of the 
regulatory control of E2. Moreover, integrated-derived transcripts are more stable than 
those originating from episomes, which represent a growth advantage (Doorbar 2005; 
Woodman et al. 2007). 
                                                 
7 Episome - A segment of DNA that can exist and replicate either autonomously in the 
cytoplasm or as part of a chromosome. 
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Figure 1.5 Representation of the integration of HPV DNA into the host cell DNA (Woodman et al. 2007). 
 
1.3.4 Grading 
Dysplasia, characterised by increased mitotic activity8 of the cells and decreased 
glycogen levels in cytoplasmic regions, usually develops in the transformation zone. 
Dysplasia is a pre-cancer condition in which dysplastic cells have increased nuclear size 
and resemble undifferentiated basal cells, but unlike normal basal cells, these abnormal 
cells exhibit large nuclei, chromatin9 clumping, scant cytoplasm and irregular nuclear 
borders. Low grade and moderate cervical dysplasia can spontaneously regress without 
leading to cervical cancer, however some may progress to severe dysplasia, and finally 
invasive cancer (Koss et al. 2006; Cibas et al. 2009; Moscicki et al. 2010a). 
The three-tier cervical intraepithelial neoplasia (CIN) nomenclature is directly linked to 
the severity of dysplastic changes in the cervix epithelium and is widely used for 
histology reporting of cervical tissue; whereas the two-tier squamous intraepithelial 
lesion (SIL) nomenclature corresponds to the cytological diagnosis defined by the 
Bethesda system  (Apgar et al. 2003). The Bethesda system was introduced in 1988 in 
an attempt to standardise the cytology reporting. Its revision in 2001 created the 
nomenclature currently recommended for reporting cervical cytology (Appendix 2). 
Despite this, some laboratories still report cytology using CIN nomenclature.   
                                                 
8 Mitotic activity – Mitosis, the process in cell division by which the nucleus divides. 
9 Chromatin – The complex of DNA and protein that makes up chromosomes. 
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CIN 1 [low to mild dysplasia] and changes associated with HPV are classed as low 
grade squamous intraepithelial lesions (LSIL), whereas high grade squamous 
intraepithelial lesions (HSIL) correspond to CIN 2 [moderate dysplasia] and CIN 3 
[severe dysplasia] as shown in Figure 1.6.  
 
Figure 1.6 Representation of the progression from normal cervical epithelium to invasive carcinoma adapted 
from (Lowy et al. 2006). SIL (red) and CIN (blue) reporting systems are indicated as well as the grade of 
dysplasia associated with each classification. 
 
In 2012, the American College of Pathology in an international consensus conference, 
called the Lower Anogenital Squamous Terminology (LAST) Project, made 
recommendations on the use of SIL as a uniform, two-tiered terminology to describe the 
histology of human papillomavirus-associated squamous disease across all anogenital 
tract tissues. SIL is recommended to be used in the reporting of cervical biopsies with 
p16 (discussed in more detail in section 1.6.1.1 of this chapter) tissue immunostaining 
also recommended to better classify lesions that would earlier have been diagnosed 
morphologically as CIN 2 (Waxman et al. 2012). 
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1.3.5 Symptoms 
Cervical cancer is typically the last stage of a somewhat slow carcinogenesis process. 
Precancerous changes occur gradually; usually taking several years until full 
transformation from normal epithelium to dysplasia and subsequently to invasive SCC 
is completed.  
Although, initial abnormal changes in the cervix are asymptomatic, the development of 
cervical dysplasia may cause various symptoms such as vaginal bleeding outside 
menstruation periods or after intercourse and/or atypical vaginal discharges. In late 
stages, SCC can spread into the pelvic tissues causing pain (Arends et al. 1998; Franco 
et al. 2003). 
1.3.6 Risk factors 
While HPV is recognised as the main aetiological agent, it is not the only factor for 
cervical cancer. Potential co-factors to persistent HPV infection reported for cervical 
cancer are as follows: 
• Sexual behaviours and other sexually transmitted infections (STI). Women 
with a promiscuous and unsafe sexual behaviour, or those whose partner is, are 
at increased risk of contracting STI such as HPV, the principal aetiology factor 
in cervical cancer. There has been a renewed interest in the possible role of other 
STIs, especially Herpes simplex virus (HSV) and Chlamydia trachomatis as 
potential HPV cofactors (American Society of Clinical Oncology 2012). 
Although some studies suggest that women who have genital herpes have a 
higher risk of developing cervical cancer, a recent longitudinal meta-analysis 
reported the evidence supporting a harmful effect of HSV infection on cervical 
cancer was inadequate and recommended further studies are needed to fully 
clarify any association (Cao et al. 2014). Similarly, more evidence is still needed 
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to elucidate the possible role of Chlamydia trachomatis in cervical 
carcinogenesis but recent studies have reported higher prevalence of HPV 
multiple infections in women affected with chronic Chlamydia trachomatis 
infection, further suggesting Chlamydia infection may promote a favourable 
microenvironment for HPV infection through disruption of both apoptotic and 
cellular pathways (Seraceni et al. 2014; Vriend et al. 2015). 
• Immunosuppression. When immunosuppressed, the human body does not 
monitor and respond to internal, such as mutations, and external, such as HPV 
infections, challenges efficiently. Therefore, by allowing these aggressions and, 
their subsequent abnormal and malignant induced changes to proceed, the 
immunosuppressed state is one of the risk factors for cervical cancer. This state 
can be caused by immune suppression from corticosteroid medications, organ 
transplantations, treatments for other types of cancer, or from human 
immunodeficiency virus (HIV), the virus that causes acquired immune 
deficiency syndrome (AIDS) (Palefsky 2007; Dugué et al. 2013; Chen et al. 
2015) . 
• Oral contraceptive use. The plausibility of this association rests on the 
possibility that hormones affect HPV infected cells; it has been shown that oral 
contraceptive use increases the risk of cervical cancer (Gierisch et al. 2013; La 
Vecchia et al. 2014; Roura et al. 2016) and that steroid stimulation may trigger 
viral oncogene-related events leading to the integration of the virus into the 
host’s genome (Moodley et al. 2003). However, further research is needed to 
understand how oral contraceptive use and the development of cervical cancer 
are associated. 
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• Reproductive history. High parity has consistently been found to increase the 
risk of cervical cancer. A recent study found the number of full-term 
pregnancies was positively associated with increased risk of CIN3/cervical 
cancer with a p-value of 0.03 (Roura et al. 2016). Independently of the sexual 
behaviour, multiple pregnancies may induce a cumulative traumatic or 
immunosuppressive element on the cervix, facilitating HPV infection. Moreover, 
pregnancy hormonal alterations could affect HPV genome elements that respond 
to progesterone (Castellsagué et al. 2003; Jensen et al. 2013).  
• Smoking habits. Several studies suggest that women who smoke are about 
twice as likely to develop cervical cancer as women who do not smoke 
(Castellsagué et al. 2003; Louie et al. 2011). It has also been reported that 
smoking increases the risk of high-grade cervical lesions in women with 
persistent high-risk HPV infection (Jensen et al. 2012). However, the 
mechanism by which smoking affects cervical carcinogenesis is not clear 
(Fonseca-Moutinho 2011). 
• Race and Ethnicity. Even though the genetic/biological principles demand 
further clarification, recent epidemiological research showed HPV associated 
cervical cancer to be more common amongst Black and Hispanic women despite 
an overall decrease in the incidence of disease (Viens et al. 2016). Similarly, a 
study of the population of Singapore reported it was still unclear why Chinese 
women remain at higher risk of cervical cancer, as compared to Malay and 
Indian women (Lam et al. 2015). However, a microRNA genotype study showed 
miR-146a (rs2910164) polymorphism to be correlated with ethnicity and tumor 
dimension, with the odds ratio of cervical cancer for Uygur women 3.332 times  
that found for Han women (Ma et al. 2015). 
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• Diet. There is biological plausibility for a protective effect of diet in 
carcinogenesis. Epidemiological studies have been relatively consistent 
indicating protective effects for consumption of fruits and vegetables, beta-
carotene and, vitamins A, C and E; Carotenoids, tocopherols and ascorbic acid, 
to mention a few, are shown to be potent antioxidants as they are able to reduce 
intracellular reactive radicals, thus potentially preventing DNA damage and 
oxidative stress (Franco et al. 2003; Gutierrez-Salmean et al. 2015). 
• Microbiome. The role of microbiome in disease has been the subject of much 
research in recent years. Studies concerning cervical cancer found vaginal 
microbiota to be significantly associated with HPV infection (Brotman et al. 
2014); HPV positivity was also associated with greater microbiome diversity 
(Gao et al. 2013; Lee et al. 2013) and higher vaginal pH (Clarke et al. 2012) due 
to a decrease in Lactobacilli species (Clarke et al. 2012; Lee et al. 2013).  
• Frequency of screening & Low socioeconomic status. Medical surveillance 
which comprises an appropriate screening frequency is crucial to detect cervical 
abnormalities at the early stages and thus prevent cervical cancer. Women from 
lower socioeconomic status are less likely to be aware of these risk factors and 
attend regular medical appointments so this might be one of the reasons that 
drive later diagnosis and consequent poor prognosis for cervical cancer for this 
group (Ibfelt et al. 2013; Tadesse 2015). 
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1.4 Current diagnostic methods and technologies for cervical cancer  
1.4.1 Papanicolau (Pap) test 
Also called the Pap smear, cervical smear or smear test, the Pap test is a screening 
method invented independently by George Papanicolaou and Aurel Babeş. Introduced 
in the United States of America in the mid 1940s, only in the 1970s did it become a 
routine screening test for cervical cancer (Koss et al. 2006; Safaeian et al. 2007). .   
The Pap test consists of cytological screening, under a light microscope, of a cervical 
smear according to standard guidelines with the Bethesda system the most widely used. 
The smear is collected by scraping the cervix with a cervical brush and it should ideally 
obtain representative material of the transformation zone where the stratified squamous 
epithelium of the ectocervix turns into the columnar mucus-secreting epithelium of the 
endocervix as this is the most common onset site of cervical cancers (Koss et al. 2006), 
as shown in Figure 1.7.  
 
Figure 1.7 Representation of the cervical smear collection, with indication of the transformation zone location 
(The Johns Hopkins University 2012). 
 
The cells are then transferred onto a slide by one of the two following methods: 
1. Conventional method – where, immediately after collection, the cells are 
spread along the slide and fixed with a spray fixative as illustrated in Figure 1.8 
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by the clinician or the trained nurse who carried out the collection (Safaeian et 
al. 2007). 
 
Figure 1.8 Schematic representation of the conventional method adapted from (Rovers Medical Devices B.V. 
2006).  
 
2. Liquid Based Cytology (LBC) – introduced in the late 1990s was quickly 
adopted because it allowed the laboratories to prepare the slides rather than 
having them sent from the collection sites with various degrees of fixation and 
preparation. Moreover, LBC methodologies provide a clearing of the samples 
from obscuring elements such as blood or mucus, which is one of the reasons 
cited to justify its lower unsatisfactory rates compared with conventional 
cytology (Fontaine et al. 2012). The two main platforms or LBC methods are: 
a. ThinPrep® method (Hologic) where the cells, instead of being spread 
on the slide after collection, are transferred into a vial with PreservCyt® 
solution10 and subsequently processed in an automated system that 
prepares the slides through 3 steps: first the cells are dispersed (to get rid 
of debris that may obscure them), then collected by a thin filter and 
finally transferred onto a slide by imprinting the filter on the slide 
(Hologic 2010), as shown in Figure 1.9.  
                                                 
10 PreservCyt® solution – methanol based preservative/fixative solution. 
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Figure 1.9 Schematic representation of the ThinPrep® method (West Coast Pathology Laboratories 2011). 
 
b. SurePath® method (Becton Dickson), uses a broom-like device or 
combination brush/spatula with detachable heads for the collection of 
the smear; the detachable head is then dropped into the BD SurePath™ 
vial 11 assuring that 100% of the collected sample is sent for processing 
(Figure 1.10). The BD PrepStain™ Slide Processor allows processing 
the samples in a standardized way and also enhancing the concentration 
of cells needed for diagnostic testing (Becton Dickson 2016). 
 
Figure 1.10 Schematic representation of the SurePath® method (Becton Dickson 2016). 
 
Until 1996, when the ThinPrep® method was introduced, the conventional method was 
the most widely used. However, over recent years, the new LBC methods were shown 
to be more efficient by a 65% increase in the detection of low grade and severe lesions 
while simultaneously reducing the false negative rate by 39%, this led to LBC being 
widely implemented and used routinely (Koss et al. 2006).  
                                                 
11 BD SurePath™ vial – preservative/fixative solution. 
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Research comparing ThinPrep® and SurePath® methods are still ongoing to find if 
there is any significant difference between the specificity and/or sensitivity of the two 
methods. Although ThinPrep® appears to be the most accepted in many developed 
countries, literature shows that SurePath® allows lower unsatisfactory rates of available 
cells for diagnosis (Fontaine et al. 2012). 
Once on a slide, the cells are stained and evaluated by a highly trained technician or a 
pathologist according to the Bethesda system nomenclature (Appendix 2). 
The Pap test has the advantages of being minimally invasive, inexpensive and a widely 
accepted technique. And, although it has a high specificity of 95-98%, sensitivity rates 
vary from 74 to 96% due to sampling ( incorrect or inadequate collection), technical 
(inaccuracy of technical procedure) and/or inter-observer (subjectivity of screening 
system) errors therefore frequent intra and inter-laboratory testing is necessary to obtain 
the highest specificity values reported (Nanda et al. 2000b; Koss et al. 2006). 
Moreover, an abnormal Pap smear is normally followed by colposcopy, biopsy and 
histological confirmation of the diagnosis. Regardless of its slowness, the major 
concerns of this process are the subjectivity of the grading characteristics and the fact 
that pre-malignancy or early malignancy stages could be missed due to their low 
morphological perceptibility (Nanda et al. 2000a; Bengtsson et al. 2014). 
1.4.1.1 Papanicolaou (Pap) stain 
The Papanicolaou (Pap) stain is a multichromatic staining technique developed by 
George Papanicolaou and it is the “gold standard” stain for gynaecological cytology. 
Its most common form involves the application of three different stain solutions. A 
nuclear stain, haematoxylin, is used to stain cell nuclei; then orange G (OG)-6 (where -6 
denotes the used concentration of phosphotungstic acid) is used to stain keratin; and 
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finally, eosin azure (EA)-50 (where -50 denotes the proportion of 3 different dyes in 
solution) is employed to counterstain the cytoplasm (Gil 2013).  
On a well prepared specimen, the cell nuclei are dark blue to black. Superficial cells are 
orange to pink, and intermediate and parabasal cells are turquoise green to blue. Some 
intermediate cells called navicular cells stain a yellowish colour due to a high keratin 
and glycogen content. Figure 1.11 shows a bright-field microscopic image of a negative 
ThinPrep® cervical smear at low magnification. 
 
Figure 1.11 Bright-field image of a Pap stained negative ThinPrep® cervical smear showing superficial cells 
with orange stained cytoplasm and intermediate cells with blue stained cytoplasm. 
 
1.4.1.2 Semi-automated screening systems 
Semi-automated screening systems consist of a highly automated microscope coupled to 
a computer that works on image interpretation. The “semi” nomination is due to the fact 
that none of the currently available systems provides fully automated screening without 
human intervention at some stage. In fact, in the majority of cases, the final decision 
still lies with cytology screener, not overcoming the subjectivity problem found in 
manual screening. 
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The procedure starts with the scanning of the slide and the identification of cells deemed 
useful for analysis by their separation from the surrounding “background” (such as 
inflammatory cells, cellular debris or overlapping cell clusters). Subsequently, image 
segmentation algorithms perform a separation of the nuclei from the cytoplasm of the 
cells allowing the calculation of morphometric parameters such as nuclear size, nucleus 
to cytoplasm ratio or even definition of the texture of the observed object (Birdsong 
1996; Desai 2009; Kitchener et al. 2011).  
From all the systems available, there are only two FDA12 approved automated 
machines, the FocalPoint™ GS Imaging system by BD Diagnostics and the ThinPrep™ 
Imaging system by Hologic, both represented in Figure 1.12.  
The FocalPoint™ GS Imaging system (Figure 1.12 A) initially called TriPath 
AutoPap® system, is able to process up to 144,000 SurePath™ slides annually, while 
the ThinPrep™ Imaging system (Figure 1.12 B) formerly known as Cytyc ThinPrep™ 
Imaging system can process 100,000 ThinPrep™ slides, if allowed to run continuously 
(Desai 2009; Kitchener et al. 2011).  
The FocalPoint™ can sort and rank the slides using the FocalPoint™ Slide Profiler 
(Figure 1.12 A (a)) without requiring a first stage of human intervention as needed for 
the ThinPrep™ Imaging system. Moreover, it is also able to process conventional smear 
slides (Desai 2009; Kitchener et al. 2011).  
Both systems are expected to double the productivity of cervical cancer screening 
(Desai 2009); and, despite reports that semi-automated screening systems increase 
sensitivity and specificity of Pap smear testing when compared to the manual screening 
                                                 
12 Food and Drug Administration agency of the government of the United States of 
America; responsible for protecting and promoting public health through products and 
medical procedures regulation. 
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method, a recent publically funded trial by the National Institute of Health Research 
(UK), found that automated reading was 8% less sensitive than manual, 6.3% in 
absolute terms. Furthermore, this allied with an uncertainty over cost-effectiveness, led 
to no recommendation being made on the implementation of semi-automated systems in 
screening programmes (Desai 2009; Kitchener et al. 2011). 
 
Figure 1.12 Automated slide screening systems. A - The FocalPoint™ GS Imaging system, (a) - FocalPoint™ 
Slide Profiler, (b) - Guided Screener Workstation, (c) – a screenshot of the screening window (IARC 2012a). B 
– The ThinPrep™ Imaging system, (a) - Image Processor, (b) - Review Scope, (c) – an example of the field of 
view with the guiding marker showing stained cervical cells (Franco et al. 2003).  
 1.4.2  HPV Testing  
HPV testing has recently been added to the range of clinical options for cervical cancer 
screening. The latest published inventory reported that there are a total of 193 distinct 
HPV tests commercially available and in excess of 120 variations (Poljak et al. 2016) 
which could be grouped into eight categories as follows: 
I. hr-HPV DNA screening tests 
II. hr-HPV DNA screening tests with concurrent or reflex partial 
genotyping for the main hr-HPV types 
III. HPV DNA full genotyping tests 
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IV. HPV DNA type- or group-specific genotyping tests 
V. HR-HPV E6/E7 mRNA tests 
VI. In situ hybridization DNA-based HPV tests 
VII. In situ hybridization mRNA-based HPV tests 
VIII. HPV DNA tests targeting miscellaneous HPV types 
However only 57% of these had at least one publication in peer-review literature and 
only 35.7% have their analytical/clinical performance documented (Poljak et al. 2016).  
For the sake of clarity, only the more widely used HPV tests are explained in more 
detail in the following subsections. Although, substantial research suggests that HPV 
testing could be cost-effective and an accurate primary screening method especially in 
women over 30 and it has indeed been recommended in some countries including in the 
UK;  much debate is still ongoing within the scientific and clinical communities about 
whether cytology could be replaced by HPV DNA testing as a primary screening tool 
(Dudding et al. 2015).  Highly sensitive and specific screening algorithms are still 
needed to identify all women at risk of developing cervical cancer and its precursor 
lesions, further research is still required (Brown et al. 2012a; Poljak et al. 2016). 
1.4.2.1 DNA-based HPV assays 
HPV DNA-based assays can further be divided into target-amplification methods like 
polymerase chain reaction (PCR) with consensus or type specific primers and HPV 
mRNA amplification; and, signal amplification methods such as liquid phase and in situ 
hybridization (Chan et al. 2012). 
The Hybrid Capture 2® (HC2®) test developed by Qiagen and approved by FDA in 
2003; was initially the most widely used. It is capable of detecting 13 different HPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) through the use of full 
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genomic probes complementary to HPV DNA, specific antibodies, signal amplification 
and chemiluminescent detection (Brink et al. 2006; Brown et al. 2012a).  
Hologic laboratories introduced to the market the Cervista® HPV HR test, also 
approved in 2003, capable of detecting the same 13 types as HC2®, and then the 
Cervista® HPV 16/18, approved in 2009, for specific detection of HPV types 16 and 
18. Both tests consist of applying an isothermal enzymatic DNA amplification process 
followed by fluorescent read out (Brink et al. 2006; Brown et al. 2012a). 
The cobas® HPV Test developed by Roche is an automated test which is able to 
identify HPV DNA from 14 high-risk types. The test specifically identifies types HPV 
16 and HPV 18 while concurrently detecting the rest of the HR types (31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 and 68) (U.S. Food and Drug Administration 2013). Cobas® 
is FDA approved since 2011 and in 2014 it became the first test to receive FDA 
approval for primary screening of cervical cancer. 
1.4.2.2 E6/E7 mRNA-based HPV assays 
As discussed in section 1.3.3, E6 and E7 are oncoproteins involved in cervical 
carcinogenesis.  The principle behind mRNA-based assays is that the detection of 
mRNA encoded by E6 and E7 may provide a better predictive value for malignant or 
high-grade lesions as it would establish not only if the virus is present but also if its 
proteins are being expressed.  
The PreTect HPV-Proofer (Norchip) and the NucliSENS Easy Q (BioMerieux) are 
based on the same technology but marketed under different brand names in different 
countries. Both systems detect E6/E7 mRNA from five HR-HPV types (16, 18, 31,33 
and 45) (Chan et al. 2012). 
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Providing a broader coverage, the APTIMA HPV Assay (Gen-Probe), FDA approved 
since 2012, targets mRNA from 14 HR-HPV types  (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68) (Chan et al. 2012).    
1.4.3 Colposcopy 
Colposcopy (Figure 1.13) is a medical procedure developed in 1925 by the German 
physician Hans Hinselmann. Usually suggested as follow up for an abnormal Pap test, it 
is based on the visual examination of the cervical and vaginal tissues using a 
magnifying colposcope – a binocular magnification of x4-12 that provides a three-
dimensional view of the cervix and the adjacent vagina (Leeson 2005). 
 
Figure 1.13 Colposcopic examination scheme (National Screening Unit 2016).  
 
The abnormal areas can be identified followed by the application of 3-5% acetic acid or 
Lugol’s iodine (Schiller’s test) on the cervix. The acetic acid causes the precipitation of 
nuclear and cytoplasmic proteins and, at the same time, induces cellular swelling that 
confers an opalescent/white appearance to dysplastic tissue while the Lugol’s iodine 
stains mature glycogen-containing tissue allowing the identification of unstained 
epithelium as columnar, immature or dysplastic (Leeson 2005). 
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Although the “whitening” level of the epithelium is assessed according to standard 
guidelines through a scale of 0, ½+, 1+ to 2+, its grading  is subjective and, if any 
abnormality is suspected, colposcopy directed punch biopsies may be taken or, in more 
severe cases, a loop excision performed  (Leeson 2005). Given its critical significance 
as primary onset site of cervical cancers, a careful visualization of the transformation 
zone is also mandatory (Abdel-Hady et al. 2006).  
Colposcopy can be considered a sensitive technique, about 92%, for identifying 
abnormal cervical changes; however, its specificity is reported to be approximately 
67%, requiring further diagnostic confirmation, usually through biopsy/histology 
(Cantor et al. 2008; Barut et al. 2015) 
1.4.3.1 Dynamic Spectral Imaging (DSI) 
Developed by Dr Balas (Balas et al. 1999), Dynamic Spectral Imaging represented in 
Figure 1.14, has been showing promising results through quantitative measurements and 
mapping of dynamic light-scattering characteristics of the cervical epithelium (Soutter 
et al. 2009; Louwers et al. 2011). 
The DSI system DySIS™ (Figure 1.14 A), is an imaging platform technology by 
DySISmedical® which aims to improve cervical cancer diagnosis (DySISmedical Ltd. 
2001). It was granted FDA approval and it is currently the only system recommended 
by NICE13 as a clinical and cost-effective option to aid standard colposcopy (National 
Institute for Health Care and Excelence (NICE) 2015). 
By enabling the detection and mapping of functional and structural alterations occurring 
in abnormal epithelial cells during the progression of the disease, DySIS™ aims to 
                                                 
13 National Institute for Health and Care Excellence is a non-departmental public body, 
part of the Department of Health in the United Kingdom, which makes 
recommendations to the National Health Service (NHS). 
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improve the in vivo examination of the cervix (Balas et al. 2008). It applies an image 
processing algorithm that measures the acetowhitening level, which can be highly 
correlated with the altered structure and functionality of the abnormal epithelium 
(Soutter et al. 2009).  
Parameters characterising the acetowhitening process are used to create a dynamic map 
(Figure 1.14 B) which is overlaid onto the colour image of the tissue and is used for 
grading of the lesion, diagnosis and/or screening (DySISmedical Ltd. 2001; Soutter et 
al. 2009). 
 
Figure 1.14 The DSI. A - The DySIS™ instrumentation, B – example of application of the DySIS™ to map the 
acetowhitening level (DySISmedical Ltd. 2001). 
 
Nevertheless, a recent study reported the DySISTM colposcopy system to be inferior to 
conventional colposcopy in detecting high-grade lesions and therefore was not 
recommended to replace conventional colposcopy with random biopsies (Roensbo et al. 
2015). 
1.4.3.2 LUMA™ Cervical imaging system 
As an adjuvant to colposcopy, the LUMA™ Cervical Imaging System (Figure 1.15) 
received market approval from the FDA in 2006. This system allows the examination of 
the cervix  based on the results of three combined optical measurements: fluorescence 
33 
 
excitation (337nm), white light backscattering (360-720nm) and video imaging 
(Kendrick et al. 2007). 
The cervix is scanned for 12 seconds while a 337nm ultraviolet nitrogen laser induces 
fluorescence, then two xenon flash lamps provide broadband white light in order obtain 
reflectance measurements and finally, a video system record the image. The measured 
spectra are afterwards analyzed by a multivariate classification algorithm which 
determines whether or not the tissue contains neoplastic changes and displays the results 
in 30 seconds (Kendrick et al. 2007).  
A colour overlay superimposed on the video image of the cervix indicates the areas with 
the highest degree of abnormality (Figure 1.15 B) thus guiding a more accurate 
colposcopic biopsy; which have shown to improve detection of more high-grade 
precancerous abnormalities (26%-33%) compared to colposcopy alone (Kendrick et al. 
2007). 
 
Figure 1.15 The LUMA™ Cervical Imaging System. A - LUMA™ console (Scranton Gillette Communications. 
2014), B – Image of the cervix utilising LUMA™ Cervical Imaging System to identifying high grade dysplasia 
(in blue), adapted from (Poliakoff 2012). 
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1.4.4 Histopathology 
Derived from the Greek words: “histos”, “pathos” and “logos”, meaning respectively 
tissue, disease-suffering, and study, histopathology is the evaluation of pathology at a 
tissue level (Orchard et al. 2012). It is the study of pathological processes in tissues by 
microscopic examination of stained tissue sections obtained from biopsy and/or surgical 
procedure (Quirk et al. 1999).   
The histopathological process begins with specimen collection, in other words, with the 
acquisition of tissue from the body. Two main methods can be used to tissue collection: 
biopsy or surgical removal. While surgical removal is typically performed to extract an 
already diagnosed tumour or malignant lesion, which, in many cases can reach the 
whole organ; biopsy is a less invasive procedure where only a small, representative 
sample of tissue is removed with preservation of the histological architecture. There are 
different types of biopsies according to the target tissue that consequently require 
different techniques and equipment (Bancroft et al. 2008).  
1.4.4.1 Cervical Biopsy 
Cervical biopsy is performed for diagnosis of cervical cancer and its precursor lesions; 
normally guided by colposcopy or a similar real-time imaging technique such as DSI. 
The most common types of cervical biopsy are punch biopsy to conform diagnosis prior 
to ablative therapy and, LLETZ (large loop excision of the transformation zone of the 
cervix), LEEP (loop electrosurgical excision procedure) and cone biopsy to excise 
abnormal tissue.  
Punch biopsy (Figure 1.16 a) uses a punch instrument for cutting and removing a disk 
of tissue from the cervical area appearing to be abnormal (white after swabbing with 
acetic acid) during the colposcopy examination. Cone biopsy (Figure 1.16 b) also 
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known as conisation, is the surgical procedure in which a cone-shaped piece of tissue 
from the cervix and cervical canal is removed (Cook 2006).  
 
Figure 1.16 Biopsy of the cervix a) punch biopsy, b) cone biopsy adapted from (Penn Medicine 2008). 
1.4.4.2 Fixation, Processing & Embedding 
After collection, the tissue is fixed in order to prevent degradation and preserve all its 
characteristics, ensuring it to be as similar to in vivo as possible; this normally occurs by 
submersion of the sample in a fixative solution for an optimal period of time. 10% 
formaldehyde is the most common fixative solution used in routine histopathology 
(Cook 2006; Orchard et al. 2012). 
After fixation, the specimen is then processed through several chemical solutions which 
prepare the tissues for embedding in a mounting medium – normally paraffin wax – that 
provides physical support for tissue sectioning (Orchard et al. 2012).  
1.4.4.3 Sectioning & Staining 
Tissue sectioning is performed on a microtome which allows micron (μm) thickness of 
sample to be cut. The section thickness relies on internal optimization and may differ 
according to different tissue types and their molecular constitutions; typically between 2 
and 7 μm for cervical samples. The section is then transferred onto a microscope slide to 
be stained (Orchard et al. 2012).  
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Different stains can be used to distinguish between different tissues and cellular 
components yet the primary and the most commonly used in histopathology is the 
Haematoxylin & Eosin (H&E) stain (Orchard et al. 2012). 
1.4.4.4 H&E stain 
H&E is based on the principle that the cell’s cytoplasm and nucleus have different 
acidic and basic properties; the cytoplasm and connective fibres stain with eosin and the 
nucleus stains with haematoxylin, allowing good nuclear detail (Bancroft et al. 2008).  
Haematoxylin is extracted from the heartwood of the logwood Haematoxylon 
campechianum tree and because it stains poorly itself, it is firstly oxidised to its 
haematein form which is then combined with a mordant, usually a metal salt, staining 
the tissue sections a deep blue to a black colour (Bancroft et al. 2008). 
The most common haematoxylins used are the aluminium ones that stain the nuclei red 
which is then converted into blue to black by washing the tissue in a weak alkaline 
solution, usually tap water. Harris’s haematoxylin is an example of this type of 
haematoxylin and it is also the most widely used, both regressively (over-stained and 
then differentiated) or progressively (for 1 to 3 minutes stopping the reaction when the 
desired intensity colour is achieved) (Carson 1990; Bancroft et al. 2008). 
After nuclear staining there is a counterstain of the cytoplasm and connective tissue 
with eosin because this is the most suitable stain to contrast with haematoxylin in order 
to demonstrate the general histological architecture of the tissue (Bancroft et al. 2008). 
Among all the eosins commercially available, the most widely used is eosin Y, a 0.5% 
or 1% solution in distilled water which gives varying shades and intensities of pink, 
orange and red to its staining components. After staining, dehydration is performed 
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through a series of alcohol concentrations, the section is then cleared in Xylene and a 
glass coverslip applied using a resin mounting media. (Bancroft et al. 2008). 
1.4.4.5 Diagnosis: Staging & Grading 
After staining and mounting, the histological slide is ready for examination under a light 
microscope by a trained pathologist. The diagnosis is formulated and a 
histopathological report enclosing any abnormal or important findings is available to 
clinicians and patients to consult (Cook 2006). 
The information generated by the histopathology procedure can be divided into 
diagnostic, staging and grading categories; and regardless which disease is diagnosed, a 
correct staging and grading is essential for an efficient treatment approach. In case of a 
cancer diagnosis, an accurate staging and grading is even more crucial as it will 
determine the disease prognosis and therapeutic decisions (Cross et al. 2011). 
Based on histopathological characteristics of the tissue, grading assesses the degree  of 
malignancy or aggressiveness of the abnormal cells by comparing various parameters 
such as cellular anaplasia, differentiation and mitotic activity with counterparts in 
normal cells and tissue (Yarbro et al. 2010). In general terms, a lower grade indicates a 
slower-growing cancer and a higher grade refers to a faster-growing cancer (NHS 
2012). The histological grades of cervical cancer are summarized in Table 1.3. 
Table 1.3 Cervical cancer grades adapted from (Sobin et al. 2009). 
Cancer 
grades Microscopic Characteristics 
Grade X Grade cannot be assessed 
Grade I Well differentiated Cancer cells resemble normal cells and are not growing rapidly. 
Grade II Moderately differentiated 
Cancer cells have features between grades I and III - they do 
not look like normal cells and are growing somewhat faster 
than normal cells. 
Grade III Poorly or undifferentiated 
Cancer cells that look more abnormal and grow or spread 
more aggressively. 
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Staging on the other hand, is probably the most important characteristic for treatment 
selection and evaluation, and is used to assess the extent of the disease. It also 
constitutes the most reliable information for prognosis as  it describes the size of a 
tumor and how much it has spread from where it originally started (Yarbro et al. 2010; 
Sobin et al. 2009). Table 1.4 details the staging guidelines in use for cervical cancer 
created by the International Federation of Gynecology and Obstetrics (FIGO) in 1995 
(Sobin et al. 2009).   
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Table 1.4 FIGO Staging for Cervical Cancer adapted from (Sobin et al. 2009). 
 
Stage 0 
Carcinoma in situ. 
  
Stage I 
Carcinoma is strictly confined to the cervix. 
 
Stage I A 
Invasive cancer identified only 
microscopically. Invasion is limited to 
measured stromal invasion with a maximum 
depth of 5 mm and no wider than 7 mm. 
Stage I A1 
Measured invasion of the 
stroma no greater than 3 mm in 
depth and no wider than 7 mm 
diameter. 
Stage I A2 
Measured invasion of stroma 
greater than 3 mm but no 
greater than 5 mm in depth and 
no wider than 7 mm in 
diameter. 
Stage I B 
Clinical lesions confined to the cervix or 
preclinical lesions greater than Stage IA. All 
gross lesions even with superficial invasion 
are Stage IB cancers. 
Stage I B1 
Clinical lesions no greater than 
4 cm in size. 
Stage I B2 
Clinical lesions greater than 4 
cm in size. 
Stage II 
Carcinoma that extends beyond the cervix, but does not extend into 
the pelvic wall. The carcinoma involves the vagina, but not as far as 
Stage II A 
No obvious parametrial involvement. Involvement of up to the upper two-
thirds of the vagina. 
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the lower third. 
 
Stage II B 
Obvious parametrial involvement, but not into the pelvic sidewall. 
Stage III 
Carcinoma that has extended into the pelvic sidewall. On rectal 
examination, there is no cancer-free space between the tumor and the 
pelvic sidewall. The tumor involves the lower third of the vagina. All 
cases with hydronephrosis or a non-functioning kidney are Stage III 
cancers. 
Stage III A 
No extension into the pelvic sidewall but involvement of the lower third of the 
vagina. 
Stage III B 
Extension into the pelvic sidewall or hydronephrosis or non-functioning 
kidney. 
Stage IV 
Carcinoma that has extended beyond the true pelvis or has clinically 
involved the mucosa of the bladder and/or rectum. 
Stage IV A 
Spread of the tumor into adjacent pelvic organs. 
Stage IV B 
Spread to distant organs. 
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1.5 Guidelines for cervical cancer screening programmes 
Despite the implementation of organised cervical cancer screening programmes 
throughout much of the developed world, there is no international strategy and different 
countries have different recommendations as to which screening methodology(ies) to 
use, the target population and referral intervals. There can also be wide-ranging 
guidelines within different parts of the same country as different trials are run in order 
to evaluate new procedures to improve performance and cost-effectiveness. Here, for 
the sake of clarity, the Republic of Ireland guidelines are presented along with those of 
the UK and United States of America (USA). 
1.5.1  Republic of Ireland 
CervicalCheck is the national cervical screening programme currently in place in the 
Republic of Ireland. Managed by the National Screening Service (NSS) and funded by 
the Department of Health through the Health Service Executive (HSE); the programme 
stated on September 1st 2008 and it provides free cervical screening through the means 
of cervical smear tests, to women aged 25 to 60 resident in the Republic of Ireland. 
Smear tests are provided every three years to women aged 25 to 44 and following two 
consecutive ‘no abnormality detected’ results, women aged 45 to 60 are screened every 
five years (The National Cancer Screening Service 2009). Figure 1.7 shows a flowchart 
of the screening process offered by CervicalCheck until 2015.  
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Figure 1.17 CervicalCheck Screening Process adapted from (The National Cancer Screening Service 2009). The 
actions taken by different partners are indicated by different colours with the programme office in black, 
smear-taker in green, cytology laboratory in red, colposcopy clinic in blue and histology laboratory in purple.  
ASC-US: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells of 
undetermined significance, cannot exclude high grade; AGUS: atypical glandular cells of undetermined 
significance; AGC: atypical glandular cells AGH: atypical glandular cells, favour neoplastic process. 
 
Since April 2015 HR-HPV testing is used as a triage test when atypical cells of 
undetermined significance (ASCUS) or LSIL cells are detected on cytology specimens. 
The HR-HPV test result is used to determine the recall recommendation; if HPV 
negative,  screening resumes as appropriate every 3 or 5 years; if HR-HPV positive, the 
women are referred to colposcopy. A cytological result of HSIL, atypical squamous 
cells, cannot exclude HSIL (ASC-H), atypical glandular cells (AGC), atypical glandular 
cells of undetermined significance (AGUS), or atypical glandular cells, favour 
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neoplastic process (AGH) are also referred to colposcopy without HR-HPV testing 
(CervicalCheck 2015a).  
1.5.2  UK - England and Northern Ireland 
A similar screening programme based on cytological evaluation of cervical smears with 
HR-HPV triage is also provided by National Health Service (NHS) England. The NHS 
cervical screening programme is available free of charge to women aged 25 to 64 
resident in England. Women aged 25 to 49 receive screening invitations every 3 years 
and women aged 50 to 64 every 5 years (Public Health England 2015). Following the 
review of the pilot sites data, the UK National Screening Committee recommended in 
January 2016 that HPV primary screening should be adopted by this screening 
programme (NHS Cervical Screening Programme 2016). Information regarding the new 
screening guidelines and implementation has not yet been released.  
In Northern Ireland, the cervical screening programme also offers cervical smears every 
3 or 5 years to women aged 25 to 49 years and 50 to 64, respectively. As in 
CervicalCheck, HPV triage is also used to further evaluate LSIL and ASCUS cytology 
results, with all other abnormal results being referred to colposcopy (HSC Public Health 
Agency 2013).     
1.5.3  USA  
In the United States of America, a National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP) is available to low-income, uninsured, and underserved women. 
In 2012 the American Cancer Society, the American Society for Colposcopy and 
Cervical Pathology and the American Society for Clinical Pathology issued joint 
guidelines to which screening method should be used in a particular population (Saslow 
et al. 2012). A summary of these guidelines is presented in Table 1.5. 
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Table 1.5 Summary of the cervical screening recommendations made by the American Cancer Society, the 
American Society for Colposcopy and Cervical Pathology and the American Society for Clinical Pathology, 
adapted from (Saslow et al. 2012). 
POPULATION RECOMMENDED SCREENING METHOD 
Aged < 21 years No screening 
Aged 21-29 years Cytology alone every 3 years 
Aged 30-65 years HPV and cytology co-testing every 5 years (preferred) 
Cytology alone every 3 years (acceptable) 
Aged > 65 years No screening following adequate negative prior screening 
After hysterectomy No screening 
HPV vaccinated Follow age-specific recommendations (same as unvaccinated women) 
1.6 Biomarkers  
As defined by the National Cancer Institute, a biomarker, also called a molecular 
marker or a signature molecule, is “a biological molecule found in blood, other body 
fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or 
disease” such as cancer that can also “be used to see how well the body responds to a 
treatment for a disease or condition” (National Cancer Institute 2016). 
There are a variety of biomarkers, from proteins (e.g. enzyme or receptor), nucleic acids 
(e.g. microRNA or other non-coding RNA), antibodies, and peptides, to mention but a 
few categories. Biomarkers can also refer to a collection of alterations, such as gene 
expression, proteomic or metabolomic signatures (Henry et al. 2012). 
Biomarkers are used in clinical and biomedical research to gain further knowledge of 
the underlying disease. A 2011 review reported that from the more than 1000 DNA and 
proteomic biomarkers discovered less than 100 have been validated for routine clinical 
practice (Poste 2011). 
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Biomarkers for the study of cancer remains one of the most interesting fields of 
biomedical research thus is in continuous innovation. The potential uses for cancer 
biomarkers are as follows: 
• Estimate risk of developing the disease; 
• Screening; 
• Differential diagnosis; 
• Prognostic determination; 
• Predict response to therapy; 
• Monitoring for disease recurrence; 
• Monitoring for response or progression in metastatic disease (Henry et al. 
2012).   1.6.1 Biomarkers in cervical cancer 
The limitations of current diagnostic strategies have accelerated the use of alternative 
and more objective methods as adjuncts to histopathology, aiming to overcome 
diagnosis difficulties (Martin et al. 2011).  
In cervical disease, the use of biomarkers in both cytology and histopathology has 
demonstrated the ability to reduce issues with false-positive and false-negative results, 
leading to an improvement in the positive predictive value of cervical screening results 
(Brown et al. 2012b).  The enormous advances in gene profiling and biomarker 
discovery technologies in recent years have led to the description of several molecular 
biomarkers for CIN and cervical cancer. Mostly involved in HPV-induced molecular 
alterations, some of these markers have already been tested and validated to identify 
dysplastic cells in cervical smear specimens, and therefore have potential to enhance 
and improve current screening performance and, in some cases, have therapeutic 
potential as well (Martin et al. 2011).  
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Although, the most extensively used and investigated are Ki-67 and p16, others like 
topoisomerase IIa (TOP2A), Survivin, MYBL2 and some of the minichromosome 
maintenance (MCM) markers also show promising results. Table 1.6 compiles the most 
promising biomarkers in the field with reference to their potential  clinical value  
(diagnostic or prognosis) as well as their reported sampling (histology and/or cytology 
samples) and the type of assay tested.  
Table 1.6  Most promising biomarkers for cervical cancer detection together with their clinical value and 
reported sample and assay type. 
Biomarker Clinical value Sampling Assay Type 
p16 Differential diagnosis of CIN 2+ 
Histology & 
cytology 
Immunohistochemistry/I
mmunocytochemistry 
p16/Ki67 Differential diagnosis of CIN 2+ Cytology 
MYBL2 Diagnosis of CIN Histology 
MCM 2/ TOP2A Diagnosis of HSIL Cytology 
Cytoactiv HPV 
L1 Capsid 
Protein 
Prognosis of LSIL Histology and Cytology 
Survivin Prognosis Histology 
p63/p73 Diagnosis of HSIL+ Cytology 
PIK3CA LSIL diagnosis Cytology 
Celldetect® Diagnosis of CIN Histology and Cytology Specialist stain 
 
1.6.1.1  p16INK4a (CDKN2A) and Ki-67 
p16INK4a is a cell-cycle regulator whose expression is tightly regulated in normal cells 
and is perhaps the most widely investigated biomarker for cervical cancer and its 
precursor lesions. 
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It is the product of the CDKN2A tumor suppressor gene; a cyclin-dependent kinase 
inhibitor protein involved in cell cycle regulation through the retinoblastoma complex 
(Murphy et al. 2005; Martin et al. 2011). 
In the absence of HPV, p16INK4a inhibits the cyclin-dependent kinases CDK4 and 6, 
which phosphorylate the retinoblastoma (Rb) protein. The binding of phosphorylated 
Rb (pRb) to the transcription factor E2F, blocks E2F and down-regulates the 
progression of the cell cycle through the G1-S transition checkpoint. However, in a 
transforming HPV infection, the viral oncoprotein E7 binds and inactivates pRb, 
thereby releasing E2F which promotes cell-cycle progression. Meanwhile, E2F is no 
longer controlled through action of CDK4 and 6 and p16INK4a, now with no effect on 
cell-cycle activation, accumulates in the cell nucleus and cytoplasm over time. The 
overexpression of p16INK4a at cellular levels can be detected by immunocytochemistry 
(ICC) and serves as a surrogate biomarker for persistent HPV infection (Martin et al. 
2011; Pinto et al. 2012; Brown et al. 2012b). 
It is widely accepted that p16INK4a is a sensitive and specific marker of dysplastic cells 
of the cervix and several studies have tested the application of  p16INK4a in cytology 
samples and, the majority have demonstrated the effectiveness for improving the 
cytological detection of HSIL (Pinto et al. 2012). 
Many antibodies have been tested in research studies in order to detect p16; however the 
E6H4 clone appears to be the most commonly used. 
Ki-67 is a nuclear protein expressed during all the phases of the cell cycle (G1, S, G2 
and M), except G0 - resting cells. While its function remains unclear, its expression 
appears to be an absolute requirement for progression through the cell division cycle; 
for that reason Ki-67 has been used as a cellular proliferation marker to help the 
diagnosis and prognosis of many pathologies (Martin et al. 2011; Brown et al. 2012b). 
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Although extensively used as an aid for CIN grading, it is not thought to be involved 
specifically in cervical cancer carcinogenesis or progression (Martin et al. 2011). Many 
studies have however reported that dual ICC of ki-67 and p16 using the CIN Tec PLUS 
kit (Roche) is useful to diagnose CIN2+ in cytology samples as it combines superior 
sensitivity and non-inferior specificity over Pap cytology alone (Ikenberg et al. 2013). 
More recently, it has been suggested this dual ICC could be especially useful in the 
triage of abnormal cytology in younger women where HPV testing has limitations.  
CINtec PLUS showed similar performance to  the Cobas 4800 HPV test in the 
prediction of HSIL among women with cytology diagnosed  LSIL (Possati-Resende et 
al. 2015). 
1.6.1.2  MYBL2 
MYBL2 or B-MYB is a member of the MYB proto-oncogene family which encodes the  
DNA-binding proteins involved mainly in cell proliferation and cellular differentiation 
(Ansieau 1997). 
Its transcription levels have been shown to be tightly regulated during the cell cycle by 
an E2F dependent mechanism, being of higher level only in late G1 and S phase which 
suggest that MYBL2 is involved in activating G1/S phase progression genes (Bessa et 
al. 2001; Martin et al. 2011). 
MYBL2 also appears to play a role in prevention of apoptosis and HPV16 affects its 
expression levels (Sala 2005; Lam et al. 1994).  
Different groups have shown MYBL2 to be over expressed in malignancies such as 
breast and colorectal cancer (Sheffer et al. 2009; Williams et al. 2009). The over-
expression of MYBL2 in cervical CIN and invasive cancer was not identified in normal 
cervical epithelial cells (Astbury et al. 2011; Martin et al. 2014). This is in agreement 
with previous microarray data that showed MYBL2 expression was absent from normal 
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cervix while present in CIN and cervical cancer, suggesting a potential role for the 
biomarker in histological diagnosis of CIN (Chen et al. 2003; Astbury et al. 2011).  
1.6.1.3  TOP2A & MCM2 – BD ProEx C 
MCM 2 functions during DNA replication loading the pre-replication complex onto 
DNA and unwinding DNA through helicase activity in order to permit DNA synthesis, 
while TOP2A is responsible for the enzymatic unlinking of DNA strands during 
replication. Consequently, these two proteins play an important role in the regulation of 
DNA replication during S-phase and are over-expressed whenever cell cycle induction 
is aberrant (Pinto et al. 2012). 
BD ProEx C is a protein-based biomarker reagent developed by BD Diagnosis 
(Burlington, NC, USA) that contains antibodies to both MCM 2 and TOP2A (Brown et 
al. 2012b). In the normal cervical epithelium, BD ProEx C staining is limited to the 
basal proliferating layer, but strongly present throughout a whole dysplastic epithelium. 
This is mostly due to the increased transcription of S-phase genes (aberrant S-phase 
induction) resulting from the action of HPV E7 oncoprotein (Brown et al. 2012b; Pinto 
et al. 2012). Created in 2006, this combined biomarker test was aimed to identify HSIL 
in cytological samples (Kelly et al. 2006). 
1.6.1.4  Cytoactiv HPV L1 Capsid Protein (L1) 
L1 is the name of the major capsid protein of the HPV family and is also the name of an 
antibody against a protein of the HPV16 capsid that is only expressed in early 
productive phase of the viral infection and therefore is progressively lost during cervical 
carcinogenesis (Hilfrich et al. 2008). This loss of L1 expression is believed to result 
from the integration of viral DNA into the human genome, which may occur by the 
disruption of the L1 gene or loss of its expression by segregating the viral promoter; or 
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an abnormality in the transcription pathways or in control of L1 protein translation 
(Sherman et al. 2006; McMurray et al. 2001). 
L1 stains predominantly the nucleus, although cytoplasmic staining can also be 
observed. And, as L1 capsid protein is one of the main targets for T cell-mediated 
immune response, cells with a lack of L1 synthesis may escape immune recognition, 
therefore allowing disease progression. Its inverse pattern of distribution along the 
evolutionary spectrum of SIL when compared to most of the other biomarkers discussed 
is in support of the notion that a progressive disease is more frequent in L1-negative SIL 
(Pinto et al. 2012; Griesser et al. 2009; Hilfrich et al. 2008; Rauber et al. 2008; Griesser 
et al. 2004). 
Griesser et al. reported that L1-negative cases tend to progress to HSIL, while L1-
positive cases do not. Since then, other groups have proposed the combination of L1 
and p16IKN4a biomarkers for a prognostic prediction of LSIL in LBC samples (Griesser 
et al. 2004; Hilfrich et al. 2008; Sherman et al. 2005; Ngureanu et al. 2010). 
1.6.1.5  Survivin 
The recently discovered member of the inhibitor of apoptosis proteins family, Survivin, 
is thought to have a role in cell death and division (Martin et al. 2011). 
Over expression of survivin is thought to be related with the degradation of p53 tumor-
suppressor proteins through interaction with HPV E6 oncoproteins and has been 
reported in a wide range of cancers including cervical cancer. It is associated with 
resistance to treatment  (chemoradiation followed by radical surgery) and increased risk 
of recurrence and poor survival (Altieri 2003; Santin et al. 2005; Borbély et al. 2006; 
Zannoni et al. 2014). 
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The expression of survivin protein and  mRNA increases in cervical pre-cancer with the 
severity of the dysplasia and it is also associated with high-risk HPV infection (Kim et 
al. 2002; Branca et al. 2005).  
1.6.1.6  p63/p73 
p63 and p73 are homologues of the p53 gene; multiple isoforms of proteins of both 
genes exist. Cheung et al conducted a study where antibodies anti-p63 4A4 (against 
isoforms TAp3 and ΔNp63 of p63) and Tap73 (against isoform TAp73α of p73) were 
tested in LBC samples. Using a scoring system, the authors concluded that 
immunoreactivity for Tap73 and p63 4A4, together with morphological assessment, 
could detect HSIL and cervical cancer. Moreover, p63 4A4 immunoreactivity in women 
with ASC-US and a high Tap73 index in women with LSIL correlated with a higher rate 
of progression to HSIL or above (Cheung et al. 2010). 
However, it is important to highlight that, similar to p16INK4a, p63 also stains the normal 
immature squamous cells present in atrophic samples and thus morphological 
evaluation is needed to minimize false positive results. These and other isoforms of p63 
and p73 should be further investigated (Cheung et al. 2010; Pinto et al. 2012). 
1.6.1.7  PIK3CA 
PIK3CA, composed of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit, is 
an important component of the lipid signalling pathway. Its subsequent activation of the 
downstream serine/threonine protein kinase has been reported to be related to ovarian 
cancer, squamous cell carcinoma of the head and neck, and uterine cervix 
carcinogenesis (Pinto et al. 2012; Redon et al. 2001).  
Goto et al. tested PIK3CA as a carcinogenic-related marker for cervical cancer in LBC. 
They concluded that Ki-67 and PIK3CA might be useful as adjuvant tools to HPV-DNA 
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testing; Ki-67 could relate to the growing potential of the cell whilst PIK3CA would act 
as a carcinogenesis-related marker for early disease (Goto et al. 2006).  
More recently, several studies have shown PIK3CA mutations to be frequent in cervical 
cancer (both adenocarcinoma and SSC) however the response to molecularly targeted 
therapies in different cervical cancer histology warrants investigation in clinical trials 
(Tornesello et al. 2014; Arjumand et al. 2016).  
1.6.1.8  CellDetect® 
CellDetect® (Zetiq Technologies Ltd, Israel) is a staining technique for cancer 
diagnosis. It has been shown to consistently differentiate cancer from normal and 
reactive tissues in histological and cytological preparations as well as cell lines 
(Idelevich et al. 2009; Sagiv et al. 2009). 
The stain targets the cytoplasm where non-neoplastic cells stain green/blue while 
neoplastic cells stain red/magenta. With these staining characteristics being presented 
even in small foci of neoplasia, CellDetect® allows a clear distinction of neoplasia from 
the surrounding tissue which can sometimes be difficult to achieve with common H&E 
(He et al. 2014).  
CellDetect® has been applied to cervical cancer research in both  histology and 
cytology specimens with the latest report showing a 95.36% sensitivity and 87.31% 
specificity for detection of  CIN+ and SCC on cytology specimens indicating a 
promising colorimetric biomarker tool for  disease diagnosis (He et al. 2014). 
1.6.1.9 DNA Methylation 
DNA methylation is a covalent chemical modification in which a methyl group is added 
to the DNA, usually to the fifth carbon ring, therefore modifying the function of the 
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genes. It is simultaneously the most common and significant epigenetic modification in 
the mammalian genome (Mersakova et al. 2015).  
The methylation of specific biomarkers has recently been suggested as a promising tool 
for cervical cancer diagnosis. It has been observed in other cancers such as breast 
(Zubor et al. 2008) and endometrial (Fiolka et al. 2013). Whilst cell adhesion molecule 
1 (CADM1), cadherin 1 (CDH1), death-associated protein kinase 1 (DAPK1), 
erythrocyte membrane protein band 4.1-like 3 (EPB41L3) family with sequence 
similarity 19, chemokine (CC motif)-like, member A4 (FAM19A4) myelin and 
lymphocyte protein (MAL), paired box 1 (PAX1), protease domain domain-containing 
14 (PRDM14), and telomerase reverse transcriptase (TERT) are among the most 
common methylating genes for samples with SSC and adenocarcinoma; in CIN, the 
methylation frequency was higher for the CADM1 gene, followed by CDH1, DAPK1, 
and TERT (Wentzensen et al. 2009). The most reliable panel seems to include genes 
from CADM1 and MAL with several groups testing its performance for cancer and CIN 
detection (Mersakova et al. 2015). Finally, alteration in the DNA methylation of death-
associated protein kinase 1 (DAPK1), retinoic acid receptor beta (RARB), Wnt-
inhibitory factor-1 (WIF1), and slit guidance ligand 2 (SLIT2) were reported to increase 
specificity of cervical cancer detection when compared to HPV testing (Siegel et al. 
2015). 
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1.7 Optical Spectroscopy  
As described in section 1.4 of this chapter, the current methods for diagnosis of cervical 
cancer hold several limitations. The cytological evaluation of Pap smears, for example, 
is subjective; HPV testing cannot inform on cellular abnormality; and colposcopy is too 
invasive to be used as a primary or co-screening method.   
Furthermore, the majority of biomarkers available are more extensively reported and 
optimized for histology specimens. Nevertheless, even when successfully applied to 
cytology specimens, only a limited amount of proteins (usually two) can be detect in the 
same sample before the stain becomes indistinguishable at microscopic evaluation. 
Optical spectroscopy methods such as vibrational spectroscopy (Raman and Infrared 
spectroscopy) probe the intramolecular vibrations and rotations of a sample when 
irradiated with light (Baker et al. 2016). The vibrations are dependent on the 
biochemical composition of the analysed sample and are therefore highly specific. 
Recent studies have shown both Raman and Infrared spectroscopy to be promising new 
biomedical tools for the diagnosis of cancer (Kong et al. 2015; Hughes et al. 2016). 
Infrared measurements display higher signal-to-noise (S/N) ratios and can be carried out 
over an entire cell in a few seconds, whereas Raman acquisition could take up to 100 
times longer, being usually used to sample a small part of the cell instead. Nevertheless, 
Raman spectroscopy has the advantages of allowing higher spatial resolution, as little as 
1 µm in diameter, and requiring minimal sample preparation; with biological specimens 
it also has the advantage of lower interference with water and not requiring expensive 
reflective substrates (Diem et al. 2008; Butler et al. 2016). Raman spectroscopy was 
therefore preferred for this study. 
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1.7.1  Raman Spectroscopy 
1.7.1.1 Theory 
The theory of Raman scattering or the Raman effect postulates that a small fraction of 
the radiation scattered by certain molecules differs from that of the incident beam, and 
that the shifts in the wavelength depend upon the chemical structure of the molecules 
responsible for scattering (Skoog et al. 1997).  
When interacting with a molecule, the incident photon may be absorbed or scattered. 
Elastic scattering, also called Rayleigh or Mie scattering occurs when the scattered 
photon is of the same energy as the incident photon.  Raman spectroscopy is however 
based on inelastic scattering phenomena when the energy of the scattered photon is of 
lower (Stokes scattering) or higher (anti-Stokes scattering) energy than that of the 
incident photon (Skoog et al. 1997; Ball 2001). A simplified diagram illustrating these 
concepts is presented in Figure 1.18.  
 
Figure 1.18 Energy level diagram for Rayleigh, Stokes and anti-Stokes scattering (Ostrowska 2011). 
 
In order for Stokes scattering to occur a molecule needs to be excited to a virtual energy 
level that comprises a distortion of an electron cloud so when it then returns to the first 
excited vibrational state, a photon with a lower energy (longer wavelength) is emitted. 
The energy difference between the incident and emitted photon excite the molecule to a 
higher vibrational state (Skoog et al. 1997; Gauglitz et al. 2003; Ball 2001). 
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In anti-Stokes scattering the molecule is in a higher vibrational energy level so when 
subsequently excited to a virtual energy level, relaxes, and returns to the ground 
vibrational state. In this case, the energy difference between emitted and excited photon 
is converted to radiant energy and a vibrational quantum has been annihilated (Skoog et 
al. 1997; Gauglitz et al. 2003; Ball 2001). 
For a molecular vibration to be Raman active, a change in net molecular polarizability 
must occur. The polarizability (α) represents the ability of an applied electric field, E, to 
induce a dipole moment, μ0, in an atom or molecule; a process represented 
mathematically by the equations below (Ball 2001): 
o Eµ α=  
Equation 1.1 Dipole moment. 
At the molecule’s nuclear geometry equilibrium the polarizability has a value, α0. In 
case of displacement, ∆r, away from the molecule’s equilibrium geometry, the 
instantaneous polarization α is given by: 
o rr
α
α α
∂ = + ∆ ∂ 
 
Equation 1.2 Instantaneous polarization at equilibrium displacement where 
r
α∂ 
 ∂ 
 represents the change in 
polarizability as a function of displacement. 
If the molecule is vibrating in a sinusoidal fashion, ∆r can be written as a sinusoidal 
function in terms of the frequency of the vibration, νs, and the time, t: 
∆𝑟 = 𝑟𝑚𝑎𝑥  𝑐𝑜𝑠(2𝜋𝑣𝑡) 
Equation 1.3  Equilibrium displacement when the molecule vibrates in a sinusoidal fashion where rmax is the 
maximum vibrational amplitude. 
Light of a particular frequency, νo, has an associated electric field, E, which also has 
sinusoidal behaviour: 
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( )max 0cos 2E E v tπ=  
Equation 1.4 Electric field where Emax is the maximum electric field frequency. 
Equations 1.1 to 1.4 can thus be written into equation 1.5 so that the first term 
represents the scattered phenomenon of a photon with the same intensity as the incident 
photon – Rayleigh scattering. The second term represents the Raman scattering of 
frequency v0+vs (anti-Stokes scattering) when the frequency of the scattered photon 
increases by molecular motion, vs; and v0-vs (Stokes scattering) when the frequency 
decreases.  
0 0 max 0 max max 0cos(2 ) cos(2 )cos(2 )s
dE t E r t t
dr
α
µ α πυ πυ πυ = +   
⇔ 
⇔ ( ) ( )( ) ( )( )max maxmax cos 2 cos 2 cos 22o o o o s o s
E rE v t t v v t v v
r
α
µ α π π π
∂ = + + + − ∂ 
 
Equation 1.5 Scattered light component frequencies by oscillating polarization in which v0 is the frequency of 
incident light and vs is the frequency of the scattered molecular motion.  
 1.7.1.2 Raman Spectrometer and Raman spectra 
Raman spectra are acquired by irradiating a sample with a powerful laser source 
(usually monochromatic visible, near-infrared or ultraviolet (UV) radiation) and 
measuring the scattered radiation with a suitable spectrometer (Skoog et al. 1997; Ball 
2001).  Figure 1.19 shows the process involved in collection of Raman spectra and the 
main components of a Raman spectrometer. 
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Figure 1.19 Schematic showing the process involved in Raman spectra collection. When the sample is 
illuminated by an incident monochromatic light, the majority of the scattered light is of the same wavelength - 
elastically scattered (green arrow). A notch filter is therefore used to block the elastically scattered light which 
would otherwise overwhelm the weak signal of the Raman or inelastically scattered light (orange arrow). The 
Raman scattered light may be dispersed according to wavelength through a grating and detected by a CCD 
(charge-coupled device) detector. A Raman spectrum is finally shown upon software analysis. 
Knowing the frequency of the incident light and measuring the frequency of the Raman 
scattered light, it is possible to calculate the vibrational energy difference. This energy 
is known as the Raman shift and is usually expressed in wavenumbers (cm-1) in a plot 
known as the Raman spectrum. Raman spectral features can be used as identification 
markers of particular substances as complex molecules have several specific vibrational 
energy modes allowing the Raman spectrum of each substance to be highly specific and 
distinctive (Sasic 2007). Figure 1.20 shows an example of a Raman spectrum recorded 
from a cervical cancer cell line, CaSki. The full spectral range is shown from 400-3500 
cm-1, including the fingerprint region, 400-1800 cm-1, which provides information on 
proteins, lipids and nucleic acids, and the high wavenumber region, 2800 – 3500 cm-1, 
which provides information on lipids and proteins.  
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Figure 1.20 Raman spectrum of cervical cancer CaSki cell line. The variation of Raman shift wavelength is 
expressed in wavenumbers (cm-1) and can be observed along the X-axis whilst the intensity is represented 
along the Y-axis. The fingerprint and the high wavenumber (HW) regions of the spectrum are indicated by the 
arrows. 
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1.8  Overall aims of the present study 
Despite the great success that the implementation of cytology based screening 
programmes had in decreasing disease mortality, the current LBC methods present great 
variability in the sensitivity rates reported (74 to 96%) with repetitive testing and cross-
checking needed to achieve the highest standard results (Kitchener et al. 2011). 
Furthermore, HPV testing, which is currently recommended as a co-test and even as a 
primary screening method in some countries (NHS Cervical Screening Programme 
2016), does not provide information with regards to cellular abnormality. Raman 
spectroscopy can theoretically offer a non-subjective, label-free biochemical fingerprint 
of the analysed samples with minimal sample preparation; and this present study aims to 
investigate the applicability of Raman spectroscopy to the diagnosis of cervical cancer 
and pre-cancer using LBC (ThinPrep®) samples from a screening population.  
Overall this thesis comprises a total of 9 chapters.  Chapter 1 is an introduction to 
cervical cancer and the current screening methodologies as well as the theory of Raman 
spectroscopy. Chapter 2 is a literature review of the application of Raman spectroscopy 
to the study of cervical cancer which has previously been published in a peer-reviewed 
journal. Chapter 3 describes all materials and methods used in this study as well as the 
sample databases used; the study’s results are presented in chapter 4 to 8, according to 
the specific aims addressed:  
• To establish the potential of Raman spectroscopy for liquid based 
cervical cytology samples to distinguish normal and CIN cytology; 
further investigating the best way to correct/minimize the substrate 
(glass) contribution to the sample spectra and the PCA-LDA 
classification algorithms (chapter 4). 
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• To assess the influence of age, HPV profile, menstruation cycle and 
previous disease history on the sample spectral profiles, probing if they 
can be inferred from PCA-LDA classification algorithms (chapter 5). 
• To evaluate the performance of PCA-LDA algorithms for both CIN and 
SIL reporting systems (chapter 6). 
• To further test the PCA-LDA classification models on an independent 
sample test set (chapter 7). 
• To determine the p16 and Ki-67 biomarker profiles of the samples by 
immunocytochemistry (chapter 8) 
Finally, a general discussion and future research directions are presented in chapter 9. 
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CHAPTER 2 CURRENT ADVANCES IN THE APPLICATION 
OF RAMAN SPECTROSCOPY FOR MOLECULAR DIAGNOSIS 
OF CERVICAL CANCER 
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This chapter was adapted from a peer-reviewed literature review article by Inês Raquel 
Martins Ramos, Alison Malkin, and Fiona Mary Lyng, entitled “Current Advances in 
the Application of Raman Spectroscopy for Molecular Diagnosis of Cervical Cancer” in 
BioMed Research International, vol. 2015, Article ID 561242, 9 pages, 2015. 
doi:10.1155/2015/561242. 
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2.1 Raman spectroscopy for biomedical applications 
Raman spectroscopy has been applied in numerous scientific fields, from chemistry and 
biochemistry to arts and archaeology, as a powerful spectroscopic technique which 
allows a spectral fingerprint capable of identifying and studying the structure and 
function of molecules, cells, tissues or materials (Krafft 2004; Baraldi et al. 2008). Its 
application to medical diagnostics has been of increasing interest in the past few 
decades (Diem et al. 2008). 
Raman spectroscopy has been reported for the detection of different types of 
pathologies including cancer (Kendall et al. 2009; Matousek et al. 2015; Kong et al. 
2015) .A number of studies concerning the investigation of cervical cancer with this 
particular vibrational spectroscopic technique have demonstrated its usefulness in 
understanding the disease progression at the molecular level. 
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2.2 Raman spectroscopy in cervical cancer research 
Raman spectroscopy has increasingly been reported in the cervical cancer literature 
since the late 1990s when the first exploratory experiments started to be documented. 
Table 2.1 compiles all the Raman spectroscopy studies concerning cervical cancer 
reported in the literature so far. All studies are referred to in the following sections 
which are grouped according to sample type. In vivo measurements relate to those 
acquired directly from the cervix of patients, ex vivo refers to the measurements 
acquired from the surface of biopsies and other surgical material extracted from the 
patient’s cervix, and in vitro refers to spectra obtained from cell lines.  Formalin fixed 
paraffin preserved (FFPP) histological sections and cytology are referred to separately. 
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Table 2.1 Raman spectroscopy studies concerning cervical cancer reported in the literature until November 2016 sorted by diagnosis (D), treatment response (R) and further 
conditions analysed. Sampling numbers and data analysis methodology are also indicated as maximum representation and discrimination feature (MRDF), sparse multinomial logistic 
regression (SMLR), principal component analysis (PCA), linear discriminant analysis (LDA), genetic algorithm-partial least squares-discriminant analysis (GA-PLS-DA), partial 
least squares-discriminant analysis (PLS-DA), Fisher’s discriminant analysis (FDA), principal component analysis logistic regression  (PCA-LR) and spectral analysis when no 
multivariate statistical method was reported. 
Sampling 
type 
Sampling 
numbers 
Year 
Authors (Research 
group) 
Raman 
spectroscopy 
[spectral 
region; laser 
used] 
Sort Category 
Data Analysis 
methodology 
Other considerations 
In vivo 
n=12 
Not disclosed 1998 
Mahadevan-Jansen et al. 
(Mahadevan-Jansen et al. 
1998a) 
Fingerprint 
region; 789nm 
D Spectral Analysis - 
25 2001 
Utzinger et al. (Utzinger et 
al. 2001) (Mahadevan-
Jansen group) 
1000-1800cm-
1; 789nm 
D Spectral analysis - 
66 2009 
Kanter et al. (Kanter et al. 
2009a) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D MRDF and SMLR Multiclass development 
31 2009 
Kanter et al. (Kanter et al. 
2009b) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D MRDF and SMLR Hormonal variation influence 
46 2009 Mo et al. (Mo et al. 2009) HW (2800- D PCA-LDA - 
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(Huang group) 3700cm-1) 
region; 785nm 
102 2009 
Kanter et al. (Kanter et al. 
2009c) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D MRDF and SMLR - 
172 2011 
Vargis et al. (Vargis et al. 
2011a) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D SMLR 
Normal variability and 
previous disease 
29 2011 
Duraipandian et al. 
(Duraipandian et al. 2011) 
(Huang group) 
Fingerprint 
region; 785nm 
D GA-PLS-DA 
Additional genetic algorithm 
techniques 
75 2011 
Vargis et al. (Vargis et al. 
2011b) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D MRDF and SMLR 
Investigation of normal 
patient variability 
44 2012 
Duraipandian et al. 
(Duraipandian et al. 2012) 
Fingerprint & 
HW (2800-
3700cm-1) 
region; 785nm 
D PLS-DA - 
26 2013 
Duraipandian et al. 
(Duraipandian et al. 2013) 
(Huang group) 
HW (2800-
3700 cm-1) 
region; 785nm 
- PLS-DA Vagifem treatment 
 26 2016 Shaikh et al. ((Shaikh et al. Fingerprint; D PCA-LDA - 
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2016) (Krishna group) 785 nm 
        
Ex vivo 
n=8 
20 1998 
Mahadevan-Jansen et al. 
(Mahadevan-Jansen et al. 
1998b) 
Fingerprint 
region; 789nm 
D FDA and PCA - 
150 2006 
Krishna et al. (Krishna et al. 
2006a) 
Fingerprint 
region; 785nm 
D PCA - 
66 2008 
Vidyasagar et al. 
(Vidyasagar et al. 2008) 
(Krishna group) 
Fingerprint 
region; 785nm 
R PCA - 
102 2008 
Keller et al. (Keller et al. 
2008) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
D MRDF and SMLR 
Investigation of temporal and 
spatial effects 
63 2008 
Martinho et al. (Martinho et 
al. 2008) 
Fingerprint 
region; 
1064nm 
D PCA-LR Cervicitis influence 
14 2010 
Kamemoto et al. 
(Kamemoto et al. 2010) 
Fingerprint 
region ;785nm 
D Spectral analysis - 
42 2013 
Rubina et al. (Rubina et al. 
2013b) (Krishna group) 
Fingerprint 
region; 785nm 
R PCA-LDA Chemo-radiotherapy 
 61 2016 
Daniel, et al. (Daniel et al. 
2016a) 
Fingerprint 
region ; 
D PCA-LDA - 
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Polarized,  
784.14 nm 
 Not disclosed 2016 
Daniel, et al. (Daniel et al. 
2016a) 
Fingerprint 
region ; 
Polarized,  
784.14 nm 
- PCA-KMA - 
In vitro 
n=5 
- 1999 
Yazdi et al. (Yazdi et al. 
1999) (Richards-Kortum 
group) 
600-2500cm-1; 
Resonance, 
257nm 
D Spectral analysis - 
- 2007 
Jess et al. (Jess et al. 2007) 
(Herrington group) 
Fingerprint 
region; 785nm 
D PCA - 
- 2010 
Ostrowska et al. (Ostroswka 
et al. 2010) (Lyng group) 
Fingerprint 
region; 532nm 
D PCA HPV influence 
- 2010 
Kim et al. (Kim et al. 2010) 
(Goodacre group) 
Fingerprint 
region; 830nm 
- Spectral analysis 
HPV16 influence (E6 
protein) 
In vitro & Cytology 50 2012 
Vargis et al. (Vargis et al. 
2012) (Mahadevan-Jansen 
group) 
Fingerprint 
region; 785nm 
- SMLR HPV detection 
Cytology 94 2013 Rubina et al. (Rubina et al. Fingerprint - PCA-LDA - 
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n=3 2013a) (Krishna group) region; 785nm 
 63 2014 
Bonnier et al. 
(Bonnier et al. 
2014) (Lyng 
group) 
Fingerprint ; 
532nm 
- PCA 
Protocol for evaluation of 
ThinPrep samples 
FFPP 
n=3 
18 2006 
Krishna et al. (Krishna et al. 
2006b) 
Fingerprint 
region; 785nm 
D PCA - 
60 2007 
Lyng et al. (Lyng et al. 
2007) 
Fingerprint; 
514.5nm 
D PCA-LDA - 
 20 2014 
Rashid et al.(Rashid et al. 
2014) (Lyng group) 
Fingerprint; 
785nm  
D 
PCA ; K-means cluster 
analysis 
- 
Cervical Fluids 
n=2 
9 2015 Choi et al. ((Choi et al. 
2015) 
Fingerprint; 
SERS, 785nm 
-  HPV detection  
9 2016 
Kim et al.  (Kim et al. 2016) 
(Choi group) 
Fingerprint; 
SERS, 785nm 
D  HPV and dysplasia detection 
Blood 
n=2 
plasma 110 2013 
Feng et al. (Feng et al. 
2013) (Huang group) 
350-1750cm-1; 
SERS, 785nm 
D PCA-LDA - 
serum 42 2013 
González-Solís et al. 
(González-Solís et al. 2013) 
Fingerprint 
region; 830nm 
D PCA - 
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2.2.1  In vivo - spectra recorded from the patient 
Mahadevan-Jansen et al. in 1998 were the first to report the Raman spectrum of cervical 
tissues and acknowledged the potential of Near Infrared (NIR) Raman spectroscopy to 
detect cervical pre-cancers amongst other pathologies. They developed a compact fibre-
optic probe which they used to record ex vivo and in vivo spectra (Mahadevan-Jansen et 
al. 1998b; Mahadevan-Jansen et al. 1998a).  
The overall ex vivo conclusions stated that in the Raman spectrum of squamous 
intraepithelial lesions, peaks attributed to collagen (1656, 1070 cm-1) consistently 
decreased in intensity while peaks assigned to phospholipids, DNA and glucose 1-
phosphate (1454, 1330, 978 cm-1) increased in intensity. Although the authors 
acknowledged these findings to be consistent with tumour progression, as the number of 
cells in the epithelium increases with lesion development, further evidence was 
recommended in order to quantitatively relate the differences in the tissue NIR Raman 
spectra to tumour biochemical changes. Furthermore, the application of multivariate 
methods to data analysis allows the differentiation of precancers from all other tissues 
with a sensitivity and specificity of 82% and 92% (Mahadevan-Jansen et al. 1998a). 
Their exploratory in vivo results appear to be in line with those observed ex vivo 
showing similar Raman spectra obtained in the fingerprint region (Mahadevan-Jansen et 
al. 1998b). The main differences reported were a band at 936 cm-1 only observed in 
vivo, a peak at 978cm-1 that was not consistently observed ex vivo and the amide band at 
1252 cm-1 that was more prominent in vivo.  The need to increase patient numbers was 
pointed out along with possible solutions towards in vivo technology improvement 
(Mahadevan-Jansen et al. 1998a). 
72 
 
With advances in fiber-optic technology by 2001, Utzinger et al. designed a more 
comprehensive study to assess the viability of Raman spectroscopy not only to detect 
but also classify cervical precancer lesions (Utzinger et al. 2001). A small clinical trial 
was undertaken using histopathology biopsies as the gold standard classification and it 
was concluded that useful Raman spectra could be acquired from in vivo sampling. The 
results showed agreement with their group’s ex vivo experiments (Mahadevan-Jansen et 
al. 1998b) with a consistent increase in Raman intensity of phospholipids and DNA 
assignments, ~1330, 1454 and 1650 cm-1 respectively, as the lesions progressed to high-
grade dysplasia (Utzinger et al. 2001). Despite these encouraging results the authors 
noted the heterogeneity of the tissue and thus the possible contribution of normal 
epithelial cells to the spectral data; they also suggested that further technological 
advances were once again needed to test the viability of large scale clinical trials 
(Utzinger et al. 2001). 
The influence of normal patient variability, hormonal variation and proximity to disease 
contributing to the accuracy of cervical cancer diagnosis by Raman spectroscopy has 
also been explored by the same group. 
Characterizing the hormonal changes, particularly menstrual cycle and menopausal state 
and introducing them into the in vivo diagnosis algorithm, Kanter et al. improved the 
accuracy of Raman spectroscopy to 94% (Kanter et al. 2009a) reaching  97 % for low-
grade dysplasia detection (Kanter et al. 2009b). With the main mean normal and low-
grade dysplasia Raman spectral differences observed within the 1230-1300 cm-1 range,  
the analysis of postmenopausal, perimenopausal, premenopausal normal cervix before 
and after ovulation showed subtle but consistent differences at 1250 cm-1 and 1300-
1320 cm-1, assigned to collagen and other cellular features like lipids, Amide III and 
nucleotides  (Kanter et al. 2009b).   
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Similarly, previous disease history and the proximity to malignant lesions were also 
shown to influence Raman spectral profiles. ‘True’ normal and ‘previous disease’ 
normal spectra do not appear to differ greatly, the principal qualitative differences were 
found in the 1200-1400cm-1 range with assignments to proteins and collagen type I 
being higher in ‘true’ normal spectra whilst the DNA and glycogen assignments (~1330 
cm-1) were higher in ‘previous disease’ normal Raman spectra (Vargis et al. 2011a). The 
1200-1400 cm-1 range was also found to comprise the most significant differences 
between Raman spectra of ‘true’ normal, ‘adjacent to disease’ normal, low-grade 
dysplasia and high-grade dysplasia. Collagen assignment was yet again higher in both 
‘true’ and ‘adjacent to disease’ normal whereas DNA was higher in low and high-grade 
dysplasia (Vargis et al. 2011a). 
In an attempt to further establish the greatest sources of intra-class variation among 
normal Raman spectra, Vargis et al. addressed race & ethnicity, body mass index 
(BMI), parity and socioeconomic status in their in vivo study. Their results concluded 
that BMI and parity were the only significant sources of separation within normal 
spectra. The influence on dysplasia and disease remains to be assessed as they were not 
investigated (Vargis et al. 2011b).  
Daniel et al. compared polarized and conventional Raman spectroscopy and reported 
additional information about the orientation of tyrosine, collagen and DNA molecules in 
cervical tissue. DNA/RNA assignments at 785, 1084, 1174, 1375 and 1578 cm−1 were 
found to be enhanced in cancer samples whereas collagen (817, 937, 1247, 1265, 1340 
and 1656 cm−1), glycogen (850 and 1022 cm−1) and lipids (968, 1032, 1057, 1087, 1264, 
1372 and 1445 cm−1) were characteristic of normal tissue samples. In addition, cross-
validated LDA of polarised Raman spectra was found to yield better accuracy, with 
96.7% of cases being correctly classified as either normal or cancer against 80.3% 
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accuracy using conventional Raman spectroscopy. The authors concluded polarized 
Raman spectroscopy therefore offers a better diagnostic potential than conventional 
Raman spectroscopy for the detection of cervical cancer and it warrants further 
investigation (Daniel et al. 2016a). 
Conventional Raman spectroscopy was also compared against diffuse reflectance 
spectroscopy (DRS) in a study by Rubina et al. Based on the elastic scattering process, 
DRS is able to detect changes in tissue morphology, vasculature, and chromophores; it 
has previously been reported to detect cervical cancer in real-time and non-invasive 
matter (Mirabal et al. 2002; Marín et al. 2005). In this in vivo study, the cervix of 26 
patients (20 cancer and 6 negative controls) was accessed with both Raman 
spectroscopy and DRS; PCA-LDA with LOPOCV was used to classify between cancer 
and normal sites. The overall accuracy (>91%) for the model generated by Raman 
spectral data was superior to that of DRS (>85%) and, although recommended for 
centralized facilities, the authors point out that the lower cost and easier handling of 
DRS might be more suited for cervical cancer screening in rural communities (Shaikh et 
al. 2016). 
2.2.2 Ex vivo – spectra recorded from excised patient tissue 
Krishna et al. reported Raman spectral differences between normal and malignant 
biopsy samples. Amide I, III and structural proteins such as collagen seemed to be 
characteristic of normal tissue whilst the presence of DNA, lipids and non-collagenous 
proteins dominated the abnormal spectral features (Krishna et al. 2006a). 
A Raman microspectroscopy study provided deeper insights by showing Raman 
spectroscopy could detect changes to adjacent regions of dysplasia or HPV infection 
that cannot be detected histologically. The average Raman spectra profiles from the 
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stroma below tissue presenting HPV associated histological changes show visible 
differences for DNA (1316 and 1334 cm-1) and glycogen (1048, 1083, 1256, 1333 cm-1) 
assignments. Whilst increased DNA levels and decreased levels of glycogen in the 
epithelium has been extensively described before as dysplasia progresses, Keller et al. 
argued that nothing was ever reported concerning alterations of the histologically 
normal stroma below diseased epithelium. Further differences at 1260 and 1304 cm-1 
Amide III band are proposed to be related to the angiogenesis process or the disease has 
extended without histologically visible effects (Keller et al. 2008). Either way, further 
study of this phenomenon is warranted as disease classification depends on stromal 
invasion.  
Martinho et al. investigated the role of cervicitis in Raman spectroscopy diagnosis of 
low-grade dysplasia. Despite an overall 93% sensitivity and a specificity of 85%, the 
results showed that the main spectral changes observed at 857, 925, ~1247, 1370 and 
1525 cm-1 vibrational bands made the cervicitis group fall mid-way between the normal 
and low-grade dysplasia groups and were intrinsically identified as dysplasia. Data 
showed that a severe inflammatory condition such as cervicitis makes the identification 
and correct diagnosis of early malignancy stages such as low-grade dysplasia difficult 
and must therefore be taken into account when developing the data analysis algorithms 
(Martinho et al. 2008). 
Finally a NIR micro-Raman spectroscopy study by Kamemoto et al. showed that 
Raman spectra from collagen bands at the low frequency 775-975 cm-1 region 
distinguish normal from cervical cancer cells, and is concordant with the analysis of C-
H stretching in high wavenumber (HW) region (2800-3700 cm-1) (Kamemoto et al. 
2010). 
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2.2.3 FFPP sections – spectra recorded from histological sections 
Raman spectroscopy studies have been undertaken on histological FFPP sections in 
parallel, further confirming Raman spectroscopy as a powerful informative tool in 
cervical cancer research. Archival FFPP material is extremely valuable as it allows 
retrospective studies to be undertaken after diagnosis and outcome is known.  
Krishna et al. studied formalin fixed cervical tissues by both Raman and FTIR 
spectroscopy, reporting the discrimination of malignant tissues through both techniques. 
In Raman spectra, differences in protein, lipids and nucleic acid peaks were observed 
along with stronger Amide III assignments suggestive of disordered, helical secondary 
structure of protein components in malignant conditions (Krishna et al., 2006).  
Further confirmation of the potential of Raman spectroscopy as a solid powerful 
diagnosis tool for cervical cancer was reported by Lyng et al. when their work 
demonstrated the viability of using formalin fixed paraffin preserved samples and 
investigated the underlying biochemical changes associated with cervical cancer (Lyng 
et al. 2007). Results showed glycogen bands at 482, 849 and 938 cm-1 are absent from 
carcinoma spectra which similar to previous reports show prominent nucleic acid bands 
(724, 779, 829, 852, 1002, 1098, 1240 and 1578 cm-1). An increase intensity of Amide I 
was also reported for carcinoma spectra (Lyng et al. 2007).    In 2014 our group further 
reported a Raman microscpectoscopy study on FFPP cervical biopsies.  Results showed 
Raman spectroscopy could distinguish tissues classified as negative for intraepithelial 
lesion and malignancy (NILM) from LSIL and HSIL tissues.  Furthermore, K-means 
cluster analysis (KMCA) allowed the differentiation of NILM cervical tissue into three 
clear epithelial layers, stroma, basal/para-basal and superficial, dominated by collagen, 
DNA and glycogen assignments respectively. For LSIL and HSIL samples, KMCA 
clustered the superficial layer together with the basal layer suggesting a loss of 
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differentiation in these groups. Furthermore, PCA showed that this feature could also be 
observed in normal areas of LSIL and HSIL samples where morphological changes 
were not yet apparent (Rashid et al. 2014).  
More recently, another study comprising the Raman micro-spectroscopy mapping and 
k-mean clustering analysis of normal cervix, including endocervical and ectocervical 
regions, neoplastic cervix and cervical carcinoma was also published by Daniel et al. 
NNLS was further used to extract chemometric information of the molecular 
components present in each tissue type. DNA, histone and cholesterol content were 
found to be increased in cancer as opposed to actin, beta-carotene, protein and collagen 
content which all decreased. Glycogen content in neoplasia was found to be lower than 
in normal tissue but increased slightly on progression to carcinoma (Daniel et al. 
2016b). 
2.2.4 In vitro – spectra recorded from cell lines 
Yazdi et al. described the use of UV resonance Raman spectroscopy at 257nm to 
distinguish between normal and malignant breast [MCF-10A, MCF-7 McGuire and 
MDA-MB435] and cervical [CrEc-Ec 4665 (primary culture from normal cervix 
epithelium), SiHa and HeLa] cultured cells. They reported an increase in DNA/protein 
ratio and a change in purine scattering in malignant cells that could allow the 
application of resonance Raman spectroscopy in cytology screening by monitoring 
DNA and RNA differences between normal and abnormal cells (Yazdi et al. 1999). 
Despite being the main aetiology factor in cervical cancer, HPV was only brought under 
Raman spectroscopy investigation towards the end of the last decade with a cell culture 
study by Jess et al. Raman microspectroscopy was applied to discriminate PHK 
(primary human keratinocytes), PHK E7 and CaSki cells, where PHK E7 cells express 
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the E7 gene of HPV16 and CaSki expresses HPV16. The mean Raman spectra showed 
variations at DNA and protein level, consistent with HPV gene expression and 
malignancy in both live and fixed cells. Together with principal component analysis 
(PCA) results, it proved Raman spectroscopy to be a valuable tool in identifying and 
characterizing the different stages of HPV-associated malignancies which is compatible 
with the current screening methods (Jess et al. 2007). 
Ostrowska et al. applied both FTIR and Raman spectroscopy to the study of cervical 
cancer cell lines. Their data suggest that HPV negative (C33a) and low HPV copy 
number (SiHa with 1-2 copies) cell lines are biochemically very similar whilst 
significantly different from mid (HeLa) and high (CaSki) HPV copy number cell lines. 
The main variations were encountered at protein, nucleic acid and lipid levels, and 
confirmed by both mean spectra and PCA analysis (Ostroswka et al. 2010). In the PCA, 
a discrimination of cell lines suggestive of HPV integration dependence constituted a 
major breakthrough compounding the potential of Raman spectroscopy to identify HPV 
induced biochemical changes (Ostroswka et al. 2010). 
Worthy of highlight is also a comparative study by Kim et al. of the distribution of 
intracellular components in cells expressing HPV16 E6 oncoprotein. The key finding of 
Raman mapping data suggests that E6 oncoprotein expression induces major phenotypic 
changes in the cells which are also targeted by an HIV antiviral drug – Indinavir, further 
acknowledging Raman spectroscopy as an powerful imaging technique (Kim et al. 
2010).    
Vargis et al. also reported Raman micro-spectroscopy to successfully detect HPV and 
differentiate among specific virus strains, in a complementary cell line and in vitro 
study with cellular pellets from cytology samples. Normal HPV negative cell line 
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NHEK was used alongside three cervical carcinoma cell lines: HPV positive (HeLa and 
SiHa) and HPV negative C33a.  Once again, specificity values of 89-97% for cell lines 
and 98.5% for cytology samples are extremely encouraging and confirm the enormous 
potential of Raman spectroscopy to provide an accurate differential diagnosis (Vargis et 
al. 2012). 
2.2.5 Cytology – spectra recorded from exfoliated patient cells 
Rubina et al. used Raman spectroscopy to distinguish between 49 cervical cancer and 
45 negative control cytology samples. Cellular pellets were generated from ThinPrep® 
material and subjected to Raman analysis.  Amide I (1660 cm-1), ∂CH2 (1450 cm-1) and 
phenylalanine (1002 cm-1) are the main features dominating the control Raman spectra 
whereas the spectra of cervical cancer samples was dominated by blood features such as 
fibrin (1570 cm-1) and heme (1620 cm-1). The profile loadings of the PCA-LDA (linear 
discriminant analysis) yield a classification efficiency of ~90% also suggestive of blood 
as the major discriminative factor between the two groups. As bleeding is a common 
occurrence in cervical infections, uterine cancer and menstrual cycle, 57 samples (28 
controls and 29 cancers) were further treated with RBC (red blood cell) lysis buffer 
prior to Raman acquisition. The absence of heme and fibrin bands confirms the effective 
removal of blood from the samples and makes evident an increase in protein content (at 
1006, 1450 and 1660 cm-1) and changes in their secondary structure due to positive 
Amide III bands. In this case the PCA-LDA analysis yields a classification efficiency of 
~80% which the authors suggest is comparable to the Pap test. Sample heterogeneity 
and the fact that the distribution of the abnormal cells in the cervical cancer specimens 
vary from 1-2% to 20-40% are suggested as the major causes of misclassification; the 
authors suggest further studies on pure cancerous and pre-cancerous specimens as a 
80 
 
means to build standard and validation models that could then be applied to blinded 
specimens (Rubina et al. 2013a). 
In 2014 a study by our group reported a protocol for the preparation of ThinPrep® 
samples for analysis by Raman spectroscopy (Bonnier et al. 2014).  The protocol 
suggested ThinPrep® samples should be submitted to a hydrogen peroxide (H2O2) 
treatment to remove the presence of blood residue which would otherwise be detected 
by Raman spectroscopy swamping the true signal of the cervical cells. Results showed 
that after treatment, the blood features were removed from the data without altering 
either the cell morphology or their spectral features. PCA of the spectral region between 
1150 and 1800 cm-1 showed clear separation between spectra from normal and CIN 3 
samples. This separation was dominated by assignments at 1381, 1426 and 1581 cm-1 
related to the DNA/RNA content of the cells. This work demonstrated the improved 
potential of Raman spectroscopy for the analysis of ThinPrep cervical cytology samples 
based on improved protocols for sample preparation (Bonnier et al. 2014). 
2.2.6 Cervical Fluids 
In 2015, Choi et al. reported the use of surface-enhanced Raman spectroscopy (SERS) 
to detect HPV infection in cervical fluids collected by centrifugation of saturated 
cervical brush (SurePathTM) used for smear collection. Results show different Raman 
spectral profiles between HPV positive (n=5) and HPV negative (n=4) patients. Raman 
acquisition from the central zone of the cervical fluid drop further allowed different 
HPV types (-11 & 35; 16; 18; 20 & 21; and 52) to be detected, with HPV16 and 18 
showing similar band patterns after 1000 cm-1 and dissimilar pattern before this spectral 
region (Choi et al. 2015). A more recent report by the same group described not only 
the detection of HPV infection but also of cervical dysplasia through SERS analysis of 
cervical fluids. Despite the limited number of samples (n=9), the results suggested it 
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was feasible to detect both HPV infection and cervical dysplasia with different Raman 
profiles based on HPV type. In healthy controls, the Raman spectra of cervical fluids 
displayed stronger intensities for symmetric C-C stretching and phosphate assignments 
at 877 and 963 cm-1 respectively; and for the C-H deformation modes at 1448 cm-1  
(Kim et al. 2016).  
2.2.7 Treatment response 
In their dual Raman and FTIR study, already mentioned in the FFPP section, Krishna et 
al. also presented data concerning Raman spectra after radiotherapy cycles, showing 
small changes, especially in antioxidant levels.  Hence, at the same time whilst 
validating the use of formalin fixed tissue for Raman spectroscopy analysis, it opens the 
door to research aimed not only at cervical cancer diagnosis but also prognosis and 
treatment response monitoring (Krishna et al., 2006).  
A further study to detect the response of radiotherapy was attempted by Vidyasagar et 
al. in an ex vivo pilot study (Vidyasagar et al. 2008). Tissues were collected after a 
second fraction of radiotherapy, classified based on clinical evaluation into complete, 
partial and no response, Raman spectra were then acquired and compared against the 
malignant spectra through PCA. The authors concluded that PCA results provided a 
clear separation between responding and non-responding samples as well as between 
complete and partial radiotherapy response. Such results indicate the potential of Raman 
spectroscopy in early radiotherapy response prediction (Vidyasagar et al. 2008).   
In a more recent ex vivo study, Rubina et al. explored the feasibility of fibre-optic-based 
Raman spectroscopy in predicting tumor response to concurrent chemoradiotherapy 
(CCRT) through a PCA classification pattern which also showed encouraging results 
despite needing a  greater body of evidence (Rubina et al. 2013b). 
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A study Duraipandian et al. confirmed Raman spectroscopy as a broad diagnosis and 
treatment assessment tool not only for cervical cancer but also to help in other 
conditions and possibly in the gynaecology clinic. HW Raman spectroscopy was used to 
non-invasively, in vivo, assess the effect of Vagifem treatment in women (Duraipandian 
et al. 2013). The conclusions indicated that a bimolecular Raman spectroscopy model 
can not only successfully identify hormone/ menopausal related changes in cervical 
epithelium, but also assess the effect of Vagifem treatment during colposcopic 
inspections as the protein and lipid Raman signals increase after treatment and start to 
resemble pre-menopausal values (Duraipandian et al. 2013).  
2.2.8 Improving data analysis & recording 
The refinement of subtleties on the overall sensitivity and specificity of Raman 
spectroscopy for in vivo diagnosis of cervical cancer has also led researchers to address 
better statistical analysis algorithms and methods.  
A study by Kanter et al. explored binary and multiclass discrimination algorithms to 
analyse Raman spectroscopy data: maximum representation and discrimination feature 
(MRDF) and sparse multinomial logistic regression (SMLR). It concluded that although 
both provide an improvement over the current method of diagnosis – colposcopy-guided 
biopsy (with sensitivity of 87% and specificity of 72%), the use of a multiclass 
algorithm improves the overall Raman spectroscopy sensitivity from 92% to 98% and 
the specificity from 81% to 96% thus advocating that the key benefit of multiclass 
algorithms for the prevention of misdiagnosis can overcome the downside of more 
complex implementation (Kanter et al. 2009c).  
Similarly, the use of genetic algorithm techniques to complement Raman spectroscopy 
data was also proposed and explored by Duraipandian et al. through the application of 
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genetic algorithm-partial least squares-discriminant analysis (GA-PLS-DA) with double 
cross-validation (dCV). By employing a GA-PLS-DA algorithm which used significant 
Raman bands selected from 925-935, 979-999, 1080-1090, 1240-1460, 1320-1340, 
1400-1420 and 1625-1645 cm-1, a 72.5% specificity and 89.2% sensitivity for pre-
cancer detection was achieved and could therefore be further investigated as a feasible 
alternative to current PCA methods (Duraipandian et al. 2011). 
Still in the in vivo context, modifications in the recording process have also been 
considered and reported in the literature.  
HW Raman spectroscopy, 2800-3700 cm-1, was successfully described by Mo et al. 
with 93.5% and 97.8% diagnostic sensitivity and specificity respectively (Mo et al. 
2009). The results showed that the intensity of the Raman signal within the 2800-3035 
cm-1 range, which comprises proteins and lipids, from dysplastic tissue, is significantly 
lower than observed for normal tissue. An increase in the vibrational signal of water 
from the dysplastic tissue was also observed and in line with that reported with FTIR 
spectroscopy (Kondepati et al. 2008; Hornung et al. 1999). The authors further support 
these observations with literature concerning the increase of aquaporins at the dysplastic 
cell membrane and the fact that higher DNA levels or hydration of DNA due to the 
unfolding step in cell division could also account for this observation (Mo et al. 2009).    
Simultaneous fingerprint and HW Raman spectroscopy has also been described by 
Duraipandian et al. who acknowledged their complementary potential and ability to 
improve early disease detection. The results showed a significant intensity increase in 
dysplastic tissue spectra at 1001, 1095, 1313 and 3400 cm-1 along with a decrease at 
854, 937, 1445, 1654 and 2946 cm-1. The sensitivity and specificity values of 85% and 
81.7% respectively for integrated fingerprint and HW Raman spectroscopy were shown 
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to be higher than those of fingerprint or HW Raman spectroscopy alone (Duraipandian 
et al. 2012).  
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CHAPTER 3 MATERIALS AND METHODS 
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3.1  Samples 
3.1.1  Sample reception and database construction 
3.1.1.1 Modelling set database 
A total of 98 negative, 43 CIN1, 23 CIN2 and 34 CIN3 cytology samples were received 
from Altnagelvin Hospital, Northern Ireland. As per ethical approval (Appendix 1) the 
samples received consisted of one unstained ThinPrep® slide per case, accompanied by 
clinical information regarding the final cytological diagnosis, patient’s age, HPV test 
result (as appropriate), previous disease history, date of last menstruation period (LMP) 
(if available) and collection date.  
Some of the samples received were considered unsuitable for Raman spectroscopy due 
to insufficient cellularity and/or masking effects of debris which can be common when 
the ThinPrep® slide is obtained from the end of the collection vial. From the 32 samples 
considered unsuitable for Raman spectroscopy, 10 were negative, 8 CIN1, 2 CIN2 and 
12 CIN3. Appendix 3 compiles all the samples considered in this study and respective 
clinical information. 
3.1.1.2  Independent test set database 
A total of 39 negative, 20 CIN1, 9 CIN2 and 10 CIN3 cytology samples were received 
from Altnagelvin Hospital, Northern Ireland. Like the modelling set samples, each test 
set sample received consisted of one unstained ThinPrep® slide per case, accompanied 
by clinical information regarding the final cytological diagnosis, patient’s age, HPV test 
result, previous disease history, LMP and collection date. The test set samples were 
subjected to the exact same protocols as the modelling set samples. 
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Similar to the modelling set, some of the samples received were considered unsuitable 
for Raman spectroscopy  due to insufficient cellularity and/or masking effects of debris 
as a result of the ThinPrep® slide being collected from the end of the collection vial. 
From the 31 samples considered unsuitable for Raman spectroscopy, 12 were negative, 
11 CIN1, 3 CIN2 and 5 CIN3.  All the test set samples considered in this study as well 
as their clinical information are as indicated in Appendix 4. 
3.1.2  Hydrogen peroxide (H2O2) Treatment 
Following reception, as per in-house protocol (Bonnier et al. 2014), all samples were 
treated with hydrogen peroxide (H2O2)  (Sigma-Aldrich, UK ) for 10 minutes at room 
temperature to clear the samples from blood and debris. Samples were then air-dried in 
a fume hood, at room temperature for a minimum of 24 hours prior to Raman 
spectroscopy. 
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3.2  Raman spectroscopy  
Raman spectroscopy measurements presented in this study were performed on an 
XploRA (Horiba Jobin Yvon) system represented as shown in Figure 3.1 operating with 
a 532nm laser.  
 
Figure 3.1 Xplora (Horiba Jobin Yvon) confocal microscope. 
 
3.2.1  Calibration Procedures 
Daily calibration of the system was carried out according to the in-house standard 
operating procedure (SOP) developed by Lyng and Bonnier (Appendix 5). The system 
was calibrated to the 520.7 cm-1 spectral line of silicon. Dark current, reference 
spectrum of polystyrene (from a clean petri dish lid) and laser intensity were also 
monitored. 
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3.2.2 Measurements’ Settings 
Raman measurements were performed using a HORIBA Jobin Yvon XploRATM system 
(Villeneuve d’Ascq, France), described earlier in this section. To avoid any photo 
damage to the sample, the power of the laser was set at 50% (~7.5mW). The confocal 
hole was set at 100µm and the 1800 lines/mm grating was used, which gave a spectral 
dispersion of ~3 cm-1 per pixel. The backscattered light was collected using an air-
cooled CCD detector (Andor, 1024 x 256 pixels) and the spectrometer was controlled 
by Labspec V5.0 software.  
Raman signals from each cell nucleus were integrated twice for 20 seconds in the 
spectral range of 400-1800 cm-1. Manual focus (Z plane) was used to minimise substrate 
contribution to the nuclear spectra which was acquired from the centre of each nuclei. 
Spectra from a minimum of 10 cell nuclei were recorded per sample, depending on the 
quality of each slide.  The data is presented as the average of all 10 cellular spectra 
recorded from each individual patient. Figure 3.2 shows a cervical ThinPrep® sample as 
presented upon Raman microscopy.  
For negative samples in the modelling set, cells were selected at random whereas for 
CIN samples abnormal looking cells were chosen based on their morphology.  All test 
set samples were recorded in a similar fashion. 
 
 
 
   
Figure 3.2 Negative ThinPrep® cervical cytology sample as presented upon Raman microscopy.  
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3.3 Statistical Techniques 
3.3.1  Pre-processing Procedures 
Data analysis was performed in Matlab [Mathworks, CA, USA] according to protocols 
developed in house (Bonnier et al. 2014; Bonnier et al. 2012). Pre-processing of the raw 
Raman spectra included the application of a Savitsky-Golay filter (5th order, 13 points) 
to smooth the spectra. The data set was also corrected for baseline and vector 
normalized to facilitate comparison. 
3.3.2 Glass correction methods 
3.3.2.1 [1200-1800 cm-1] Spectral Range 
In this model, the recorded spectral range of 400-1800 cm-1 was cut and only the 
spectral range between 1200-1800 cm-1 was considered for data analysis; thus leaving 
out of the data analysis the major regions where glass spectral features can be observed 
around 550 and 1100 cm-1. 
3.3.2.2  Iterative glass correction method  
This in-house model (Bonnier et al. 2014) reduces the intensity of a given glass 
spectrum by a factor of 10 which is then sequentially subtracted from the cellular 
spectrum until the ratio between the phenylalanine peak (~1005 cm-1) and the main 
glass peak (~1093 cm-1) is equal or less than 1.5. This ratio was established by Bonnier 
(unpublished data 2011) by recording cervical cells on calcium fluoride slides. 
3.3.2.3  Non-negative least squares (NNLS)   
This in-house model (Ibrahim et al. 2016) considers the spectral data obtained as linear 
functions resulting from the underlying cellular components and the glass substrate. 
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 It aims to reconstitute a vector x that explains the observed spectra as well as possible, 
based on known observations. So, given the spectra obtained and a set of known 
observations such as a matrix of (1) glass recorded from the 166 model set samples 
considered in the study and (2) a selection of cellular components listed in Table 3.1; it 
is possible to find a nonnegative vector that estimates the contribution of these known 
observations to the spectra. The known observations are then multiplied by the 
nonnegative vector before being subtracted from the initial spectral matrix, correcting 
for the glass contribution. 
Table 3.1 Cellular components used for the NNLS model. 
Cellular component 
DNA 
RNA 
Cholesterol 
Collagen 
Glutathione reductase 
Glutathione oxidase 
Acetic acid 
Phosphatidylinositol 
Myrestic acid 
Steric acid 
Phosphatidylserine 
Phosphatidylethanolamine 
Thymidine 3.3.3 Principal Component Analysis (PCA) 
Principal component analysis (PCA) is a statistical method widely used in exploratory 
analysis and model prediction. Developed in 1901 by Karl Pearson (Pearson 1901). It is 
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an unsupervised data reduction technique that allows the user to identify variances 
within the dataset that may be used to classify objects into certain groups. 
PCA involves the calculation of the eigenvalue decomposition of a data matrix, usually 
after mean centring the data for each attribute. The results of a PCA are usually 
discussed in terms of component scores and loadings (Martens et al. 1989).  
In Raman spectroscopy, PCA is used to reduce the matrix of spectral data in which 
objects (individual spectra) are measurements of a large number of variables 
(wavenumbers), whilst retaining most of the variation within the dataset. It works by (1) 
subtracting the mean of the dataset to obtain the mean centred matrix, (2) calculating the 
covariance matrix (linear relationships between the individual spectra) of the mean 
centred matrix and (3) finding the eigenvectors and eigenvalues of the covariance 
matrix (Gautam et al. 2015).  
The eigenvector with the highest eigenvalue explains the most variance in the data set 
and is called the first principal component (PC). The first PC therefore describes the 
largest source of variance across all the spectra, the second PC the next largest source of 
variance and so on, with all PCs describing mutually independent sources of variance in 
decreasing proportions of spectral variance (Gautam et al. 2015; Bonnier et al. 2012). 
Generally, the first three PCs represent the highest variance present in the data sets, up 
to 99%, therefore allowing the best visualisation of the differentiation of the data set 
clusters.  However when recording Raman data from single cells, the noise present in 
the spectra can increase the intragroup variability, thus reducing the specificity of the 
PCA; in such cases, typically the first 10 PCs can be taken into account for specific 
analysis (Bonnier et al. 2012; Varmuza et al. 2009). 
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3.3.4  Principal component analysis – linear discriminant analysis (PCA-
LDA)  
Linear discriminant analysis (LDA) (Rao 1948) is a classification method that aims to 
find linear functions in a dataset which can then be used to classify the data in two or 
more classes. It produces a line or hyperplane that represents the maximum separation 
of two or more classes in the dataset.  
Whereas unsupervised PCA looks for projections to maximize overall variance, 
supervised LDA looks for projections to maximize the variance ratio of inter to intra-
class. LDA can be used in conjunction with PCA, in PCA-LDA, where it uses PCA 
scores as latent variables and tries to find the linear hyperplane that discriminates 
between the two or more populations of PCA scores (Gautam et al. 2015).   
3.3.5  Leave one patient out cross validation (LOPOCV) 
Cross validation of any spectral classification models is important firstly to avoid over 
or under-fitting the model due to inappropriate selection of the components used, and 
secondly to determine the prediction error of the model.   
In leave one patient out cross validation (LOPOCV) one observation is excluded at a 
time from the training set and the resulting model is evaluated on the left out 
observation. The procedure is repeated for all observations in the data set and the 
average performance across all interactions is considered the performance of the 
classification model (Gautam et al. 2015). 
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3.4  Immunocytochemistry (ICC) 
3.4.1  CINTec® PLUS kit dual staining 
The CINTec® PLUS kit (Ventana for Roche, Ireland) is an immunocytochemistry 
(ICC) assay for the simultaneous detection of p16IKNK4a and Ki-67 antigens in cervical 
cytology preparations. The interest of these antigens in cervical cancer diagnosis 
research has already been discussed in depth in Biomarkers section 1.6 (chapter 1). 
The CINTec® PLUS kit works on the principle that the simultaneous expression of 
p16IKNK4a and Ki-67 can be used as an indicator of transformed cell status as virtually all 
high grade CINs have been shown to over-express p16IKNK4a and a high proportion of 
epithelial cells in CIN lesions show proliferative activity. 
The kit includes a primary antibody cocktail comprising a mouse anti-human p16IKNK4a 
antibody and a rabbit anti-human Ki-67 antibody, which are then revealed by a 
horseradish peroxidase (HRP) polymer conjugated goat anti-mouse and an alkaline 
phosphatase (AP) polymer conjugated goat anti-rabbit secondary antibodies 
respectively. Figure 3.3 shows the mechanism of detection utilized in the CINTec® 
PLUS kit. A positive reaction will result in simultaneous brown cytoplasmic and red 
nuclear staining. 
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Figure 3.3 CINTec® PLUS detection mechanism. The individual antigens are first detected by the primary 
antibodies which are then bound by the secondary antibodies. Secondary antibodies are HRP and AP polymer 
conjugated which allows them to be revealed by reaction with hydrogen peroxidase & DAB and naphthol 
phosphate & fast red, respectively. The HRP reaction results in a brown precipitate which allows the detection 
of p16 in the cell cytoplasm whilst the AP reaction results in a red precipitate which allows the detection of 
Ki67 in the nucleus.  
Before staining all samples were hydrated for an hour in dH2O, after which ICC was 
performed as per the manufacturer’s guidelines. High temperature antigen retrieval (pH 
9.0) was performed in a water bath at 95oC for 10 minutes followed by a 20 minute cool 
down period. The kit peroxidase blocking reagent was applied to block the endogenous 
peroxidase, and the solution containing both primary antibodies incubated for 35 
minutes, both at room temperature (RT). The HRP visualization reagent was then 
incubated for 35 min followed by AP visualization reagent for 35 minutes. Finally the 
3,3'-diaminobenzidine (DAB) working solution was applied, followed by the fast red 
working solution both for 15 minutes at RT. Four drops of the CINTec® aqueous 
mounting medium were applied to each sample and allowed to dry overnight before the 
slides were mounted using DPX as a mounting medium. Protocol was optimised from 
manufacture’s guidelines available in https://pim-
eservices.roche.com/eLD_SF/gb/en/Documents/GetDocument?documentId=af58dbf3-
38f5-e311-98a1-00215a9b0ba8&referrer=Dialog.   
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3.5  Pap stain  
The Pap stain is the “gold standard” stain for gynaecological cytology. All the samples 
not subjected to ICC were Pap stained according to in-house optimised protocol. All 
reagents were purchased from Sigma-Aldrich, UK. Firstly the samples were hydrated 
for an hour in dH2O before staining. After this they were rinsed in tap water and 
submerged in Harris' haematoxylin for 3 minutes. The samples were then rinsed in tap 
water and in 95% ethanol for 2 minutes. OG-6 stain was applied for 1.5 minutes, 
following which the samples were again rinsed in 95% ethanol for 2 minutes before 
being stained with EA-50 for 2.5 minutes. The samples were then rinsed twice in 95% 
ethanol for 2 minutes before being placed in 2 changes of 100% ethanol for 3 minutes 
each and cleared in 2 changes of xylene of 5 minutes each. Finally the samples were 
mounted using DPX as the mounting medium. Figure 3.4 shows a cervical cytology 
sample after Pap stain. 
 
Figure 3.4 Pap stained negative Thinprep slide showing parabasal (black arrowheads), intermediate (solid 
arrows) and superficial (dashed arrows) cells and white blood cells (red arrowheads). 
  
  
X100 
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3.6 Light Microscopy 
For the microscopic evaluation of both ICC and Pap stain samples an upright an 
Olympus BX60 microscope was used. Images were captured using a digital camera and 
software program Capture Pro v8.0 (MediaCybernetics, UK), where they were saved 
without further manipulation. 
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CHAPTER 4 EVALUATION OF SUBSTRATE CORRECTION 
METHODS FOR RAMAN SPECTRA RECORDED FROM 
THINPREP® CERVICAL CYTOLOGY SAMPLES  
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This study is part of on-going technology development research that aims to use Raman 
spectroscopy in the clinic to screen and diagnose cervical pre-cancer. For this reason, 
the substrate chosen and used for our samples had to be the commonly used ThinPrep® 
glass slide. Although routinely used in the clinic and significantly cheaper than other 
substrates used for spectroscopy (eg. calcium fluoride), ThinPrep® glass slides pose a 
greater challenge to the data analysis due to the strong glass contribution to the cellular 
spectra. Moreover, although the spectrum obtained from the glass substrate is similar 
across all sample groups (Figure 4.1), the glass contribution to the cellular spectra is 
not. Due to their bigger and flatter nuclear morphology, the average spectra of CIN 1 
samples (magenta) for example have more pronounced glass features indicated by the 
arrows in Figure 4.2 than the spectra of normal cells (green) which present with small, 
round, pyknotic nuclei.  
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Figure 4.1 Mean Raman spectra of the ThinPrep® glass substrate recorded from all sampling groups. ; 
negative (green,) CIN  1  (magenta,) CIN 2 (red) and CIN 3 (black.) 
 
 
Figure 4.2 Mean Raman spectrum and SD (shadowing) obtained for each sampling group. Negative samples 
are represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. Arrows 
indicate the areas where the glass substrate contribution is visible. Highest contribution of glass spectral 
features can be seen in the average spectra of CIN 1 samples.   
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4.1  Uncorrected spectra for glass substrate 
The raw Raman spectra were smoothed by the application of a Savitsky-Golay filter (5th 
order, 13 points), baseline corrected and vector normalized to facilitate comparison. The 
mean Raman spectrum and standard deviation (SD) obtained for each sampling group 
recorded are shown in Figure 4.2. Strong contribution from the glass substrate can be 
observed, especially around 550 cm-1 and 1095 cm-1 as indicated by the arrows.  
It can be inferred that glass contribution is not of the same magnitude (1) across all 
sampling groups (intergroup), as it seems to be more prominent in the spectra of CIN 1 
samples in magenta; or (2) between samples from the same group (intragroup), as 
highlighted by the greater variability shown in the SD in the spectral regions indicated 
by the arrows, especially in CIN 3 samples in black.  
Principal component analysis (PCA) was employed to further highlight the variability of 
the data set recorded. The PCA scatterplot for all sampling groups is presented in Figure 
4.3 A. The percentage of variance explained by PC1, PC2 and PC3 is 76.1%, 9.49% and 
3.97% respectively. 
Negative samples separate from the other sampling groups according to PC1. From the 
analysis of PC loadings presented in Figure 4.3 B, it can be observed that PC1 is 
positively dominated by glass features at below 600 cm-1 and ~1100 cm-1 which are 
therefore more prominent in the spectra of CIN samples and account for the highest 
variability (76%) within the dataset. Although PC2 and 3 do not seem to contain a 
strong glass contribution, they do not provide clear separation between the sampling 
groups; and no clear separation was provided using any other PC combination (data not 
shown). Furthermore, pairwise combination of all individual sample groups is shown in 
Figure 4.4. Despite, clear separation between all sample groups being observed, when 
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looking at corresponding PC loadings, these separations are mostly dominated by glass 
features. Indeed, PC1 is completely dominated by spectral glass features which are 
therefore more prominent in the spectra of CIN samples compared to negative samples. 
It is therefore very important to somehow correct the contribution of the glass to the 
sample spectra in order to be able to compare and understand the biochemical 
differences between the cells of the different sampling groups. Similarly, the glass 
contribution needs to be addressed before true sample profiles and classification models 
are created. However, the PC 2 and 3 loadings which also account for the separation 
between some of the sample groups do not seem to present as many glass features, 
therefore indicating underlying spectral differences, other than substrate contribution, 
may be present and allow sample separation if glass is corrected from the sample 
spectra. 
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Figure 4.3 (A) PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC 
loadings for PC1, 2 and 3 which explain respectively 76.1%, 9.49% and 3.97% of the variance within the dataset.  
A 
B 
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Figure 4.4 PCA scatter plot for pairwise comparison of all sampling groups (right) and relevant PC loadings (left); Negative samples are represented in green, CIN 1 samples in 
magenta, CIN2 samples in red and CIN3 samples in black.  
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Nevertheless, PCA-LDA was used to evaluate if an accurate disease classification 
model could be generated from the raw sample spectra. LOPOCV was used and the 
sensitivity and specificity results obtained are presented in Table 4.1. 
Table 4.1 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was 
obtained based on the Raman spectra for the full spectral range without glass correction.     
Sampling 
Group 
Sensitivity 
(%) 
Specificity 
(%) 
Negative  100 98.72 
CIN 1 100 99.24 
CIN 2 100 100 
CIN 3 95.45 100 
 
Accuracy of the LOPOCV (LOPOCVacc) =0.9940; SD of the LOPOCV accuracy 
(SD_LOPOCVacc) =0.0776 
 
 
Results show the performance of this PCA-LDA model to be very encouraging with 
sensitivity varying from 95.45 to 100% and, specificity from 98.72 to 100%. However, 
the fact that the main PCs are dominated by glass features indicates these are also 
responsible for the PCA-LDA classification. Further investigation into a glass 
correction method is therefore needed to guarantee that the glass features have minimal 
influence on the disease classifiers.    
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4.2  [1200-1800 cm-1] Spectral Range 
The first approach to minimise the glass features in the samples spectra was to cut the 
recorded spectral range so that only the “glass-free” range of 1200 to 1800 cm-1 was 
analysed. 
The mean Raman spectrum and SD for each sampling group in this new spectral range 
are shown in Figure 4.5. 
 
Figure 4.5 Mean Raman spectrum and SD (shadowing) obtained for each sampling group on the 1200 to 
1800cm-1 spectral range. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples 
in red and CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to 
be the main difference between the mean spectra.  
The main difference in the mean spectra is observed in the ratio between the peaks at 
1318:1339 cm-1, indicated by the circles on Figure 4.5. The ratio seems to increase from 
negative to progressively severe grades of CIN; indeed the average ratio is 0.91 for 
negative samples (green), 0.94 for CIN 1 samples (magenta), 0.97 for CIN 2 samples 
(red) and finally 1.01 for CIN 3 samples (black) as shown in Figure 4.6. This seems to 
suggest that a decrease of CH2/CH3 wagging & twisting mode in collagen, nucleic acid 
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& tryptophan (assigned to 1339 cm-1) and/or an increase of guanine, -C-H deformation 
(proteins) and Amide III (assigned to 1318 cm-1), occurs upon disease progression.  
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Figure 4.6 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CINI 3 (black) 
cervical cytology samples. SD is also indicated for each sampling group. Mann Whitney test showed CIN 1, 2 
and 3 ratios to be significantly different from that of negative samples with **p=0.0031 and ****p<<0.0001. 
Ratio differences between CIN samples were also significant with ****p<0.0001, ***p=0.0008 and *p= 0.0420. 
PCA was once again employed to further highlight the variability of the data set and 
evaluate the glass contribution. A 2-D PCA scatterplot for all sampling groups is 
presented in Figure 4.7 A. The percentage of variance explained by PC1 and PC2 is 
65.7% and 17.16% respectively. 
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Figure 4.7 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN 1 
samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC loadings for PC1 and 2 which 
explain respectively 65.7% and 17.16% of the variance within the dataset. 
 
A 
B 
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PC scatterplots presented in Figure 4.7(B) do not seem to be overshadowed by glass 
spectral features. 
Negative samples seem to separate from the CIN samples according to PC1. PC1 is 
positively dominated by Amide III assignments at 1245 and 1375 cm-1, Amide I at 1669 
cm-1 and by several CH2 and C-H vibrations of lipids and proteins (1304 and 1552 cm-
1), indicating these are more predominant in negative samples. 
PC2 seems to suggest a separation between CIN 1 and negative samples on the negative 
side and CIN 2 & 3 samples on the positive side. Despite this separation not being as 
clear and there are some overlapping of CIN 1 samples with CIN 2 and 3, it is positively 
dominated by Amide I at 1600-800 cm-1 and by -C=C- carotenoid and amide carboxyl 
vibrations around 1520-680 cm-1 thus more intense in CIN 2 and 3 cells' spectra; and 
negatively dominated by Amide III and ring breathing modes of nucleic acids at 1250 
and 1373 cm-1, respectively.  
The peak at 1339 cm-1 also contributes to the separation of negative samples (positively 
on PC1) from CIN samples and of negative and CIN 1 (negatively on PC2) from the 
CIN 2 and 3. This is in line with what can be observed on the mean spectra (Figure 4.5) 
further supporting a decrease of these features when disease progresses gradually from 
negative to CIN 1, 2 and 3.  
Pairwise PCA analysis in Figure 4.7 provided additional separation between CIN 
samples based on other PC combinations. Negative samples seem to separate from all 
other sample groups through a similar combination of PC1 and PC2 with both loadings 
being very similar regardless of CIN sample group involved in the pairwise 
combination (1, 2 or 3). The spectra of negative samples are negatively dominated by 
assignment of the PC1 loading which are equivalent of those described for PC1 loading 
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of Figure 4.5 (B). Similarly, PC2 seems to also contribute to the separation of CIN 3 
and negative samples and its assignments are also as described before. 
The PC loadings responsible for the pairwise separation between CIN groups are 
slightly noisier. The separation between CIN 1 samples and CIN 2 and 3 is negatively 
dominated by PC1 which in the pairwise combinations in Figure 4.8 display the 
cytosine assignment at 1290 cm-1 and the C-H and C=C bending modes of proteins at 
1420-70 cm-1 and 1600-800 cm-1, respectively, as the main features. These are therefore 
more prominent in the spectra of CIN 2 and 3 samples. And finally, the CIN 2 and 3 
samples are separated according to PC3 which is dominated by negative features 
assigned to C=C (Amide I) at 1650 cm-1, overlapping asymmetric CH3 bending & CH2 
scissoring (associated with elastin, collagen and phospholipids) at 1454 cm-1 and the 
band at 1302 cm-1 attributed to Amide III and the CH3/CH2 twisting or bending mode 
of lipids, collagen and proteins; all more prominent in the spectra of CIN 2 samples.  
PCA-LDA was employed to generate a classification model based on the Raman spectra 
of the samples which was further tested by LOPOCV. The sensitivity and specificity 
results obtained are shown in Table 4.2. 
Table 4.2 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was 
obtained based on the Raman spectra for the 1200-1800cm-1 range only.    
Sampling 
Group 
Sensitivity 
(%) 
Specificity 
(%) 
Negative  92.05 92.21 
CIN 1 91.43 92.31 
CIN 2 95.24 97.06 
CIN 3 86.36 94.33 
LOPOCVacc = 0.9157; SD_LOPOCVacc =0.2787 
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This model has good specificity across all sample groups, ranging from approximately 
92% to 97% with similar sensitivity values being obtained for all sample groups part 
from CIN 3, which had the lowest value at 86.36%. These results seem to suggest that 
the analysis of 1200-1800cm-1 spectral range is enough to achieve a good spectral 
classifier however other routes ought to be explored in order to minimize the glass 
contribution to the cellular spectra whilst retaining most of the spectral data recorded. 
By not analysing the full fingerprint spectral region, a great deal of spectral 
information/data is being overlooked. For example, most literature reports the majority 
of the DNA and nucleic acids assignments to fall outside the 1200-1800cm-1 range, 
~800 cm-1 which might prove an important classification feature as the cell nuclei are 
being targeted in this study.  
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 Figure 4.8 PCA scatter plot for pairwise combination of all sampling groups (right) and relevant PC loadings (left) in the 12001800 cm
-1 spectral range. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. 
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4.3 Glass subtraction (iterative glass correction) 
Another glass subtraction method was tested; in summary it subtracted a reference glass 
spectrum from the dataset in order to eliminate/minimise the glass contribution. The 
method was developed in-house at DIT (Bonnier et al. 2014) is described in more detail 
in section 3.3.2.2 of chapter 3.  
The mean spectra for each sampling group before and after iterative glass correction are 
displayed in Figure 4.9. Although the strong glass features around 550 cm-1 and 1095 
cm-1 are reduced in the corrected spectra, the overall SD is increased after iterative 
correction as indicated by the shadowing in the middle plots of Figure 4.9. This is 
particularly noticeable in CIN 1 and CIN 3 samples, the sample groups displaying large 
SD in the spectral regions attributed to the glass features before glass correction shown 
in the upper plots.  
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Figure 4.9 Mean spectra for each sampling group before (continuous line) and after iterative correction (IT) (dotted line).  SD is represented by shadowing. Negative samples are indicated in 
green, CIN 1 samples in magenta, CIN 2 in red and CIN 3 in black.  
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The increase in SD can also be observed when the mean Raman spectra of each sample 
group after iterative correction are plotted together in Figure 4.10.  
 
 
Figure 4.10 Mean Raman spectrum and SD (shadowing) obtained for each sampling group after FC 
correction. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and 
CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main 
difference between the mean spectra. Other visible differences between the spectra are indicated by the black 
arrows and the blue arrow heads. 
The ratio between 1339 and 1318 cm-1 still appears as the main visible difference 
between the spectral profiles of the sample groups recorded. Figure 4.11 shows this 
ratio and SD for all sample groups. Similar to what was observed before, the ratio 
between these two peaks is increased in CIN samples when compared to negative 
samples (0.78). CIN 1 samples present the highest value of 1.06 as well as the highest 
standard deviation; CIN 2 and CIN 3 samples present a similar ratio value of 0.87 with a 
higher SD being observed for CIN 3 samples. The fact that the 1339:1318 cm-1 ratio no 
longer increases gradually from negative to CIN 1, 2 and 3, might be related to the fact 
that this glass correction method seems to introduce more intra-sample variability, 
especially in CIN 1 and 3 samples which seem to be more affected by the glass 
substrate.  
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Another visible difference between the sample spectra is the peak at 1370 cm-1 indicated 
by the blue arrow heads (Figure 4.11) which is assigned to saccharides. This is only 
visible in the spectra of negative and CIN 1 samples, seeming lost in CIN 2 and 3 
samples. 
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Figure 4.11 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CINI 3 (black) 
cervical cytology samples. SD is also indicated for each sampling group. Mann Whitney test showed CIN 1, 2 
and 3 ratios to be significantly different from that of negative samples with ****p<<0.0001, p=0.0069 and 
p=0.0020 respectively. Ratio differences between CIN  samples were not statistically significant. 
PCA was further employed to highlight the variability within the dataset and evaluate 
the correction of glass features from the spectra. The PCA scatterplot obtained is shown 
in Figure 4.12 A. 
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Figure 4.12 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN 
1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC loadings for PC1 and 3 which 
explain respectively 92.01% and 0.30% of the variance within the dataset. 
The combination of PC1 and PC3 accounting respectively for 92.01% and 0.30% of the 
variance within the dataset, seems to allow the separation of negative and the CIN 
sample groups. The PC1 loading in Figure 4.12 B, is suggested to relate to the overall 
spectral intensity as it looks like the average Raman spectrum of a cervical cytology 
sample; therefore suggesting the overall spectral intensity of the samples on the positive 
side of the 2-D PCA plot, namely the negative and some CIN 3 is higher than that of 
CIN 2 and CIN 1 samples on the other side of the PCA scatterplot.   
A 
B 
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PC2 (not shown), which explains 7.43% of the variation within the dataset, does not 
provide any separation between the sample groups. PC3 suggests a separation between 
negative samples, on the negative side of the 2-D PCA plot, from CIN samples on the 
positive side. However, the PC3 loading is positively dominated by what seem to be 
glass spectral features at around 600cm-1 and 1100cm-1 which are therefore more 
prominent in the spectra of CIN samples. 
Other PC combinations did not provide further separation between the sample groups, 
especially between CIN sample groups (data not shown). PCA pairwise combinations of 
all sampling groups were also plotted and are shown in Figure 4.13.  All sample groups 
are shown to separate from one another through a combination of PC1 and PC3 with the 
loadings shown to the left of Figure 4.13. Similar to what was observed before, the PC1 
loading of pairwise PCA combinations resembles the sample average spectra. 
Furthermore, some glass features can still be observed in the loadings for PC3, further 
suggesting incomplete glass correction from the sample spectra. The visual separation 
between CIN 3 and negative samples and also between CIN 3 and CIN 2 samples is 
however not marked with much overlap observed between both sample groups. 
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Figure 4.13 PCA scatter plot for pairwise combination of all sampling groups (right) and relevant PC loadings (left) after iterative glass correction. Negative samples are represented in 
green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. 
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Nevertheless, PCA-LDA was employed to generate a classification model based on the 
Raman spectra of the samples which was further tested by LOPOCV. The sensitivity 
and specificity results obtained are shown in Table 4.3. 
Table 4.3 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was 
obtained based on the Raman spectra after iterative glass correction.   
Sampling 
Group 
Sensitivity 
(%) 
Specificity 
(%) 
Negative  100 97.44 
CIN 1 100 98.47 
CIN 2 100 100 
CIN 3 90.91 100 
LOPOCVacc = 0.9880; SD_LOPOCVacc = 0.1094 
The sensitivity and specificity values obtained after the iterative glass correction are an 
improvement on what was previously reported for the analysis of only the 1200-1800 
cm-1 spectral range. Despite good specificity and sensitivity values, above 90%, across 
all the samples, this glass correction method seems to only provide partial glass 
correction of the samples spectral profiles. Glass features are still observed and seem to 
account for the third (PC3) highest source of variability within the dataset, which 
provides the separation between negative and CIN samples. Furthermore, iterative glass 
correction seems to increase the overall intra-group spectral variability as shown by an 
increase in the SD of the mean spectra after correction; and, the fact that this increase, 
especially higher in CIN 1 samples (the most affected by glass contribution) seems to 
impact on further analysis like the peak ratio analysis. These results suggest further 
research is needed to achieve a more effective glass correction method. 
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4.4 Non-negative least squares (NNLS)   
The non-negative least squares (NNLS) glass correction model, described in section 
3.3.2.3 of chapter 3, was initially developed in-house at DIT by Ibrahim et al (2016) to 
correct wax contribution to the Raman spectra of FFPP oral tissues.  
Unlike the iterative glass correction that uses one single glass spectrum, NNLS uses a 
glass matrix composed of the glass spectra recorded from each analysed sample in this 
study. This matrix together with a matrix of cellular components such as DNA and 
RNA, aims to better fit the glass contribution to the spectra, therefore allowing a more 
precise glass subtraction from each sample.  
The mean spectra of each sampling group after NNLS correction does not seem to be as 
variable as observed for the iterative glass correction (Figure 4.9 and Figure 4.10) which 
can be observed through the SD indicated by the shadowing in all plots.  The mean 
Raman spectra after NNLS correction for each sampling group are plotted together as in 
Figure 4.14.  
 
Figure 4.14 Mean Raman spectrum and SD(shadowing) obtained for each sampling group after NNLS 
correction. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and 
CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main 
difference between the mean spectra. Another visible difference between the spectra is the peak ~1093cm-1 
indicated by the black arrows. 
128 
 
Furthermore, when plotting the mean spectra for each sampling group before and after 
correction, Figure 4.15, it is possible to observe that the most prominent glass features 
around 550 cm-1 and 1095 cm-1 are reduced in the corrected spectra and, unlike the 
iterative glass correction, the overall SD does not seem to be increased after NNLS 
correction.  
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Figure 4.15 Mean spectra for each sampling group before (continuous line) and after correction (dotted line). SD is represented by shadowing. Negative samples are indicated in green, CIN 1 
samples in magenta, CIN 2 in red and CIN 3 in black. 
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Similar to what has been observed before, the ratio between 1339 and 1318 cm-1 
appears to be the main visible difference between the spectral profiles of the sample 
groups.  
Figure 4.16 shows this ratio and its SD for all sample groups. The ratio between 1339 
and 1318 cm-1 is increased in CIN samples when compared to negative samples (0.89). 
CIN 3 samples present the highest overall value of 0.99, with CIN 1 and CIN 2 samples 
presenting very close values of 0.95 and 0.94 respectively.  
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Figure 4.16 1339:1318 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CIN 3 (black) 
cervical cytology samples. SD is indicated for each sampling group. Mann Whitney test showed CIN 1, 2 and 3 
ratios to be significantly different from that of negative samples with **p=0.0042 and ****p<<0.0001. Ratio 
differences between CIN 1 and 2 samples were not statistically significant whilst CIN 3 ratios displayed a 
****p<0.0001 and p=0.0011 against CIN 1 and 2 respectively. 
Furthermore, the peak at 1093 cm-1 assigned to the PO2- stretching vibration of the 
DNA backbone and indicated in Figure 4.14 by the black arrows, seems to be more 
prominent in the spectral profile of negative and CIN 3 samples, with the peak being 
more broad in CIN1 and 2 samples. The average Raman intensity at this peak is 
represented in Figure 4.17. Negative samples show the highest intensity at this peak 
when compared to CIN samples. Amongst the CIN samples, the peak intensity seems to 
increase with the severity of disease from 0.02 in CIN 1, to 0.03 in CIN 2 and finally 
0.03 in CIN 3. 
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Figure 4.17 Mean Raman intensity at the 1093 cm-1 peak for negative (green), CIN 1 (magenta), CIN 2 (red) 
and CINI 3 (black) cervical cytology samples. SD is indicated for each sampling group. Mann Whitney test 
showed all intensity differences to be statistically significant with ****p< 0.0001 and **P=0.0094. 
PCA was also used to highlight the variability within the dataset and results are 
presented in Figure 4.18. The 2-D PCA scatterplot between PC1 and PC2 (Figure 4.18 
A) which account respectively for 76.81% and 7.548% of the variance explained in the 
dataset, shows separation between all sample groups with the distinction between CIN 2 
(red) and CIN 3 (black) samples being not so obvious. Both PC loadings are also shown 
in Figure 4.18 B and they seem free of the major glass spectral features observed thus 
far. 
The negative samples (green) seem to separate from the CIN 1 samples (magenta) 
according to PC1, with negative samples having more DNA (~814 cm-1), protein and 
lipids (1307, 1446, 1453 cm-1), and Amide III (1242 cm-1) and I (1690 cm-1) also 
featuring prominently. Furthermore, the negative samples separate to a large extent 
from both CIN 2 and 3 samples according to PC2. Negative samples therefore show 
stronger Amide III (1243, 1375 cm-1) and protein/lipid (1339 cm-1) features, whereas 
CIN 2 and 3 samples display stronger Amide I (1606 cm-1) and Amide II (1544 cm-1). In 
addition, the PC2 loading also highlights differences in nucleic acids, the features at 
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1458 and 1485/7 cm-1 being more prominent in the spectra of negative samples. DNA 
features at 481 and 786 cm-1 are also more prominent in negative samples, whereas the 
feature at 893 cm-1 is more prominent in CIN 2 and 3 samples. Similarly, phosphate and 
phosphodiester bonds at 812 cm-1 are more prominent in the spectra of CIN 2 and 3 
samples, whereas those at 1087-9 cm-1 are more prominent in negative samples. The 
separation between CIN 1 and CIN 2 and 3 samples results from a combination of PC1 
and PC2. Taking the PC1 and PC2 assignments for the negative samples as a reference, 
the CIN 1 samples have a similar PC2 profile to the negative samples whereas the CIN 
2 and 3 samples have a similar PC1 profile to the negative samples.  
 
 
 
Figure 4.18 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC 
loadings for PC1 and 2 which explain respectively 99.54% and 0.15% of the variance within the dataset. 
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PCA of pairwise combinations between CIN sample groups (Figure 4.19) were further 
explored to investigate the differences between these sample groups. The PCA 
comparison of CIN 2 and 3 samples is particularly important as the separation between 
these sample groups was not clear in the overall PCA shown in Figure 4.18. 
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Figure 4.19 PCA scatter plot for pairwise combination of all  CIN sample groups (right) and relevant PC loadings (left) after NNLS glass correction. CIN 1 samples in magenta, CIN2 
samples in red and CIN3 samples in black. 
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Despite some overlap, CIN 1 and CIN 2 samples seem to separate along PC1 which is 
positively dominated by Amide I (1663 cm-1) and other protein features (~1309, 1449 
cm-1), as shown on the left side of Figure 4.19, indicating that these are more prominent 
in CIN2 samples.  Similarly, CIN 1 and CIN 3 show separation along PC1 which in this 
case, is also positively dominated by Amide I (1669 cm-1) and other protein features 
(~1308, 1453 cm-1), therefore more prominent in CIN 3 samples compared to CIN 1 
samples. Finally, CIN 2 and CIN 3 samples show reasonably good separation along 
PC3. From its loading, it can be observed that PC3 is positively dominated by nucleic 
acid features at 722, 786, 810 and 850 cm-1 and Amide III at 1242 cm-1, which are 
therefore more intense in the spectra of CIN 3 samples, whereas Amide I features at 
1651 cm-1 and C-H vibration of proteins and lipids at 1449 cm-1 are more prominent in 
the Raman spectra of CIN 2 samples. 
 
PCA-LDA was employed to generate a classification model based on the Raman spectra 
of the samples which was further tested by LOPOCV. The sensitivity and specificity 
results obtained are shown in Table 4.4. 
Table 4.4 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was 
obtained based on the Raman spectra after NNLS glass correction.   
  
Sampling 
Group 
Sensitivity 
(%) 
Specificity 
(%) 
Negative  100 100 
CIN 1 100 99.24 
CIN 2 100 99.31 
CIN 3 95.45 100 
LOPOCVacc = 0.9940; SD_LOPOCVacc = 0.0776 
With all sensitivity and specificity values above 95% this glass correction method 
provides the best PCA-LDA classifier so far. Furthermore, the fact that no glass features 
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are observed in PCA loadings, suggests this classifier to be independent from glass 
contribution and NNLS to be an efficient glass correction method whilst retaining 
valuable spectral information to allow discrimination between the samples. 
Based on the results presented in this chapter, NNLS can be inferred to be the best glass 
correction method and will therefore be applied to all further analysis. 
4.5  Discussion 
Healthcare systems worldwide are under increasing financial stress to provide a variety 
of services ranging from disease prevention to diagnosis and treatment. Screening 
programmes such as for cervical cancer have led to a decrease in both disease incidence 
and mortality, showing early diagnosis and monitoring of pre-cancer conditions has a 
positive impact on the overall disease burden (Kitchener et al. 2011). 
The Pap smear test has evolved since it was first introduced for cervical cancer 
screening (Safaeian et al. 2007). Indeed, the introduction of LBC and standardised 
reporting systems allowed sensitivity and specificity rates to improve significantly. 
However, the subjectivity of the grading characteristics and the constant intra and inter-
laboratory cross-validation needed to achieve the highest rates reported in literature 
(Kitchener et al. 2011) lead to research into improved, less subjective screening 
methods like HPV-testing (Poljak et al. 2016) and optical methods such as Raman 
spectroscopy (Ramos et al. 2015).  
This project is part of a technology development programme aiming to incorporate 
Raman spectroscopy into the current cytology screening programmes for cervical 
cancer, providing a non-subjective, automated diagnosis outcome for each case.    
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In this chapter it was demonstrated that Raman spectroscopy can successfully be 
applied to the study and diagnosis of cervical ThinPrep® cytology samples. Although 
spectroscopy substrates like calcium fluoride slides would prove easier to obtain a good 
“clean” spectrum, they are too expensive to be cost effective for healthcare systems.  
Recording spectra from the routinely used ThinPrep® glass slides is imperative if the 
technology is ever to make headway into the clinical setting. However, using glass 
slides as a substrate for Raman spectroscopy results in a glass contribution to the overall 
spectral profile which our group and others have been trying to overcome.   
Despite many wavelengths being reported in the literature for the study of biological 
samples, and indeed 785 and 830 nm being the most widely reported for biological 
samples (Butler et al. 2016), in this project 532nm was used as previous studies by our 
group found this wavelength to provide reduced glass fluorescence in the spectra of 
ThinPrep® cervical samples and therefore was found to be the most suitable wavelength 
for this application (Ostrowska 2011; Bonnier et al. 2014). More recently, this 
wavelength was also reported on a study of urine cytology samples also on glass 
substrate (Kerr et al. 2016), following a study on the optimal substrate and laser 
wavelength for Raman spectroscopy analysis of biological samples (Kerr et al. 2015). 
PCA and PCA-LDA results for the analysis of Raman spectroscopy data collected for 
the full fingerprint range are reported. Despite showing good separation across all 
sample groups, this was dominated by glass features. It was observed that glass 
substrate spectral features not only contributed to the spectral profile of the samples but 
they further had different degrees of interference across the sampling groups. Glass 
contribution seems to be directly related to the morphology of the cell and its nucleus; 
the bigger and less compact the nucleus, the higher the glass contribution. For this 
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reason, different glass correction methods were explored in order to minimise the glass 
interference in the sample spectra and discrimination algorithms.  
Results for three different models of glass correction are also presented. The first 
method consisted of restricting the spectral range analysed in order to avoid the areas of 
the Raman spectrum with more significant glass features. Although this method allowed 
PCA discrimination between all sample groups and the PCA-LDA classification model 
with LOPOCV achieved good performance with high sensitivity and specificity, this 
method ignores more than half the spectral information contained in the fingerprint 
region, including the region around 800 cm-1 to which many nucleic acid features are 
assigned. Despite the so called spectral fingerprint region between 400 to 1800 cm-
1 being the most extensively studied for biological and biomedical applications, several 
reports have emerged in recent years exploring the diagnosis potential of the high 
wavenumber region (2400-3800 cm-1). Indeed, it is conceivable that not all 
spectroscopic information is necessary in order to achieve accurate discrimination 
between disease and non-disease samples. By focusing on the cell nuclei we expected to 
find very subtle biochemical changes able not only to differentiate between normal and 
high grade of abnormality but also between normal and early abnormal stages. The 
biochemical difference between a normal cervical squamous cell and high grade 
dysplastic one is, even morphologically, more pronounced than the difference between a 
normal and early dysplastic cell or an HPV infected cell where morphologically the 
cells are not as different. For this reason we set to investigate two further glass 
correction methods to attempt to minimise the glass contribution to the full fingerprint 
spectrum whilst retaining the most spectral and biochemical information possible. 
Firstly the analysis of mean spectra after iterative glass correction (Bonnier et al. 2014), 
which performs sequential subtractions of a reference glass spectrum from the sample 
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spectra until a specific peak ratio, determined by spectral studies of cervical cytology on 
calcium fluoride substrates, is achieved, showed a decrease in glass features observed in 
the sample spectra. However, glass features were still visible in the loadings of the third 
PC, responsible for the discrimination of the different sample groups on PCA, 
indicating the glass removal from the sample spectra to be incomplete and still 
influencing the highly sensitive and specific PCA-LDA classification model.  
Secondly, a more sophisticated NNLS glass correction method (Ibrahim et al. 2016) 
was used which estimated the contribution of the glass spectral features to the sample 
spectra after modelling with a reference matrix of glass spectra and several other 
biomolecules. On analysis of the mean spectra, a more marked reduction of glass 
spectral features was observed after NNLS correction in comparison with the iterative 
method. In addition, no obvious glass features were observed in the PC loadings 
indicating these do not dominate the PCA-LDA classification model.  
Although both iterative and NNLS corrected samples achieved very high performance 
on PCA-LDA models with LOPOCV with sensitivity and specificity rates across all 
sample groups above 90% and with no statistically significant difference in the accuracy 
of the two models; NNLS provides a more complete subtraction of the glass features 
from the sample spectra, minimising substrate contribution towards the discrimination 
of the samples.  
In the literature, very few spectroscopic studies of biological samples are reported on 
glass substrates. The glass contribution to the spectra and its necessary removal or 
minimisation constitutes a major challenge, as a balance between glass removal and 
intrinsic sample spectra needs to be achieved.  
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In 2010, Kamemoto et al. reported that despite the investigation of several transparent 
substrates, such as quartz, sapphire, plexiglass, and mica, none were found to be 
suitable for Raman spectroscopy of cervical cancer tissue and “the search for an ideal 
transparent substrate suitable for 785 nm Raman investigation was terminated” 
(Kamemoto et al. 2010). Gardner’s group reported that relevant spectral information 
was contained in “glass free” HW areas of the infrared spectrum of breast tissue 
microarray samples, in an approach similar to the one described here restricting the 
analysis to a defined spectral range (Bassan et al. 2014).  The relevance of the HW 
region of the Raman spectrum in cervical cancer has only been investigated by 
Duraipandian et al. in an in vivo study (Duraipandian et al. 2012). Results showed 
overall diagnostic accuracies of 80.3%, 74.2%, and 82.6%, respectively, for fingerprint 
region, high-wavenumber region and integrated fingerprint and high-wavenumber 
regions for in vivo diagnosis of cervical precancer. This project however, was focussed 
on the fingerprint region of the Raman spectrum; This was due in part to time 
constraints but mostly to the fact that this is the spectral region which is reported to 
contain more significant biochemical information from nucleic acids, Amide and 
protein features, most likely to have an impact on the underlying cervical cancer 
progression and its consequent detection. 
More recently, Kerr et al. reported the use a multiplicative signal correction (EMSC) 
algorithm for the correction of glass substrate for Raman spectra of bladder cell lines 
T24 (high grade urothelial carcinoma) and RT112 (low grade urothelial carcinoma)  
(Kerr et al. 2016).  This least squares algorithm fits a reference Raman spectrum 
obtained from the mean of a dataset recorded on a calcium fluoride substrate, the glass 
signal and an N order polynomial. It computes a background signal from the N order 
polynomial and a weighted glass signal. Sensitivity and specificity results for 
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classification of the samples with PCA-LDA LOPOCV were similar to what are 
reported here, about 90%. The project timeframe did not allow this EMSC algorithm to 
be analysed as part of this study however it could constitute a further line of analysis of 
cervical cytology spectral data acquired thus far and in the future. It seems to 
incorporate principles of both iterative and NNLS corrections by fitting a reference 
glass spectrum until a particular cell reference spectrum (recorded on CaF2) is reached. 
Nevertheless, our results show that using a glass matrix (for NNLS) as opposed to one 
single reference glass spectrum (for the iterative correction method) allows for a more 
complete glass correction. The fact that other cellular components are included in the 
NNLS fitting of the glass spectra, should in principle allow for a more realistic 
estimation of how much glass actually contributes to a particular spectral feature as real 
cellular components can also show in similar spectral ranges.  
In the next chapter, clinical features, such as age and HPV inflection, are correlated with 
the samples spectral profiles in order to investigate their influence to the PCA-LDA 
classifier constructed after NNLS correction. 
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CHAPTER 5 THE INFLUENCE OF CLINICAL FEATURES ON 
THE RAMAN SPECTROSCOPIC PROFILES 
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Despite the cytological screening outcome, all samples in this study arise from a 
heterogeneous group of patients comprising different biological and clinical 
characteristics such as age, menstrual cycle, HPV infection or previous disease, all of 
which could contribute to the biochemical composition of the sample and therefore the 
Raman spectroscopy profile. In this chapter the Raman profile was analysed according 
to each feature in order to not only evaluate the influence on spectral profiles but also to 
establish any interference to the disease classification algorithms.   
5.1  Age  
 All samples considered in the study were divided according to age of the patients into 
four categories: 
• [20-29] years old  
• [30-39] years old 
• [40-49] years old 
• [50-60+] years old. 
The number of samples in each category, according to disease classification is presented 
in Figure 5.1. 
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Figure 5.1 Sample database according to patient’s age by decades; [20-29] years are represented in green, [30-
39] in blue, [40-49] in red and [50-60+] in black. 
The mean Raman spectra for negative and CIN samples according to age categories are 
presented in Figure 5.2. Although no significant differences were found in the mean 
spectra of each sample group or PCA results due to this feature, an increased variability 
can be observed in the SD of CIN 3 samples namely the ones aged 20 to 29 and 40 to 49 
years old. In the latter group, the increased variability could be a result of the small 
sample number which compose this group (n=2); which may exacerbate a slightly 
different biochemical profile perhaps as a result of age itself or other clinical feature like 
menopausal status associated with this age group. For the 20 to 29 age group (n=9), the 
increased sample variability is however harder to explain. Perhaps women in this age 
group have severe dysplasia for a shorter period of time therefore display higher 
variability in their cells. Nevertheless both sample numbers are too low to allow further 
conclusions. 
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Figure 5.2 Mean spectra for each sampling group according to patient’s age interval. Standard deviation is represented by shadowing. Samples where patient is between [20-29] years old are 
indicated in green, [30-39 ]in magenta, [40-49] in red and [50-60+] in black. 
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It should also be noted that the sample database in this study is asymmetrical not only 
with regards to the abnormality grade of the samples but also with regards to patient 
age. Because the samples are from a screening population, it was expected most 
samples to be negative for abnormality. With increased sample numbers in this group it 
is understandable that samples span all different age decades. Furthermore, screening 
programmes are aimed at younger women; the Northern Ireland Cervical Screening 
Programme, from which the samples in this study originated, offers cytology screening 
every 3 years from women aged 25 to 49; with women aged 50 to 64 offered screening 
every five years. 
In this study, most negative samples arise from patients aged between 30 and 49 years 
old whereas the majority of CIN samples arise from patients aged 20 to 39, with very 
few cases of 50 years or above. Nevertheless, PCA was also employed to highlight any 
differences related to this clinical feature; a 3-D scatterplot is presented in Figure 5.3.  
 
Figure 5.3 3-D PCA scatterplot of all samples according to age and disease classification. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN 2 samples in red and CIN 3 samples in black. Each 
sample is also represented according to the patient age interval with [20-29] represented by a circle, [30-39] 
represented by a square, [40-49] represented by an inverted triangle and [50-60+] represented by an upright 
triangle. 
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All samples seem to separate according to their disease classification and no visible 
separation can be attributed to the different age groups. Nevertheless, PCA-LDA with 
LOPOCV was also used to evaluate the influence of age in the spectral profile of the 
samples. For sample group analysis, only negative and CIN 1 samples could be 
considered as they were the only groups with more than one sample across all age 
subgroups allowing cross validation. Sensitivity and specificity results are presented in 
Table 5.1 and Table 5.2 respectively. 
Table 5.1 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the negative samples by age group. 
Negative samples by age group Sensitivity (%) Specificity (%) 
[20-29] 25.00 44.07 
[30-39] 29.63 45.65 
[40-49] 39.29 37.50 
[50-60+] 33.33 42.31 
LOPOCVacc=0.3295; SD_LOPOCVacc=0.4727 
 
Table 5.2 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the CIN 1 samples by age group. 
CIN 1 samples by age group Sensitivity (%) Specificity (%) 
[20-29] 13.33 61.54 
[30-39] 54.55 25.53 
[40-49] 14.29 45.00 
[50-60+] 50.00 30.00 
 
 
LOPOCVacc=0.2857; SD_LOPOCVacc=0.4583 
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Both Table 5.1 and Table 5.2 indicate that PCA-LDA models to predict age from 
negative and CIN 1 sample groups respectively perform poorly, with limited sensitivity 
and specificity. Such results are therefore suggestive that age cannot be predicted from 
the Raman spectroscopy profiles of cervical cytological samples. Nevertheless, the 
complete dataset was analysed, regardless of abnormality outcome, based on age. 
Sensitivity and specificity results are presented in Table 5.3.  
Table 5.3 Sensitivity and specificity values obtained for PCA-LDA classification model with LOPOCV for the 
complete dataset by age group. 
Sample by age group Sensitivity (%) Specificity (%) 
[20-29] 37.04 41.67 
[30-39] 34.62 45.65 
[40-49] 31.58 49.48 
[50-60+] 41.67 41.67 
 
LOPOCVacc =0.3571; SD_LOPOCVacc = 0.4806 
Similar to what was observed for individual age group analysis (Table 5.1 and Table 
5.2), this new PCA-LDA model also showed limited sensitivity and specificity to 
predict patient age. This result further suggests that this feature does not bear 
significance towards the disease classification algorithm as it cannot be inferred from 
the samples regardless of their cytological classification. 
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5.2 Menstrual cycle  
Information concerning the patients last menstruation period (LMP) was also provided 
to this study as part of each patient’s clinical information for both negative and CIN 
samples. The patient’s menstrual cycle day was calculating by comparing the LMP with 
the smear date. Table 5.4 summarises the menstrual cycle information for each sampling 
group.   
Table 5.4 Sample database, information regarding menstrual cycle day.  
Day of the 
Menstrual 
Cycle 
Number of samples  
Negative CIN 1 CIN 2 CIN 3 
1     
2     
3     
4    1 
5 3   1 
6  1   
7 4  1  
8 2 2  1 
9 1  1  
10 3    
11 1   1 
12 1 1 1  
13 13    
14 1 2 1  
15 1 1 1  
16 4    
17 1    
18 1 1   
19 1 3 1  
20 4 1 1 2 
21 3 1   
22 2    23     
24 2    
25     
26     
27 2 1   
28  1   
TOTAL 
no 
samples 
40 15 7 6 
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It can be observed that the study’s sample database is also asymmetrical with regards to 
menstrual cycle information. As the largest sample group, it is understandable that 
negative samples also display higher numbers of samples (n=40) with available 
menstrual cycle information, followed by CIN 1 with 15 samples and CIN 2 and 3 with 
7 and 6 samples respectively. Menstruation cycle day was therefore only available for 
less than 50% of the samples studied; this was because some patients did not know or 
chose not to disclose their last menstrual period date upon smear collection meaning 
that menstruation cycle date could not be inferred.  
The analysis of the spectral data based on specific menstrual cycle days is therefore not 
viable due to the limited sample numbers across each day of the cycle. The samples 
were consequently grouped according to their menstrual cycle phases. Samples within 
day 5 to 13 were considered to be in the proliferative phase of the cycle whereas 
samples from day 14 to 28 were considered to be in the secretory phase as described in 
chapter 1 section 1.1.2.  
 
 
Figure 5.4 Sample database according to menstrual cycle phases. Only samples with known menstrual date 
could be included. 
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To further explore the influence of menstrual cycle to the samples spectral profiles both 
negative and CIN (1, 2 and 3) samples were studied with PCA and PCA-LDA. 
5.2.1 Negative Samples 
Results of PCA of the negative samples according to their menstrual cycle phase are 
shown in Figure 5.5. Negative samples in the proliferative phase of the cycle are 
represented by a light green circle whilst a dark green square represent those in the 
secretory phase. Combined PC1, PC2 and PC3 represent approximately 81% of the 
explained variance within the dataset but no visible separation can be observed between 
negative samples in both phases of the menstrual cycle. Despite other PC combinations 
being further tested (data not shown) no clear separation was observed between the two 
groups. 
 
Figure 5.5 3-D PCA scatterplot of negative samples according to their menstrual cycle phase. Samples in the 
proliferative phase, from day 5 to 13, are represented by a light green circle whereas samples in the secretory 
phase, from day 14 to 28, are represented by a dark green square. PC1, PC2 and PC3 represent 45.56%, 
21.09% and 13.66% of the explained variance within the dataset. 
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Nevertheless, a PCA-LDA model was generated to classify negative samples according 
to their menstrual cycle phase. LOPOCV was used and the sensitivity and specificity 
results obtained are presented in Table 5.5. 
Table 5.5 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the menstrual cycle phase of negative samples. 
Negative samples’ 
menstrual cycle phase 
Sensitivity (%) Specificity (%) 
Proliferative 66.67 100 
Secretory 50.00 100 
LOPOCVacc =0.5750 SD_LOPOCVacc =    0.5006 
PCA-LDA results indicate the model is 100% specific for classification of menstrual 
cycle phase in the negative samples; whilst displaying moderate sensitivity of 66.67% 
for proliferative and 50% for secretory phase. However the model overall accuracy of 
57.5% might be compromised by the low sample numbers which undermine more 
robust conclusions. 
5.2.2 CIN 1, 2 and 3 Samples 
Similar to what was described for negative samples, the analysis of CIN samples 
according to their specific day of the cycle was likewise not viable as only one or no 
sample was available for some days. However, specific days were grouped into cycle 
phases (proliferative and secretory) to allow PCA to be performed and a PCA-LDA 
classification model to be tested. The PCA of CIN samples according to their menstrual 
cycle phase is shown in Figure 5.6. CIN 1 samples are represented in magenta, CIN 2 in 
red and CIN 3 in black; samples in the proliferative phase are represented by a circle 
whilst those in the secretory phase are represented by a square.  
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Figure 5.6 (A) 2-D PCA scatterplot of CIN 1, 2 and 3 samples according to their menstrual cycle phase. 
Samples in the proliferative phase, from day 5 to 13, are represented by a circle whereas samples in the 
secretory phase, from day 14 to 28, are represented by a square. CIN 1 samples are represented in magenta, 
CIN 2 in red and CIN 3 in black. PC2 and PC4 represent 0.23% and 0.07% of the explained variance within 
the dataset. (B) PC2 loading. 
No visible separation of the CIN samples according to their menstrual cycle phase could 
be observed in the 2-D PCA scatterplot (Figure 5.6 A). PC2 and PC4 account 
respectively for 0.23 and 0.07% of the variance within the dataset and despite other PC 
combinations being tested (data not shown), no clear separation could be observed 
between CIN samples in proliferative (circles) or secretory (squares) phase of the 
menstrual cycle. The samples seem to rather separate based on their CIN classification 
into CIN 1 (magenta), CIN 2 (red) and CIN 3 (black) according to PC2, in a similar 
fashion to what was described in section 4.4 of chapter 4. PC2 is negatively dominated 
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by assignments of phenylalanine (1005 cm-1), Amide I and fatty acids at 1657 cm-1 and 
Amide I C=C stretching at 1672/3 cm-1. In addition, Amide II at 1247 and 1260 cm-1, 
desoxyribose at 1457 cm-1 and guanine & CH deformation of proteins and 
carbohydrates at 1342 cm-1, the latter also assigned to the peak at 1449 cm-1, further 
dominate the loading negatively. In contrast, PC2 is positively dominated by nucleic 
acids assignments between 700-800 cm-1 and the bands at 1540–680 cm-1 assigned to 
the Amide carbonyl group vibrations and aromatic hydrogen, as well as Amide I (at 
early 1600 cm-1).  
Nevertheless, PCA-LDA was used to investigate if classification of CIN samples 
according to their menstrual cycle phase could be achieved. The sensitivity and 
specificity results for the PCA-LDA classification model of CIN 1 samples according to 
their menstrual cycle phase are shown in Table 5.6. 
Table 5.6 Sensitivity and specificity results for the PCA-LDA classification model with LOPOCV of CIN 1 
samples according to their menstrual cycle phase. 
Samples Sensitivity (%) Specificity (%) 
CIN 1 
Proliferative 25.00 100 
Secretory 63.64 100 
LOPOCVacc =0.5333 SD_LOPOCVacc = 0.5164 
The model is 100% specific for the classification of menstrual cycle phase of CIN 1 
samples and, although moderately sensitive for classification of the secretory phase 
(63.64%), it is only 25% sensitive for the classification of the proliferative phase. 
Similar PCA-LDA models could not be constructed for CIN 2 and CIN 3 samples 
individually as the total number of samples in these groups was less than 10, therefore 
not allowing the 10-fold cross-validation used thus far to test the optimal number of PCs 
to generate the PCA-LDA model.  
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Given the somewhat encouraging results obtained for PCA-LDA models of negative 
and CIN 1 samples alone, and that CIN 1 samples are the first grade of cervical 
abnormality, a PCA-LDA model was generated to evaluate the distinction of the two 
sample groups according to their menstrual cycle phase. The sensitivity and specificity 
results obtained after LOPOCV are represented in Table 5.7.    
Table 5.7 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
menstrual cycle phase for negative and CIN 1 samples. 
Samples Sensitivity (%) Specificity (%) 
Negative 
Proliferative 44.44 88.89 
Secretory 54.55 86.96 
CIN 1 
Proliferative 50.00 60.00 
Secretory 40.91 52.38 
LOPOCVacc = 0.5818 SD_LOPOCVacc =    0.4978 
For this model, the specificity values obtained for both negative and CIN 1 sample 
groups were below the 100% reported for the PCA-LDA models considering each 
group individually, in Table 5.5 and Table 5.6. Similarly, the sensitivity for negative 
samples in the proliferative phase of the cycle and for CIN 1 samples in the secretory 
phase was also decreased by approximately 22%. The opposite was however observed 
for the sensitivity of negative samples in the secretory phase and CIN 1 samples in the 
proliferative phase which increased by approximately 5 and 25% respectively. 
Given the potential for false positive results arising mainly between negative and CIN 1 
samples, an additional PCA-LDA model was also tested which would classify between 
negative samples in the proliferative and secretory phase of the menstrual cycle against 
CIN 1 samples. The sensitivity and specificity results after LOPOCV are presented in 
Table 5.8. 
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Table 5.8 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of 
negative samples according to their menstrual cycle phase and CIN 1 samples. 
Samples Sensitivity (%) Specificity (%) 
Negative 
Proliferative 55.56 100 
Secretory 54.55 100 
CIN 1 100 55.00 
 
LOPOCVacc = 0.7600 SD_LOPOCVacc =  0.4300 
When CIN 1 samples are included in the PCA-LDA classifier for negative samples 
according to their menstrual cycle phase, the model still shows 100% specificity for 
classification of both proliferative and secretory phase in the negative samples as seen 
in Table 5.5. And, despite an increase in sensitivity for negative samples in the secretory 
phase, a decrease can also be observed for the negative samples in the proliferative 
phase, both by approximately 5%. For the detection of CIN 1 samples, the model was 
shown to be 100% sensitive and 55% specific.  
Nevertheless, PCA-LDA was further used to generate a model which would not only 
classify the samples between negative and CIN cytology but further subcategorise 
negative samples according to their menstrual cycle phase. LOPOCV was performed 
and sensitivity and specificity results are presented in Table 5.9. 
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Table 5.9 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
Negative - proliferative or secretory menstrual cycle phase, and CIN 1, 2 and 3 samples. 
Sampling group Sensitivity (%) Specificity (%) 
Negative 
Proliferative 44.44 100 
Secretory 63.64 100 
CIN 1 100 78.31 
CIN 2 100 81.44 
CIN 3 100 81.25 
LOPOCVacc =  0.8475 SD_LOPOCVacc = 0.3611 
Despite being 100% specific to detect proliferative and secretory phase of negative 
samples; this PCA-LDA model has moderate sensitivity of 44.44% for negative samples 
in proliferative phase and 63.64% for those in the secretory phase of the menstrual 
cycle. The model’s sensitivity of 100% to all CIN categories represents an increment to 
CIN 3 samples compared to the classification model reported in Table 4.4 (chapter 4); 
however, a decrease in specificity can be observed across all CIN groups, by 
approximately 21% for CIN 1, 19% for CIN 2 and 18.75% for CIN3. It should be noted 
that although the sample numbers remained unaltered for CIN groups, the negative 
sample database in this model is reduced by half, from 88 (in Table 4.4, chapter 4) to 40 
as this is the number of samples which had menstrual cycle data available.  
Overall, PCA-LDA results for menstrual cycle phase suggest the models to be limited in 
terms of sensitivity which varies from 50 and 66.67% for negative samples and from 25 
to 63.64% for CIN 1 samples, despite being highly specific (100%) when both sample 
groups are considered independently; not improving when the PCA-LDA models also 
considered other sample groups. The small sample databases (n<10) for CIN 2 and 3 
samples meant the PCA-LDA analysis of these samples was not feasible. Similarly, the 
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spectral data could not be analysed with regards to the specific days of menstrual cycle 
due to insufficient numbers across most days. 
Another PCA-LDA model was created to evaluate the menstrual cycle phase regardless 
of cytological classification. After LOPOCV, sensitivity and specificity results are 
shown in Table 5.10. 
Table 5.10 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the menstrual cycle phase of all samples considered in the study regardless of cytological classification. 
Menstrual cycle phase Sensitivity (%) Specificity (%) 
Proliferative 34.14 100 
Secretory 43.59 100 
LOPOCVacc =    0.3881SD_LOPOCVacc = 0.4910  
This PCA-LDA model is still limited in terms of sensitivity ranging from 34.14 to 
43.59%, despite showing high specificity (100%). 
Nonetheless, the results presented in this section are suggestive that menstrual cycle 
phase could potentially be inferred for negative samples.  Normal patient variation due 
to this feature was hypothesised to potentially increase false positive rates as normal 
samples could be deemed abnormal in case their spectral profile variations due to 
different menstrual cycle phases resembled abnormal signatures. However, the PCA-
LDA classifier that further discriminates negative samples according to their menstrual 
cycle phases (Table 5.9) did not perform as well as the model which did not use this 
information (Table 4.4, chapter 4). This seems to suggest that menstrual cycle might not 
act as a confounding factor to the correct classification of the samples. It would 
however be important to monitor this clinical feature in future studies as the limited 
database restricted the PCA-LDA analysis and undermines a definitive conclusion.  
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5.3 HPV status 
Cervical cytology samples included in this study were also analysed according to their 
HPV status and profile. At the time of diagnosis HPV testing was performed at the 
Altnagelvin Hospital using the Cobas 4800 HPV Test (Roche Molecular Systems, 
Pleasanton, Calif). According to in-house procedures only samples diagnosed as CIN 
were tested for HPV so no information regarding HPV was provided for the negative 
samples included in this study.  
As described in chapter 1 (section 1.4.2) , the Cobas HPV test is a qualitative multiplex 
assay that provides specific genotyping information for HPV types 16 and 18 while 
concurrently detecting the other 12 high-risk HPV types in a pooled result. Table 5.11 
shows the sample database according to HPV result, as well as the number of samples 
in each HPV category.  
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Table 5.11 HPV test results for CIN samples. 
HPV test result 
Sample group 
Total no. of 
samples CIN 
1 
CIN 
2 
CIN 
3 
HPV negative 15 1  16 
HPV positive for 12 other high risk HPV 
types 16 10 7 
32 
HPV 16 positive 1 6 8 15 
HPV 16 and 12 other high risk HPV types 
positive  3 5 
8 
HPV 18 positive 2  2 4 
HPV 16 and 18 positive 1   1 
HPV 16, 18 and 12 other high risk HPV 
types positive  1  
1 
Total no. of samples  35 21 22 78 
5.3.1 CIN 1 samples according to HPV test 
PCA was performed to evaluate the influence of HPV on the CIN 1 sample population. 
A 2-D PCA scatterplot is presented in Figure 5.7 A.  Results seem to suggest a 
separation of HPV negative from HPV positive CIN 1 samples according to PC2 which 
accounts for 0.21% of the variability within the dataset. A separation between HPV 
positive subsets could not be inferred due to the low sample number across all 
categories. 
The PC2 loading presented in Figure 5.7 B indicates the separation is negatively 
dominated by assignments of phenylalanine (1007cm-1), C-C stretch (1100, 1339 and 
1674 cm-1), Amide III (1246 cm-1), nucleic acids (1458 cm-1) and Amide I & fatty acids 
(1657 cm-1) , which are more prominent in the spectra of CIN 1 HPV negative samples. 
Assignments for Amide II and I, specifically the C=C stretch at 1628 cm-1 are however 
more prominent in the spectra of HPV positive samples.  
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Figure 5.7 (A) 2-D PCA scatterplot of CIN 1 samples according to HPV. HPV negative samples are represented in 
green, HPV positive for 12 other high-risk types in magenta, HPV 18 in blue, HPV 16 and 18 in orange and HPV 
16 in red. PC1 and PC2 account for 99.53% and 0.21% of the variability within the dataset respectively. (B) PC2 
loading. 
As some of the HPV testing results arise from only one to two samples cross validation of 
a PCA-LDA model to predict a stratified HPV result was not viable. However, a PCA-
LDA model that would report CIN 1 samples as either HPV positive or negative was tested 
with LOPOCV and the sensitivity and specificity values obtained are shown in Table 5.12. 
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Table 5.12 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
HPV positive or negative CIN 1 samples. 
CIN 1 HPV 
sampling 
group 
Sensitivity 
(%) 
Specificity 
(%) 
HPV negative 73.33 100 
HPV positive 75.00 100 
LOPOCVacc =0.7429; SD_LOPOCVacc = 0.4434 
This PCA-LDA model is 100% specific and presents a sensitivity of 73.33 and 75% to 
classify CIN 1 samples into either HPV positive or negative, respectively. 
PCA and PCA-LDA were also used to investigate the potential to not only classify 
cytology negative samples from CIN 1 samples but to further sub-classify CIN 1 
samples into HPV negative or positive. The PCA results are presented in Figure 5.8. 
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Figure 5.8 (A) 3-D PCA scatterplot of Negative and CIN 1 HPV negative and positive samples. Negative 
samples are represented in  green,  CIN 1 HPV negative samples in magenta and CIN 1 HPV positive samples 
in red. PC1, PC2 and PC3 account for 99.56%, 0.18% and 0.08% of the variability within the dataset 
respectively. (B) PC2 and PC3 loadings. 
Negative samples (green) seem to separate from CIN 1 samples according to PC2 whilst 
CIN 1 HPV negative (magenta) separate from CIN 1 HPV positive (red) according to 
PC3 (Figure 5.8 A). Both loadings are presented in Figure 5.8 B and account for 0.26% 
of the variance found within the dataset. PC2 is dominated by positive features assigned 
to phenylalanine (1000cm-1) and Amide I C=O and C=C vibrations of proteins and 
lipids (1655-6 cm-1) which are more prominent in the Raman spectral profile of negative 
samples. PC3 is negatively dominated by C-C vibrations (855, 938, 1086-7 and 1339 
A 
B 
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cm-1) and glycogen (484 cm-1), more prominent in the spectra of CIN 1 HPV negative 
samples; and, on the other hand, positively dominated by Amide I around 1600 cm-1, 
more prominent in the spectra of HPV positive CIN 1 samples. The sensitivity and 
specificity values obtained for the PCA-LDA model after LOPOCV are reported in 
Table 5.13. 
Table 5.13 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
Negative and CIN 1 samples - HPV positive or negative. 
Sampling Group Sensitivity 
(%) 
Specificity 
(%) 
Negative 100 85.71 
CIN 1 
HPV negative  86.67 100 
HPV positive  85.00 100 
LOPOCVacc =0.9593; SD_LOPOCVacc = 0.1983 
The sensitivity and specificity results obtained for this PCA-LDA classification model 
(Table 5.13) were superior to those obtained for the CIN 1 model alone (Table 5.12). 
When the negative category is included, the specificity to detect CIN 1 both HPV 
positive and negative samples remains at 100% but the sensitivity is increased by 
approximately 10% to 86.67% and 85% respectively. The model further displayed 
100% sensitivity and 85.71% specificity to detect negative samples. Such promising 
results show the potential to not only distinguish CIN 1 from negative samples based on 
their Raman spectroscopy profiles, but also to sub-classifying CIN 1 samples according 
to their HPV positivity or negativity. 
5.3.2 CIN 2 and CIN 3 samples according to HPV test 
PCA was also performed to evaluate the influence of HPV in the CIN 2 sample 
population. A 3-D PCA scatterplot of PC1, 2 and 3 which together represent more than 
99% of the variance found within the dataset is represented in Figure 5.9.  As no clear 
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separation was observed, even when other PC combinations were tested (data not 
shown), results suggest it is not possible to sub-classify CIN 2 samples spectra 
according to their HPV test result outcome.  PCA-LDA was not performed due to the 
low number of samples overall and the fact that no sample was available for some HPV 
test results would undermine the cross validation of the model.  
 
Figure 5.9 3-D PCA scatterplot of CIN 2 samples according to HPV. HPV negative samples are represented in 
green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV 16 and 12 other high-risk 
types in orange and HPV 16, 18 and 12 other high-risk types in blue. PC1, PC2 and PC3 account respectively 
for 99.77, 0.11 and 0.03% of the variability within the dataset. 
For CIN 3 samples, the 3-D PCA scatterplot of PC1, PC2 and PC3 is represented in 
Figure 5.10. Together they account for more than 99% of the variance found within the 
dataset. However, similar to what was observed for CIN 2 samples, no clear separation 
was observed in the PCA plot or when other PC combinations were tested (data not 
shown). PCA results therefore suggest it is not possible to sub-classify CIN 3 samples 
according to their HPV test results. As found for CIN2 samples, a PCA-LDA model 
with LOPOCV was not viable for CIN 3 according to HPV test results due to the low 
sample numbers across all categories. 
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Figure 5.10 3-D PCA scatterplot of CIN 3 samples according to HPV. HPV negative samples are represented 
in green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV 16 and 12 other high-risk 
types in orange and HPV 18 in blue. PC1, PC2 and PC3 account respectively for 99.66%, 0.17% and 0.06% of 
the variability within the dataset. 
In an attempt to increase the sample numbers across each category, PCA was also 
performed on CIN 2 and 3 samples according to HPV test result. A 3-D scatterplot of 
PC1, PC2 and PC3 is presented in Figure 5.11. No clear separation can be seen based on 
the HPV profiles represented by different symbols; rather the most visible separation 
was found to be between CIN 2 and  3 samples in red and black respectively.  
 
Figure 5.11 3-D PCA scatterplot of CIN 2 and 3 samples according to HPV. CIN 2 samples are represented in 
red and CIN 3 are represented in black. HPV negative samples are represented by a circle, HPV positive for 
12 other high-risk types by a square, for HPV16 by an upright triangle, for HPV 16 and 12 other high-risk 
types, for HPV 18 by an asterisk mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 other high-risk 
types by a cross. PC1, PC2 and PC3 account respectively for 99.67%, 0.15% and 0.06% of the variability 
within the dataset. 
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The limited sample numbers across all HPV outcome categories is however an 
important limitation and does not allow PCA-LDA models to be generated and tested. 
Sub-classification of CIN 2 and 3 samples into HPV negative or positive was not 
attempted as only one CIN 2 sample tested negative for HPV.  
Despite this, a model was created to evaluate the classification between all CIN samples 
(1, 2 and 3) with the subclassification of CIN 1 samples into HPV positive or negative, 
which seemed to be achieveble as reported in the previous section (5.3.1). The 
sensitivity and specificity values obtained for this PCA-LDA model are shown in Table 
5.14. 
Table 5.14 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of 
negative, CIN 1 HPV negative or positive, CIN 2 and 3. 
Sampling Group Sensitivity 
(%) 
Specificity 
(%) 
CIN 1 
HPV negative 60.00 94.83 
HPV positive  70.00 94.34 
CIN 2 90.48 78.95 
CIN 3 95.65 77.78 
LOPOCVacc =  0.8101; SD_LOPOCVacc =  0.3947 
Despite showing encouraging results ranging from 60 to 95.65% for both sensitivity and 
specificity, the model did not perform as well as those reported in Table 5.12 and Table 
5.13. The specificity to detect HPV positive and negative CIN 1 samples dropped from 
100% to approximately 94% whereas the sensitivity now varies from 60 to 70% 
respectively. In addition, the sensitivity and specificity to detect CIN 2 and 3 samples is 
also reduced when compared to those obtained for the PCA-LDA CIN classification 
model in Table 4.4 of chapter 4 (section 4.4).  
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5.3.3 All CIN samples according to HPV test result 
PCA and PCA-LDA were further used to analyse all CIN samples according to their 
HPV test result. A 2-D PCA scatterplot of PC2 and PC3 accounting for 0.36% of the 
dataset variance is presented in Figure 5.12.   
 
Figure 5.12 2-D PCA scatterplot of all sampling groups according to HPV test result. Negative samples are 
represented in green, CIN 1 samples in magenta, CIN 2 samples in red and CIN 3 samples in black. 
Furthermore, HPV negative samples are represented by a circle, HPV positive for 12 other high-risk types by 
a square, for HPV16 by an upright triangle, for HPV 16 and 12 other high-risk types, for HPV 18 by an 
asterisk mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 other high-risk types by a cross. PC2 
and PC3 account respectively for 0.27% and 0.08% of the variability within the dataset. 
As reported previously, apart from the distinction between the different CIN groups 
(CIN 1 in magenta, CIN2 in red and CIN 3 in black), and the slight separation between 
CIN 1 HPV positive (dark magenta) and negative (light magenta), no other separations 
were observed which could be attributed to the specific HPV profiles of the samples. 
All CIN samples were also studied according to their HPV profile only, to evaluate if it 
was possible to identify different HPV profiles regardless of the CIN classification. 
PCA results are shown in Figure 5.13. 
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Figure 5.13 (A) 3-D PCA scatterplot of CIN samples only according to the HPV test result. HPV negative 
samples are represented in green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV 
16 and 12 other high-risk types in orange, HPV 18 in dark blue, HPV 16 and 18 by light blue and, HPV 16, 18 
and 12 other high-risk types in black. PC1, PC2 and PC3 account respectively for 99.47%, 0.27% and 0.08% 
of the variability within the dataset. (B) PC2 loading which accounts for 0.27% of the variability within the 
dataset. 
The only suggested separation seen on the PCA scatterplot (Figure 5.13 A) is between 
HPV negative samples and all HPV positive samples regardless of HPV type. This 
separation is along PC2 which accounts for 0.27% of the variability within the dataset. 
The PC2 loading in Figure 5.13 B, is similar to that shown in Figure 5.7 for CIN 1 
samples according to HPV with main assignments as described previously.  
The limited sample numbers across each HPV category did not allow for PCA-LDA 
models to be constructed which would classify (1) CIN samples further stratifying their 
B 
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HPV test result and (2) the HPV profile of the samples regardless of their CIN 
classification. 
 Nevertheless, PCA-LDA was used to generate a classification model of all categories 
further sub-classifying CIN 1 into HPV positive or negative. The sensitivity and 
specificity results obtained are presented in Table 5.15. Encouraging overall sensitivity 
and specificity values, above 73% and 87% respectively, suggest the stratification of 
CIN 1 samples into HPV positive or negative might also be achievable when negative 
and CIN 2 and 3 categories are also considered.   
Table 5.15 Sensitivity and specificity values obtained for a PCA-LDA classification model with LOPOCV that 
would classify negative, CIN 1 HPV negative, CIN 1 HPV positive, CIN 2 and CIN 3 samples. 
Sampling Group Sensitivity 
(%) 
Specificity 
(%) 
Negative  100 87.84 
CIN 1 
HPV negative 73.33 95.95 
HPV positive  80.00 95.80 
CIN 2 100 91.03 
CIN 3 77.27 94.44 
LOPOCVacc =0.9162; SD_LOPOCVacc = 0.2780 
Overall, PCA results suggest HPV typing not to have significant influence on the 
Raman spectra of CIN samples. In addition, the limited sample database did not allow 
PCA-LDA models to be created to classify HPV result (subtype).  
Nevertheless, a HPV positive or negative result seems to be relevant in the spectral 
profile of CIN 1 samples. Although CIN 1 HPV negative samples may be argued as a 
false positive, the HPV test used only tested for HPV16, 18 and 12 other high-risk HPV 
types, therefore excluding all low-risk HPV types which may be present in this group, 
causing the CIN 1 phenotype. Likewise, it may also be plausible that these samples 
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arise from patients who were able to clear a recent HPV infection, and although no viral 
DNA is detected upon HPV testing, spectrally the samples still exhibit CIN 1 profile.  
From the PCA, it is possible to observe a subtle separation between CIN 1 HPV positive 
and HPV negative samples dominated by Amide and C-C vibrational features. When 
included in PCA-LDA classification models, the sub-classification of CIN 1 samples 
according to HPV test result achieved the best results against negative samples only, 
100% specificity and approximately a 10% increase in sensitivity when compared with 
modelling with CIN 1 samples only. This may be an effect of the LOPOCV on small 
sample numbers but further investigation might provide insights with regards to the best 
stage at which to ask for a HPV result, for example, based on our PCA-LDA results, 
once it was established a sample is neither CIN 2 or 3, it seems to be more accurately 
tested on a model that classifies into negative or CIN 1 HPV positive/negative.   
As the current sample database is a major limiting factor for any robust conclusions to 
be drawn from this analysis, the need to extend the sample database in future research to 
include a greater body of samples with representative numbers of all different HPV 
types is recognized. In addition, based on the interesting CIN 1 results, it is further 
suggested that a more thorough HPV testing, including low-risk HPV types and testing 
for HPV mRNA as well as HPV DNA should be carried out. 
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5.4 Previous disease history 
As part of the sample database, information regarding previous disease history was also 
collected for all samples. To facilitate comparison, the analysis is presented in section 
5.4.1 for negative and CIN 1 samples and in section 5.4.2 for CIN 2 and CIN 3 samples. 
First smear samples that had no available history were considered to be negative for 
previous disease. When multiple disease history was recorded only the more severe was 
considered so that each sample was only analysed once. The previous disease history of 
each sample included in this study was then considered to be negative, low to mild 
dysplasia, or moderate to severe dysplasia.  Negative and CIN 1 samples also had 
previous history of borderline disease which was not observed for any of the CIN 2 or 3 
samples 
5.4.1  Negative and CIN 1 samples 
The negative and CIN 1 sample database according to their previous history is presented 
in Table 5.16.  
Table 5.16 Previous disease history for negative and CIN 1 samples. 
Previous disease history 
Sample group Total 
no. of 
samples Negative CIN 1 
Negative 70 17 87 
Borderline 4 6 10 
Low to mild dysplasia 13 11 24 
Moderate to severe dysplasia 1 1 2 
Total no. samples 88 35 123 
PCA analysis of negative samples according to their previous disease history is 
presented in Figure 5.13. Although PC1, PC2 and PC3 represent more than 99% of the 
variance found within the dataset, no separation was visible in the 3-D PCA scatterplot; 
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suggesting specific previous disease history might not act as a confounding factor to 
disease classification. 
 
Figure 5.14 3-D PCA scatterplot of negative samples according to previous disease history. PC1 , PC2 and PC3 
account respectively for 99.66%, 0.17% and 0.06% of the variability within the dataset. 
Nevertheless, PCA-LDA was also applied to further establish if specific previous 
disease could be inferred from the Raman spectroscopy profiles of negative samples. As 
only one sample had moderate to severe previous disease history this category was not 
included as LOPOCV could not be undertaken. The sensitivity and specificity values 
obtained are shown in Table 5.17. 
Table 5.17 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for negative 
samples by previous disease history. 
Negative samples previous history Sensitivity (%) Specificity (%) 
Negative 61.43 72.73 
Borderline 50.00 68.06 
Low to mild dysplasia 46.15 81.82 
LOPOCVacc = 0.5862 SD_LOPOCVacc = 0.4954 
As expected from the non-existent separation on PCA scatterplot, the PCA-LDA model 
showed limited power in sub-classifying negative samples according to their specific 
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previous disease history with sensitivity values ranging from 46.15 to 61.43%, whilst 
specificity ranged from 68.06 to 81.82%. 
Nevertheless, another PCA-LDA classification model with LOPOCV was also tested, 
this time to classify the negative samples into those with no previous disease history and 
those with previous disease history. Sensitivity and specificity results obtained after 
LOPOCV are presented in Table 5.18. 
Table 5.18 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for negative 
samples classified into negative or positive previous disease history. 
Negative samples previous history Sensitivity (%) Specificity (%) 
Negative 61.43 100 
Positive 61.11 100 
LOPOCVacc=0.6136; SD_LOPOCVacc= 0.4394  
For this “yes or no” PCA-LDA model, results were more encouraging with 100% 
specificity and approximately 61% sensitivity being obtained for both negative and 
positive previous disease history. These are therefore suggestive that previous disease 
status may be inferred from the spectral profile of the negative samples. 
As mentioned in the menstrual cycle phase section (5.2.) of this chapter, the false 
positives arise primarily from the misclassification of negative and CIN 1 samples. For 
this reason, PCA-LDA was further used to evaluate the classification of negative 
samples according to their previous disease history when compared with CIN 1 
samples. After LOPOCV, the sensitivity and specificity results obtained are presented in 
Table 5.19. 
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Table 5.19 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV 
considering negative samples according to their previous disease history and CIN 1 samples. 
Sample group Sensitivity (%) Specificity (%) 
Negative without previous disease history 77.14 91.56 
Negative with previous disease history 33.33 100 
CIN 1 97.14 68.10 
LOPOCVacc = 0.7642 SD_LOPOCVacc = 0.4262 
When CIN 1 samples were included in the PCA-LDA classification model of negative 
samples according to their previous disease history, the sensitivity of negative samples 
without previous disease history is increased by approximately 15% whereas a decrease 
of 27.78% is observed in the sensitivity of the samples with previous disease history. 
Despite a decrease in the negative samples without previous history, the specificity for 
both negative sample groups is still above 90%. The classification of CIN 1 samples has 
a high sensitivity of 97.14% and moderate specificity of 68.10%. 
Finally a PCA-LDA model was then generated to evaluate the ability to sub-classify 
negative samples according to their previous disease history as well as further classify 
samples into CIN 1, 2 and 3. LOPOCV was performed and the sensitivity and 
specificity results obtained are reported in Table 5.20. Although specificity ranges from 
71 to 99% across all categories, the model’s sensitivity to negative samples with 
previous disease was only 33%. Much like what was reported before in this chapter, the 
small sample numbers in this category might be undermining this analysis and this 
should therefore be further investigated in future research.  
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Table 5.20 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV 
considering negative samples previous disease history. 
Sample group Sensitivity (%) Specificity (%) 
Negative without previous disease history 65.71 97.62 
Negative with previous disease history 33.33 99.16 
CIN 1 97.14 71.76 
CIN 2 100 74.31 
CIN 3 95.45 74.31 
LOPOCVacc=0.7711; SD_LOPOCVacc= 0.4214  
Finally, the negative samples with previous disease history were omitted from the 
database so only "true negatives" were included, and the PCA-LDA disease 
classification algorithm was run with LOPOCV. The sensitivity and specificity results 
obtained are presented in Table 5.21. With all values ranging from 95 to 100% this 
model showed very good performance but it did not differ significantly from that shown 
in Table 4.4 (chapter 4) which also included negative samples with previous disease 
history.  
Table 5.21 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering 
negative samples previous disease history. 
Negative samples previous history Sensitivity (%) Specificity (%) 
Negative without previous disease history 100 100 
CIN 1 100 99.12 
CIN 2 100 99.21 
CIN 3 95.45 100 
LOPOCVacc=0.9932; SD_LOPOCVacc= 0.0822  
Similar results were obtained for CIN 1 samples. PCA results presented in Figure 5.15 
showed no clear separation of CIN 1 samples based on their specific disease history. 
Nevertheless, the sensitivity and specificity values obtained for the PCA-LDA model 
for CIN 1 samples by previous disease history are shown in Table 5.22. The moderate to 
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severe dysplasia previous disease category was however not considered as it contained 
only one sample. 
 
Figure 5.15 3-D PCA scatterplot of CIN 1 samples according to previous disease history. PC1 , PC2 and PC3 
account respectively for 99.53%, 0.21% and 0.07% of the variability within the dataset. 
 
Table 5.22 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 1 
samples by previous disease history. 
CIN 1 samples previous history Sensitivity (%) Specificity (%) 
Negative 47.06 55.56 
Borderline 0 54.17 
Low to mild dysplasia 45.45 57.14 
LOPOCVacc = 0.3824 SD_LOPOCVacc =    0.4933 
Results showed poor performance of the PCA-LDA model which showed zero 
sensitivity for detecting a borderline previous disease history in CIN 1 samples. These 
samples are, like for negative samples, one of the most underrepresented groups with 
only 6 samples. 
A "yes or no" PCA-LDA classification model with LOPOCV was then tested to classify 
CIN 1 samples into those with previous disease history and those without previous 
disease history. The sensitivity and specificity results obtained are presented inTable 
5.23. 
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Table 5.23 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 1 
samples by previous disease history. 
CIN 1 samples previous history Sensitivity (%) Specificity (%) 
Negative 70.59 100 
Positive 61.11 100 
LOPOCVacc=0.6571; SD_LOPOCVacc= 0.4816 
The results of this PCA-LDA model are comparable to those obtained for an analogous 
model for the negative samples Table 5.18. The “yes or no” PCA-LDA model resulted 
in 100% specificity and approximately 61% and 70% sensitivity being obtained for both 
negative and positive previous disease history, further suggesting it might be possible to 
accurately infer previous disease information based on the spectral profile of the 
samples. 
An additional PCA-LDA classification model was created to evaluate the stratification 
of CIN 1 samples according to their previous disease history against all possible 
diagnosis categories (negative and CIN 2 and 3). LOPOCV was performed and the 
sensitivity and specificity results obtained are presented in Table 5.24. 
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Table 5.24 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering CIN 
1 samples previous disease history. 
Sample classification Sensitivity (%) Specificity (%) 
Negative  100 76.62 
CIN 1 without previous disease history 52.94 99.28 
CIN 1 with previous disease history 44.44 99.29 
CIN 2 100 86.90 
CIN 3 95.45 87.50 
LOPOCVacc =0.8855  SD_LOPOCVacc =0.3193 
This model shows limited performance for the detection of CIN 1 samples according to 
their previous disease history. Although a slight decrease of less 1% in specificity was 
observed for these samples, a more significant decrease in sensitivity of 17.65% for 
samples without previous disease and of 16.67% for samples with previous disease was 
observed. The sensitivity and specificity values for the classification of the other sample 
groups was also inferior to what was observed before in this chapter and chapter 4.  
5.4.2 CIN 2 and CIN 3 Samples 
The previous disease information obtained for the CIN 2 and 3 samples considered in 
this study is presented Table 5.25.  
Table 5.25 Previous disease history for CIN 2 and 3 samples. 
Previous disease history 
Sample group Total 
no. of 
samples CIN 2 CIN 3 
Negative 11 14 25 
Low to mild dysplasia 7 3 10 
Severe to moderate dysplasia 3 5 8 
Total no. of samples 21 22 43 
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PCA analysis of CIN 2 samples according to their previous disease history is presented 
in Figure 5.17. No clear separation can be observed and PCA-LDA results in Table 5.26 
show sensitivity and specificity values to be very low for a previous disease history 
classification model.  
 
Figure 5.16 3-D PCA scatterplot of CIN 2 samples according to previous disease history. PC1 , PC2 and PC3 
account respectively for 99.66%, 0.21% and 0.05% of the variability within the dataset. 
 
Table 5.26 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2 
samples by previous disease history. 
CIN 2 samples previous history Sensitivity (%) Specificity (%) 
Negative 18.18 50.00 
Low to mild dysplasia 42.86 22.22 
Moderate to severe dysplasia 0 45.45 
LOPOCVacc =0.2381 SD_LOPOCVacc = 0.4364 
Indeed, with sensitivity values as low as 0% for CIN 2 samples with previous history of 
moderate to severe dysplasia, and specificity values ranging from 22.22% and 50%, a 
“yes or no” PCA-LDA model was generated to evaluate CIN 2 samples by their 
previous disease history. The sensitivity and specificity results obtained after LOPOCV 
are presented in Table 5.27. 
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Table 5.27 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2 
samples positive or negative previous disease history. 
CIN 2 samples previous history Sensitivity (%) Specificity (%) 
Negative 54.55 100 
Positive 60.00 100 
LOPOCVacc = 0.5714 SD_LOPOCVacc = 0.5071 
In addition to being 100% specific, the sensitivity values for this PCA-LDA model were 
54.55% and 60.00% for CIN 2 samples with and without previous history, respectively. 
The detection of CIN 2 samples according to their previous disease history was further 
tested on a PCA-LDA classification algorithm which also considered negative, CIN 1 
and CIN 3 sample groups. The sensitivity and the specificity results obtained are shown 
in Table 5.28. 
Table 5.28 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2 
samples by previous disease history versus Negative, CIN 1 and CIN 3. 
Sample group Sensitivity (%) Specificity (%) 
Negative 100 85.90 
CIN 1 100 91.60 
CIN 2 without previous history 45.45 100 
CIN 2 with previous history 50.00 100 
CIN 3 100 92.36 
LOPOCVacc =0.9337 SD_LOPOCVacc = 0.2495 
This model showed 100% specificity to detect CIN 2 samples with and without previous 
disease. The specificity values for CIN 1 and 3 samples were found to be above 90% 
whereas the specificity to detect negative samples was of 85.90%. In addition, the 
model was most sensitive to negative, CIN 1 and 3 samples (100%), with the values 
obtained for CIN 2 samples with and without disease only 45.45 and 50% respectively. 
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For CIN 3 samples, the PCA analysis according to their previous disease history is 
represented in Figure 5.17. Despite no clear separation being observed, a PCA-LDA 
classification model was created and sensitivity and specificity values are shown in 
Table 5.29.  
 
Figure 5.17 3-D PCA scatterplot of CIN 2 samples according to previous disease history. PC1 , PC2 and PC3 
account respectively for 99.23%, 0.49% and 0.12% of the variability within the dataset. 
 
Table 5.29 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3 
samples by previous disease history. 
CIN 3 samples previous history Sensitivity (%) Specificity (%) 
Negative 40.00 66.67 
Low to mild dysplasia 20.00 46.67 
Moderate to severe dysplasia 33.33 53.85 
LOPOCVacc = 0.3478 SD_LOPOCVacc =0.4870 
Much like what was observed for CIN1 and 2 samples (Table 5.22 and Table 5.26 
respectively) the PCA-LDA showed limited performance to stratify CIN 3 samples 
according to their previous history background, with the highest sensitivity (40.00%) 
and specificity (66.67%) being obtained for CIN 3 samples without previous disease 
history. Similarly, a PCA-LDA model which would classify CIN 3 samples into those 
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with previous disease history and those without was also evaluated with LOPOCV. The 
sensitivity and specificity results obtained are shown in Table 5.30. 
Table 5.30 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3 
samples positive or negative previous disease history. 
CIN 3 samples previous history Sensitivity (%) Specificity (%) 
Negative 66.67 100 
Positive 50.00 100 
LOPOCVacc = 0.6087 SD_LOPOCVacc =0.4990 
Results are similar to those obtained for a comparable model of CIN 2 samples (Table 
5.27). The PCA-LDA model is shown to be 100% specific to detect the presence or 
absence of previous disease; whilst sensitivity values range from 50 % for CIN 3 
samples with previous disease history, to 66.67% for those without. 
The ability of detect CIN 3 samples previous disease history was further tested on a 
PCA-LDA model which would also classify negative, CIN 1 and 2 samples. LOPOCV 
was used and the sensitivity and specificity results obtained are shown in Table 5.31. 
Table 5.31 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3 
samples positive or negative previous disease history versus Negative, CIN 1 and CIN 2. 
Sample group Sensitivity (%) Specificity (%) 
Negative 100 94.87 
CIN 1 100 96.21 
CIN 2 100 96.58 
CIN 3 without previous history 86.67 99.33 
CIN 3 with previous history 62.50 100 
LOPOCVacc =    0.8802 SD_LOPOCVacc =   0.3257 
Results show the model to be 100% sensitive to the detection of negative, CIN 1 and 2 
samples; whilst displaying more than 94% specificity for the same sample groups. The 
sensitivity for CIN 3 samples with and without previous disease history was better than 
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what was reported for the CIN 2 model (Table 5.28), 62.50 and 86.67% respectively. In 
addition, the model was 100 and 99.33% specific for CIN 3 samples with and without 
previous disease. 
Overall, PCA and PCA-LDA results revealed poor performance in predicting stratified 
disease history but encouraging results in “yes or no” models across all samples. Such 
results are suggestive that previous disease history might bear significance to the Raman 
spectroscopic profiles of the samples. This is particularly important in the case of 
negative samples as previous disease might induce abnormal spectroscopic profiles 
leading to false positives. Although results show limited sensitivity (33.33%) for the 
detection of negative samples with previous disease when the PCA-LDA disease 
classification models included all other sample groups (Table 5.19) and only CIN 1 
samples (Table 5.18); these might be obscured by the fact that only a small proportion 
of negative samples were previously diseased (20%), compared to CIN 1, 2 and 3 
samples with approximately 51%, 47.6% and 36% respectively. Furthermore, only one 
negative sample had a previous history of moderate to severe dysplasia.  
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5.5 Discussion 
In this chapter the influence of several biological factors such as age and menstrual 
cycle as well as clinical factors like HPV infection and previous disease history on the 
spectral profile of the analysed samples was investigated.  
However it is important to acknowledge that with the exception of age, none of these 
factors are linear and it was not possible to control or manipulate these variables 
experimentally as patient samples were used. Furthermore, the quality and amount of 
information available from the clinical collaborators was limited.  
5.5.1  Age 
The poor performance of the PCA-LDA models for the correct classification of patient 
age on negative and CIN 1 samples seems to suggest that age does not have a 
significant influence on the Raman spectral profile of cervical cytology samples. The 
results should however be re-evaluated on a more comprehensive sample database in 
which all sample groups, namely higher grade intraepithelial lesions CIN 2 and CIN 3, 
have statistically relevant sample numbers across all age groups. 
The investigation of age-related spectral changes in biological samples can be found in 
the literature. Conflicting reports can be found for breast cancer detection by Raman 
spectroscopy. On one hand, the analysis of ex vivo biopsy tissue is reported to be “free” 
of age-related trends towards the fat and collagen content used in the disease 
classification algorithm (Haka et al. 2005). On the other hand, in vivo work on a mouse 
model suggests it is possible to detect age-related spectral changes but these do not 
affect the disease classifier (Bhattacharjee et al. 2013). 
Similarly, a recent in vivo study using Raman spectroscopy for oral cancer detection 
reported that although it seemed feasible to distinguish between early and late age 
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groups, great overlap was seen among mid-age groups and the age related spectral 
features did not have any influence on the disease classifier (Sahu et al. 2012).  
In cervical cancer, only one study reported data analysed according to patient age. The 
study used ATR-FTIR spectroscopy to analyse exfoliated cervical cells and investigate 
spectral features in relation to HPV infection. Focusing on age, and using low grade 
intraepithelial lesion samples or CIN 1 only (due to higher sample numbers in this 
category), it was possible to separate between patients in their third and fourth decade of 
life and that this separation enhances further PCA-LDA classification of the number (0, 
1 or 2) of different HPV types infecting the samples.  The study claims that there is a 
fundamental biological difference between third and fourth decade women with LSIL 
(Kelly et al. 2010). Sahu et al. also argue that although age-induced biochemical 
changes might begin earlier they become more marked after 50 years. They also state 
that chronological age and biological age of organs and tissue might vary as the second 
is closely linked to internal and external stimuli which vary from individual to 
individual (Sahu et al. 2012).  
In the cervix any age-related biochemical differences are most likely to be related with 
menstrual cycle and/or menopausal status which is widely known to induce marked 
changes in the cervix and has its onset about 40-45 years of age.  Nevertheless, all the 
spectral data collected from biological samples should be thoroughly analysed in 
relation to patient age in order to establish any possible links which could help to 
enhance the performance of disease classifiers either alone or in conjunction with other 
clinical data like HPV infection.  
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5.5.2  Menstrual Cycle 
This evidence makes the case to evaluate probable menstrual cycle-related changes in 
Raman spectra of cervical cytology samples.  In this study it was not possible to analyse 
day-related changes due to the low number of samples available for each menstrual 
cycle day. Similarly, the menstrual cycle data for CIN 2 and 3 samples was limited to 
less than 10 cases each which meant that PCA-LDA analysis was not viable for these 
sample groups. However, PCA-LDA results revealed sensitivity of 50-66.67% and 
100% specificity to classify negative samples in the proliferative or secretory phase of 
the menstrual cycle. The same 100% specificity was obtained for the analysis of CIN 1 
samples according to menstrual cycle phase; with sensitivity ranging from 25-63.64% 
for this sample group.  The PCA-LDA models were also used to evaluate the 
performance of classifiers which differentiated negative samples according to their 
menstrual cycle phase, in addition to all other CIN groups and CIN 1 samples in 
particular. In this case the models did not perform well, with sensitivity and specificity 
results worse than what was observed when the menstrual cycle data was not 
considered. This might suggest that although menstrual cycle phase might be inferred 
from the negative samples spectral profiles this feature might not act as a confounding 
factor to the CIN PCA-LDA classification model obtained in chapter 4 (section 4.4).  
It should however be noted that menopausal status was not considered for this study as 
although it could be possible to model with speculation based on patient age, this would 
prove inaccurate as menopausal age varies considerably from woman to woman. 
Furthermore, without clinical information regarding current or previous menopausal 
treatments like hormonal therapy substitution which reverse the atrophy of the 
epithelium, any results would be easily undermined. 
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The influence of normal hormonal patient variability has previously been reported by 
the Mahadevan-Jansen group. Kanter et al. reported that by characterising normal 
hormonal changes, particularly menstrual cycle and menopausal state, and introducing 
them into the in vivo diagnosis algorithm, this improved the accuracy of Raman 
spectroscopy to 94% (Kanter et al. 2009a) overall reaching  97 % for low-grade 
dysplasia detection (Kanter et al. 2009b). In addition, the main differences observed in 
the average Raman spectra of normal and low-grade dysplasia were reported in the 
1230-1300 cm-1 range and, the analysis of postmenopausal, perimenopausal and 
premenopausal normal cervix before and after ovulation showed subtle but consistent 
differences at 1250 cm-1 and 1300-1320 cm-1, assigned to collagen and other cellular 
features like lipids, Amide III and nucleotides  (Kanter et al. 2009b).  
An FTIR study by Romeo et al. further showed the main differences arising from 
menstrual cycle variations to the cervical epithelial cells were observed in the 
carbohydrate region of 1200–1000 cm−1. These were mainly due to an increase in 
glycogen bands (1025 cm-1) between days 8 and 12 of the cycle compared to days 19 to 
26 due to the glycogen accumulation in the intermediate and superficial cells as a result 
of estrogenic stimulation. Women taking monophasic oral contraception were also 
investigated and it was concluded they did not exhibit the same degree of normal cyclic 
variation as women who did not. Nevertheless, PCA results showed high-grade 
dysplasia to separate from normal samples collected at different phases of the menstrual 
cycle, indicating it might not influence disease classification (Romeo et al. 2002). More 
recently, a study on the analysis of ThinPrep® samples by our group also showed 
spectral changes, such as lower levels of glycogen and higher levels of proteins, in the 
Raman spectra depending on the day of the cycle, and on the use of contraceptives. 
Nevertheless, it was concluded that such variations did not act as confounding factors 
190 
 
with abnormal cells discriminating well from normal cells regardless of the day on 
which the sample was taken or the use of oral contraceptive (Traynor et al. 2016).  
These results seem to suggest the differences reported by Kanter et al. (Kanter, 
Majumder, Kanter, et al. 2009) for in vivo Raman measurements might not apply for 
cytology samples when the cells are recorded ex vivo without the underlying connective 
tissue support.  
Finally, other hormone-related factors such as menarche age, parity, oral contraceptive 
use and induced abortions have all been linked with increased risk of developing 
cervical cancer and pre-cancer, by a wide range of molecular and epidemiological 
studies (Roura et al. 2016). Nevertheless, with many confounding and inconclusive 
reports published it would be of great interest if this information could also be collected 
and made available to future Raman spectroscopy studies, for the analysis of their 
influence on the sample spectral profiles. 
5.5.3  HPV status 
Several Raman spectroscopy studies have shown potential in identifying HPV infection 
and discriminating different HPV copy numbers and types. Jess et al. was the first to 
use Raman microspectroscopy to discriminate PHK (primary human keratinocytes), 
PHK E7 and CaSki cells, where PHK E7 cells express the E7 gene of HPV16 and CaSki 
expresses HPV16. The mean Raman spectra showed variations in DNA and protein 
levels, consistent with HPV gene expression and malignancy in both live and fixed 
cells. PCA results further proved Raman spectroscopy to be a valuable tool in 
identifying and characterising the different stages of HPV-associated malignancies (Jess 
et al. 2007). 
Ostrowska et al. studied cervical cancer cell lines with both FTIR and Raman 
spectroscopy and reported a discrimination of cell lines suggestive of HPV integration 
191 
 
dependence (Ostroswka et al. 2010). Their results suggested HPV negative (C33a) and 
low HPV copy number (SiHa with 1-2 copies) cell lines to be biochemically very 
similar whilst significantly different from mid (HeLa) and high (CaSki) HPV copy 
number cell lines. Protein, nucleic acid and lipid levels were the main variations 
encountered in both mean spectra and PCA analysis (Ostroswka et al. 2010).  
Studying cervical cytology sample pellets in addition to cell lines, Vargis et al. also 
reported Raman micro-spectroscopy to successfully detect HPV and differentiate 
between specific virus strains. In this study, normal HPV negative cell line NHEK was 
used alongside three cervical carcinoma cell lines: HPV positive HeLa and SiHa, and 
HPV negative C33a.  The specificity values of 89-97% reported for cell lines and 98.5% 
for cytology samples were extremely encouraging and highlighted the potential of 
Raman spectroscopy to provide an accurate differential diagnosis (Vargis et al. 2012). 
Therefore, HPV infection status was also investigated in this study. Information 
regarding patient HPV infection status was shared by our collaborators at Altnagelvin 
Hospital for CIN samples only, as negative cytology samples are not routinely tested for 
HPV. HPV infection was tested via the Cobas® HPV Test which amplifies target viral 
DNA by Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the 
detection of 14 high-risk HPV types in a single analysis. 
Cobas® specifically identifies HPV 16 and HPV 18 while concurrently detecting for 12 
other high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), allowing a total 
of eight different outcomes: 
i. HPV negative; 
ii. HPV16 positive; 
iii. HPV18 positive;  
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iv. HPV16 and 18 positive;  
v. 12 other high-risk types positive; 
vi. HPV16 and 12 other high-risk types positive; 
vii. HPV 18 and 12 other high-risk types positive; 
viii. HPV16, 18 and 12 other high-risk types positive.  
Due to the small numbers of available samples for each outcome in the study database, 
HPV positivity or negativity was only considered for PCA and PCA-LDA analysis. For 
CIN 1 samples, the results suggest the possibility to distinguish between HPV negative 
and positive samples with relatively good sensitivity of more than 70% and 100% 
specificity. Furthermore, PCA-LDA performance increased when classification models 
included differential diagnosis between negative and CIN 2 and 3 categories. By 
including the CIN 1 HPV result in a final PCA-LDA diagnosis model, sensitivity rates 
ranged from 73 to 100%. Sensitivity was found to be 87.84% for negative samples and 
above 90% for all CIN categories. These results are thus in line with those discussed 
previously and supportive of the potential of Raman spectroscopy to infer HPV 
infection from cytology samples as well as cytology diagnosis. 
These results are based on a fairly small sample population and are limited to (a) CIN 1 
samples due to the lack of HPV negative samples in the CIN 2 and 3 categories as most 
samples in these groups are high-risk HPV positive and (b) HPV positivity or negativity 
due to insufficient sample numbers across all HPV test outcomes. Further limitations 
include the fact that cytologically negative samples were not tested for HPV and the 
actual HPV testing method itself which is based on assessing the presence of viral DNA 
which as mentioned in the section 1.4.2 of this thesis, only informs if the virus is 
present, not if it is integrated into the host cell. It is therefore important that future 
studies include not only a wider sample database but also more comprehensive HPV 
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testing, maybe partnering with virology groups which could screen the HPV status of all 
the samples (negatives included) using different methodologies for both viral DNA and 
mRNA. Testing for low risk HPV types is equally important as HPV incidence is 
thought to change due to the HPV vaccination programmes already underway in many 
developed countries (Cameron et al. 2016; Palmer et al. 2016). Different progression 
rates have also been attributed to lesions with single and multiple HPV infections with 
high risk and/or low risk types (Spinillo et al. 2014; Seraceni et al. 2014) so evaluating 
their influence on Raman spectral profiles and progression rates would add immensely 
to the potential of the technology as a diagnosis tool.  
5.5.4  Previous disease history 
Previous disease history is seen as an increased risk for cervical cancer. Its effect on the 
Raman spectral profiles of in vivo and ex vivo cervical tissue have also been investigated 
by Mahadevan-Jansen’s group. In a first study they compared in vivo Raman spectra 
from histologically normal cervical tissue of both healthy and previously diseased 
patients. Results showed that apart from several small variations, the main spectral 
difference was observed at 1250 cm−1, a peak typically assigned to collagen, where 
spectra from previously diseased patients were less intense than that of “true normal” 
patients (Keller et al. 2008).  Following from this study, another study by the same 
group further examined in vivo spectra from 172 patients which were classified into (a) 
“true normal” with no history of disease, (b) previously diseased with current normal 
diagnosis but with history of disease, (c) adjacent normal, with spectra acquired from a 
visually normal area from a cervix with disease, (d) low grade, and (e) high grade 
disease. Classification algorithms showed a 99% accuracy to distinguish between “true 
normal” and previously diseased patients, and 97% to distinguish between “true 
normal”, adjacent normal, low and high grade disease (Vargis et al. 2011a). These 
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results argue that variations in normal spectra due to previous disease are statistically 
significant and should therefore be accounted for when creating disease classifiers.   
Additionally, a histology study by our group further demonstrated using Raman 
microspectroscopy that the clear arrangement of the cervical epithelial layers as seen in 
cervical tissue from non-diseased patients is lost in normal appearing areas of diseased 
cervix. This supports the fact that the underlying tissue abnormality might be broader 
than what can be observed by conventional histopathology (Rashid et al. 2014). Such 
results add to the finding of Cohenford et al. who reported the neoplastic process may 
be more extensive than what is recognized by morphological criteria alone; and that 
normal appearing cells from abnormal cases differ biochemically from those of normal 
cases, and that such differences result in different FTIR spectral profiles. 
In this study it was therefore hypothesised that if previous disease history might be 
responsible for variations in the spectral profiles of the samples, this would be more 
noticeable in the Raman spectra of negative samples and samples with lower grades of 
abnormality. In negative samples in particularly, such information could be important to 
reduce false positive rates as previous disease signatures could act as confounding 
factors for the disease classifiers, especially at diagnosis of negative and CIN 1 samples 
where misclassification is more problematic. 
Our results showed moderate performance of PCA-LDA models to separate negative 
and CIN 1 samples according to their positive or negative previous disease history, with 
100% specificity and approximately 61% and 61-70% sensitivity to predict negative and 
CIN 1 samples previous disease history, respectively.  
Nevertheless, sub-classifying negative samples on a PCA-LDA disease classification 
algorithm showed limited performance for predicting previously diseased negative 
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samples with only 33% sensitivity, and decreased overall sensitivity and specificity 
rates across all other sampling groups. Similar results were obtained when only CIN 1 
samples where considered in the classifier. PCA-LDA models further showed limited 
sensitivity and specificity rates to stratify the background of previous disease due to the 
small sample numbers across each category.  
On one hand PCA-LDA results suggest it may be feasible to determine previous disease 
history of negative and CIN 1 samples on a “yes or no” model. On the other hand, 
previous disease history does not seem to improve the overall disease classification 
models. The limited numbers of previous disease samples, especially in the negative 
sample group (20%) might be responsible for the poor cross validation performance of 
the final disease algorithms and therefore, previous disease history information should 
continue to be analysed in further research considering a more comprehensive sample 
database. Furthermore, only one negative sample had a previous disease history of 
moderate to severe pathology which could impact in the performance of these 
classifiers; as higher abnormality grades might induce more marked underlying changes 
in the cervix which could then be retained after the disease has cleared. Similarly, it 
would also be interesting to study the time of previous disease in relation to the current 
cervical cytology sample used for Raman spectroscopy as it could be that previous 
disease history only has a significant impact on Raman spectral profile of the samples 
during a specific timeframe. 
Furthermore, the performance of this PCA-LDA disease classification model with only 
negative samples with no previous disease history considered did not improve or 
worsen significantly so although this seems to support that previous disease history does 
not confound the PCA-LDA disease classification algorithm, the relatively small sample 
numbers being omitted from the negative sample group might not be able to 
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significantly change the PCA-LDA model performance and therefore, this clinical 
feature should continue to be explored further.    
The next chapter explores the performance of Raman spectroscopy PCA-LDA 
classifiers using both CIN and SIL reporting systems, with relevant clinical features also 
being tested.  
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CHAPTER 6 EVALUATION OF SIL VS CIN 
CLASSIFICATION MODELS 
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This chapter is adapted from the peer-reviewed original research article by Ines Ramos, 
Aidan D Meade, Ola Ibrahim, Hugh Byrne, Mary McMenamin, Michael McKenna, 
Alison Malkin and   Fiona Lyng entitled “Raman spectroscopy for cytopathology of 
exfoliated cervical cells”; Faraday Discussions 2016, 187, 187-198, 
DOI: 10.1039/C5FD00197H .  
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Thus far, the spectral data has been analysed using PCA-LDA models for the CIN 
reporting system; negative, CIN1, CIN2 and CIN3. As outlined in chapter 1, section 
1.3.3, the SIL reporting system, negative, LSIL and HSIL, is currently recommended 
for cytology screening programmes (Solomon 2002). To further explore the potential of 
Raman spectroscopy in the context of cervical cancer screening, the performance of a 
PCA-LDA classification model based on the SIL reporting system has been investigated 
in this chapter. The influence of menstrual cycle, HPV and previous disease history has 
also been investigated; similar to what was reported in chapter 5 for the PCA-LDA 
models based on the CIN reporting system. 
6.1  The performance of SIL classification  
Mean Raman spectra of cervical cytology samples in the fingerprint region of 400-1800 
cm-1 are presented according to the SIL classification in Figure 6.1. This system 
considers negative, LSIL (CIN 1) and HSIL (CIN 2 and 3) samples.  
 
Figure 6.1 Mean Raman spectrum and SD (shadowing) obtained for each sampling group after NNLS 
correction. Negative samples are represented in green, SIL samples in magenta, and HSIL samples in black. 
The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main difference between the 
mean spectra. Other visible differences are indicated by the arrow heads. 
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Overall the mean spectra of negative, LSIL and HSIL samples show similar features, 
much like what was observed for CIN classification, with the main differences being 
observed around the 1318/1339 cm-1 region, in which the ratio of the intensities of these 
two peaks increases from negative to LSIL and HSIL samples as shown in Figure 6.2. 
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Figure 6.2 1339:1318 cm-1 peak ratios for negative (green), SIL (magenta) and HSIL (black) cervical cytology 
samples. SD is indicated for each sampling group. Mann Whitney test showed LSIL and HSIL ratios to be 
statistically significant from negative with **p=0.0042 and ****p<0.0001; and between them with 
***p=0.0006. 
 
To further highlight any differences between the spectral profiles of the samples, PCA 
was employed. Figure 6.3 shows the PCA scatterplot for all SIL classified samples.  
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Figure 6.3 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. Negative samples are 
represented in green, LSIL samples in magenta and HSIL samples in black. (B) PC loadings for PC1 and 2 
which explain respectively 76.81% and 7.55% of the variance within the dataset. 
 
From the PCA scatterplot, it can be seen that negative (green), LSIL (magenta) and 
HSIL (black) samples are separated according to PC1 and PC2 which account 
respectively for 76.81 % and 7.55 % of the variance explained in the dataset. The 
loadings of PC1 and PC2 are shown in Figure 6.3 B.  The negative samples seem to 
A 
B 
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separate from the LSIL samples according to PC1, negative samples having more DNA 
(~814 cm-1), protein and lipids (1307, 1446, 1453 cm-1), Amide III (1242 cm-1) and I 
(1690 cm-1) also featuring prominently. Furthermore, the negative samples separate to a 
large extent from the HSIL samples according to PC2. Negative samples show stronger 
Amide III (1243, 1375 cm-1) and protein/lipid (1339 cm-1) features, whereas HSIL 
samples display stronger Amide I (1606 cm-1) and Amide II (1544 cm-1). In addition, 
the PC2 loading also highlights differences in nucleic acids, the features at 1458 and 
1485/7 cm-1 being more prominent in the spectra of negative samples. DNA features at 
481 and 786 cm-1 are more prominent in negative samples, whereas the feature at 893 
cm-1 is more prominent in HSIL samples. Similarly, phosphate and phosphodiester 
bonds at 812 cm-1 are more prominent in HSIL samples, whereas those at 1087-9 cm-1 
are more prominent in negative samples. The separation between LSIL and HSIL 
samples results from a combination of PC1 and PC2. Taking the PC1 and PC2 
assignments for the negative samples as a reference, the LSIL samples have a similar 
PC2 profile to the negative samples whereas the HSIL samples have a similar PC1 
profile to the negative samples.  
With PCA results similar to what was observed for the CIN reporting system in chapter 
4 (section 4.4), they are suggestive that significant differences can be found in the 
Raman spectral profile of cell nuclei to distinguish between negative, LSIL and HSIL 
samples. PCA-LDA was therefore used to generate a classification model based on the 
features highlighted by PCA analysis. LOPOCV was then used to evaluate the 
performance of the PCA-LDA classification model and sensitivity and specificity rates 
are shown in Table 5.38.  
203 
 
Table 6.1 Sensitivity and specificity values obtained for the SIL PCA-LDA classification model with LOPOCV. 
Sampling Group Sensitivity Specificity 
Negative 100 100 
LSIL 100 99.24 
HSIL 97.67 100 
LOPOCVacc = 0.9950; SD_LOPOCVacc =0.0765 
The performance of the SIL PCA-LDA model is quite encouraging, with all sensitivity 
and specificity values above 97%.  The model is also 100% sensitive and specific to the 
detection of negative samples. These results are similar to what was observed for the 
PCA-LDA model based on the CIN reporting system in Table 4.4, chapter 4. 
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6.2 Influence of Clinical features on the SIL classification 
In line with the analysis made for the PCA-LDA CIN classification, in chapter 4, the 
influence of the most relevant clinical features was also investigated in the SIL 
classification models.   
6.2.1 Menstrual Cycle phase 
In chapter 4, the limited menstrual cycle data available for CIN 2 (n=7) and 3 (n=6) 
samples did not allow the PCA of these sample groups by menstrual cycle phase. 
However, in SIL classification, CIN 2 and 3 samples are combined to form the HSIL 
group; in total, the HSIL group has 13 samples with menstrual cycle data available, thus 
allowing PCA-LDA models to be evaluated.   
First a PCA-LDA model was used to classify HSIL samples into proliferative or 
secretory phase of the menstrual cycle. The sensitivity and specificity results obtained 
after LOPOCV are shown in Table 6.2.  
Table 6.2 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of 
HSIL samples according to their menstrual cycle phase. 
Sampling group Sensitivity (%) Specificity (%) 
HSIL 
Proliferative 50.00 100 
Secretory 50.00 100 
LOPOCVacc =    0.5000 SD_LOPOCVacc =    0.5222 
Results show the PCA-LDA model to be 100% specific to the different menstrual cycle 
phases of HSIL samples with only 50% sensitivity; both in line with what was obtained 
for the comparable models of negative and CIN 1 samples (Table 5.5 and Table 5.6, 
chapter 5). 
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Another PCA-LDA model was tested to evaluate the potential to classify HSIL from 
negative and LSIL samples as well as segregate HSIL samples according to their 
menstrual cycle phase. LOPOCV was used and the sensitivity and specificity results 
obtained are presented in Table 6.3. 
Table 6.3 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of 
negative, LSIL and HSIL samples, also classifying the latter according to their menstrual cycle phase. 
Sampling group Sensitivity (%) Specificity (%) 
Negative 100 82.98 
LSIL 100 92.00 
HSIL 
Proliferative 33.33 100 
Secretory 33.33 100 
LOPOCVacc = 0.9407 SD_LOPOCVacc =0.2370  
The model shows limited (33.33%) sensitivity for the detection of HSIL according to 
their menstrual cycle phase when negative and LSIL samples are also tested, despite 
good specificity being obtained across all categories. This could either be a limitation 
arising from the small sample numbers in these categories or an indication that 
menstrual cycle phase does not bear an impact on the spectral profile of the HSIL 
samples.  
In chapter 4, a PCA-LDA disease classification model that would stratify negative 
samples according to their menstrual cycle phase as well as testing against all CIN 
categories was also tested; as it was hypothesised the spectral variation caused by 
menstrual cycle would have greater impact in negative samples. Likewise a comparable 
PCA-LDA model was also tested for SIL classification and the sensitivity and 
specificity results obtained after LOPOCV are presented in Table 6.4. 
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Table 6.4 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
negative samples according to proliferative or secretory menstrual cycle phase and LSIL and HSIL samples. 
Sampling group Sensitivity (%) Specificity (%) 
Negative 
Proliferative 44.44 100 
Secretory 59.09 100 
LSIL 100 77.11 
HSIL 100 74.67 
LOPOCVacc =0.8390 SD_LOPOCVacc =0.3691 
Again, the results are similar to those reported for the CIN model (Table 5.9, chapter 4). 
Despite 100% specificity for negative samples, the model shows only 44.44% 
sensitivity for the negative samples in the proliferative phase of the cycle and 59.09% 
(4.55% decrease compared to CIN model) for those in the secretory phase. The 
sensitivity for LSIL and HSIL remains at 100% as observed for CIN 1 and CIN 2 and 3 
samples, with a decrease observed for the specificity of LSIL samples compared to CIN 
1 (1.21% decrease) and HSIL samples compared to CIN 2 (6.77%) and CIN 3 (6.58%). 
6.2.2 HPV status  
Results in chapter 5 suggested HPV infection status of CIN 1 samples might be inferred 
from the Raman spectral profiles of the samples and impact on the CIN PCA-LDA 
classification models.  
Table 6.5 shows the sensitivity and specificity values obtained for a SIL PCA-LDA 
classification model that separates LSIL from HSIL and simultaneously informs on their 
HPV status.  
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Table 6.5 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of 
LSIL HPV negative or positive, and HSIL. 
 
 
LOPOCVacc =    0.8608 SD_LOPOCVacc =    0.3484 
Whereas the sensitivity and specificity values obtained for LSIL HPV negative and 
HPV positive samples were slightly increased and therefore an improvement to what 
was obtained in Table 5.12 (chapter 5) for the parallel CIN PCA-LDA model; the 
specificity of HSIL samples is however below the 78.95 and 77.78% obtained for CIN 2 
and 3 samples respectively.   
The samples were also evaluated on a PCA-LDA model which further included negative 
samples and the sensitivity and specificity results obtained are presented in Table 6.6. 
Table 6.6 Sensitivity and specificity values obtained for a PCA-LDA classification model with LOPOCV that 
would classify negative, LSIL HPV negative, LSIL HPV positive, and HSL samples. 
Sampling Group Sensitivity (%) 
Specificity 
(%) 
Negative 100 86.67 
LSIL 
HPV negative 66.67 97.28 
HPV positive 75.00 97.18 
HSIL 90.91 91.87 
LOPOCVacc =    0.9162  SD_LOPOCVacc =    0.2780 
Overall the specificity values are similar to those shown in Table 5.15 (chapter 5) for 
the CIN classification model. The sensitivity of negative samples remained unchanged 
at 100% and the 90.91% obtained for HSIL is superior to 77.27 % achieved for CIN 3 
samples, despite being less than the 100% sensitivity obtained for CIN 2. However, the 
Sampling Group Sensitivity (%) 
Specificity 
(%) 
LSIL HPV negative 60.00 100 HPV positive 75.00 100 
HSIL 100 68.57 
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sensitivity of HPV detection for LSIL samples in this model is approximately 5% less 
than that of the corresponding CIN model. 
6.2.3  Previous disease history  
Previous results in chapter 5 suggested that previous disease history of negative samples 
might be inferred from the Raman spectral profiles of the samples and impact on the 
CIN PCA-LDA classification models.  
The ability to stratify the previous disease history of HSIL samples was studied with 
PCA-LDA. LOPOCV was used and the sensitivity and specificity results obtained are 
shown in Table 6.7. 
Table 6.7 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the HSIL sample group by previous disease history background. 
HSIL Previous disease 
history 
Sensitivity 
(%) 
Specificity 
(%) 
Negative 46.15 69.23 
Low to mild dysplasia 66.67 50.00 
Moderate to severe 
dysplasia 16.67 76.92 
LOPOCVacc =  0.4773 SD_LOPOCVacc = 0.5053 
Similar to what was observed for CIN 2 and 3 samples (Table 5.25 and Table 5.28, 
chapter 5, respectively), results show limited performance of the PCA-LDA model to 
accurately classify HSIL samples according to their previous disease history. Sensitivity 
values range from 16.67 to 66.67%, whereas specificity is slightly higher with values 
range from 50.00 to 76.92%. 
A "yes or no" PCA-LDA was also used to classify HSIL samples into those with and 
without previous disease history. The sensitivity and specificity results after LOPOCV 
are shown in Table 6.8.  
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Table 6.8 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for 
the CIN 2 and 3 sample group by previous disease history. 
HSIL samples previous 
history 
Sensitivity 
(%) 
Specificity 
(%) 
Negative 53.83 100 
Positive 83.33 100 
LOPOCVacc =    0.6591 SD_LOPOCVacc =    0.4795 
Like what was observed for CIN 2 and 3 samples, this "yes or no" model is 100% 
specific with moderate sensitivity. Despite the sensitivity of 83.33% for HSIL samples 
with previous disease being higher than that observed for CIN 2 (Table 5.26) and CIN 3 
(Table 5.29) in chapter 5; the sensitivity for HSIL samples without previous history is 
only 53.83% and therefore lower than that of CIN 2 and 3 samples. 
The sensitivity and specificity values obtained for the PCA-LDA SIL classification 
model that further sub-classify negative samples with regards to previous disease 
history are shown in Table 6.9.  
Table 6.9 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering 
negative samples previous disease history. 
Negative samples previous history Sensitivity (%) 
Specificity 
(%) 
Negative without previous disease 
history 70.00 96.36 
Negative with previous disease history 33.33 98.40 
LSIL 97.14 72.52 
HSIL 93.02 75.95 
LOPOCVacc=0.7771; SD_LOPOCVacc= 0.4174  
It can be observed that the values obtained are comparable to those of the CIN model in 
Table 5.24 (chapter 5).The sensitivity for negative samples with previous disease 
history was still limited at 33.33%, and the specificity decreased to 98.40%. For 
negative samples without previous disease an increase of 4.29% was observed for the 
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sensitivity, whereas specificity decreased by 1.29%. LSIL samples maintained the 
specificity value of CIN 1 samples (97.14%), whilst increasing the specificity by 0.76%. 
Similarly, the detection of HSIL samples is 1.64% more specific than that of CIN 2 and 
3 samples, whilst the specificity is decreased to 93.02%.  
 
However, when only negative samples without previous disease are considered, the SIL 
PCA-LDA model achieves overall sensitivity and specificity of 100% as shown in 
Table 6.10. This is an improvement to what was observed in Table 5.27 (chapter 5) for 
the CIN classification, already a highly accurate model.  
Table 6.10 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering 
negative samples previous disease history. 
Negative samples previous history Sensitivity (%) 
Specificity 
(%) 
Negative without previous disease 
history 100 100 
LSIL 100 100 
HSIL 100 100 
LOPOCVacc=1; SD_LOPOCVacc= 0 
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6.3 Discussion 
Overall PCA-LDA results suggest a comparable performance between CIN and SIL 
reporting systems. The sensitivity and specificity of the models to detect negative and 
CIN or SIL is very encouraging and higher than that reported in the literature for other 
screening techniques such as Pap screening and HPV testing.  
The results presented in section 6.1 of this chapter constitute an improvement over what 
was reported in the Faraday Discussions publication. After publication, the data was 
reanalysed and it was found that although an optimal number of PCs was established 
(15 PCs) which maximised the performance of the PCA-LDA models, all PCs were 
considered when building the CIN and SIL PCA-LDA classification algorithms. When 
only the optimal number of PCs was used to generate both CIN (shown in chapter 4, 
section 4.4) and SIL PCA-LDA classification models, the performance was better, 
resulting in the increased sensitivity and specificity values. 
Using the SIL reporting system, CIN 2 and 3 samples are grouped to form the HSIL 
group. This allowed PCA-LDA analysis to be performed on the menstrual cycle data for 
HSIL samples due to increased numbers in the group. In line with what was observed 
for CIN 1 samples in chapter 5 (section 5.2.2), results showed limited performance of 
the PCA-LDA models to correctly classify HSIL samples according to their menstrual 
cycle phase. Moreover, when considering the menstrual cycle data of negative samples 
(the sample group expected to have increased spectral variance with result to menstrual 
cycle changes) against all other sample groups, both SIL and CIN models showed 
moderate performance with decreases of 1.21% to 6.77% being observed in the SIL 
model sensitivity and specificity values.  
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The analysis of previous disease history data showed similar results with both SIL and 
CIN models being limited to the ability to detect previous disease history of negative 
samples in addition to the other categories.   
However, when HPV detection of CIN 1/LSIL samples is considered, the specificity 
achieved for the SIL model was not as good as that reported for the CIN 2 and 3 groups 
in the parallel CIN model. In theory, the SIL model should be expected to improve 
performance as there is one less category in which to divide the samples. However, CIN 
2 samples may be a heterogeneous transition group between low and high grade lesion; 
comprising samples which might be biochemically closer to CIN 1/LSIL than to CIN 3 
and therefore HSIL. The fact that CIN 2 samples are also reported to have the ability to 
regress (Moscicki et al. 2010a) may result in those samples displaying a CIN 1-like 
profile. Follow-on studies could potentially inform if a specific regression or 
progression pattern could be inferred from the Raman spectral profile of the samples. 
A study by Doorbar et al. which investigated the correlation of CIN classification and 
HPV infection status suggested that some reported CIN 2 cases, when analysed by an 
immunohistochemistry panel of P16INK4a, MCM and HPV-encoded E4, in fact group 
with CIN 1 rather than CIN 3 cases. The study showed that the combination of 
identification of surrogates of high-risk HPV E6/E7 activity (P16INK4a and MCM), 
together with the detection of the abundant HPV-encoded E4 protein, was able to 
identify both transient and transforming lesions. This approach not only allowed to 
distinguish true papillomavirus infections from similar pathologies but also to divide the 
heterogeneous CIN 2 category into those that are CIN 1-like with transient HPV 
infection expressing E4, and those that do not express E4 and therefore are more closely 
related to CIN 3 cases with transforming HPV infection (Griffin et al. 2015). It might 
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therefore be important to consider biomarker panels and thorough HPV typing in further 
research of Raman spectroscopy for cervical cytology samples. 
The investigation of p16 expression profiles is however the most studied putative 
biomarker to aid screening and diagnosis of cervical cancer and precursor lesions 
(White et al. 2016). Commercially available kits are now available for histology and 
cytology specimens, showing promising results in the clinical setting. The cytology kit, 
CINTec PLUSTM, allows in fact a dual staining of p16 and Ki-67 and has been shown to 
be efficient in triaging women with ASC-US or LSIL cytology results by a pan-
European study (Bergeron et al. 2015). It is currently on trial in some UK screening 
centres and has more recently been reported to, in addition to HPV DNA testing, lead to 
a more accurate stratification of CIN in women presenting minor cytological 
abnormalities (White et al. 2016). In chapter 8, p16 and Ki67 expression was 
investigated in the Thinprep® cervical cytology samples (both model and test set) using 
the CINTec PLUSTM kit.  
 
CIN and SIL Raman spectroscopy PCA-LDA classifiers are further validated in the next 
chapter, where an independent sample database is used as a test set instead of 
LOPOCV. 
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CHAPTER 7 EVALUATION OF BOTH CIN AND SIL 
CLASSIFICATION MODELS ON AN INDEPENDENT TEST 
SET  
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As part of this study an independent set of samples was also acquired to further test the 
performance of the PCA-LDA Raman models presented in Chapter 6 when faced with 
new unseen ThinPrep® cytology samples. In this chapter the performance of the CIN 
and SIL classification models was evaluated on this new sample database. 
7.1 Mean Spectral Analysis of the Test Samples 
The mean Raman spectra for the test samples according to their cytology disease 
classification are presented in Figure 7.1. 
 
Figure 7.1 Mean Raman spectra of all samples composing the test set database plotted according to their 
cytology diagnosis. Negative samples are indicated in green, CIN 1 samples in magenta, CIN 2 in red and CIN 
3 in black.  
The average spectra of each test set group were also plotted against the average obtained 
for each group in the modelling set. Figure 7.2 to Figure 7.5 allows the comparison of 
the negative, CIN 1, CIN 2 and CIN 3 samples from the test set against the model set. 
Although the average Raman spectra of the CIN test set groups seemed in accordance 
with those of the modelling set, the same was not observed for the negative test set 
samples. The mean spectra of the negative test set samples appeared to be more similar 
to those of the CIN 1 modelling set. For instance, the peak intensity ratio at 1318:1339 
cm-1 looks similar to that observed for CIN 1 samples.  
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Figure 7.2 Mean spectra of negative samples test set (dark green) against each classification group where negative model set samples are indicated in green, CIN 1 samples in magenta, CIN 2 
in red and CIN 3 in black 
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Figure 7.3 Mean spectra of CIN 1 samples test set (purple) against each classification group of the model set where negative samples are indicated in green, CIN 1 samples in magenta, CIN 2 
in red and CIN 3 in black. 
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 Figure 7.4Mean spectra of CIN 2 samples testing set (orange) against each classification group of the modeling set where negative samples are indicated in green, CIN 1 samples in magenta, 
CIN 2 in red and CIN 3 in black 
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Figure 7.5 Mean spectra of CIN 3 samples test set (grey) against each classification group of the model set where negative samples are indicated in green, CIN 1 samples in magenta, CIN 2 in red 
and CIN 3 in black 
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To further confirm this similarity, the difference spectrum was also evaluated. Figure 
7.6 shows the difference spectrum between negative samples from modelling and test 
set in green and the difference spectrum between negative and CIN 1 samples from the 
modelling set in magenta. Both difference spectra show a similar spectral pattern further 
confirming negative test set samples resemble CIN 1 samples from the model set. 
 
Figure 7.6 Difference spectra plots between negative samples from model and test sets (green) and between 
negative and CIN 1 samples of model set (magenta). 
Nevertheless, when the difference between CIN 1 samples from model set and negative 
samples from test set is plotted (Figure 7.7) variation can be observed particularly after 
1200  cm-1. These results suggest that although negative test set samples resemble a CIN 
1 like profile, similar to that of the CIN 1 model samples, they are not exactly the same. 
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Figure 7.7 Difference spectra plots between CIN 1 samples from model set and negative samples from test set. 
In addition when PCA was performed with the test set alone, the 3-D scatterplot 
presented in Figure 7.8, showed no visible separation between all sample groups as 
opposed to what was observed for the modelling set shown in Figure 4.21 A (chapter 4). 
A resemblance between the PC loadings can however be observed between what was 
observed for the model (Figure 4.21 B, chapter 4) and test set (Figure 7.8 B). 
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Figure 7.8 A) 3-D PCA scatter plot of test set samples with negative samples indicated in green, CIN 1 samples 
in magenta, CIN 2 in red and CIN 3 in black. B) PC loadings. 
 7.2 Testing the PCA-LDA disease classification models  
PCA-LDA models for CIN and SIL disease classification were evaluated with the test 
set samples. Confusion matrices are presented due to the small sample numbers 
available in the test set for each classification category, in Table 7.1 and Table 7.2 
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respectively, instead of the sensitivity and specificity results as shown in previous 
chapters. 
 Table 7.1 Confusion matrix showing the result of the testing of the test set samples on the CIN PCA-LDA 
classification algorithm. 
Actual 
Classes 
Predicted Classes 
Negative CIN 1 CIN 2 CIN 3 
Negative 0 27 0 0 
CIN 1 0 9 0 0 
CIN 2 0 3 3 0 
CIN 3 1 0 0 4 
 
For the CIN classification model, all CIN 1 samples were classified correctly as were 
the majority of the CIN 3 samples except for one false negative. Half of the CIN 2 
samples misclassified as CIN 1 and so did the entire negative test set samples. This 
misclassification was expected given the similarities observed in the mean spectral 
analysis.  Although this model seems to be able to classify CIN 1 and CIN 3 correctly, 
with several plausible explanations for the CIN 2 misclassification which will be 
discussed in greater detail in the next section of this chapter; the fact that the model 
displays a 100% false positive rate with this test set of samples is of greater concern. 
Similar results were observed for the PCA-LDA SIL classification model presented in 
Table 7.2. All negative test set samples misclassified as LSIL as did 3 HSIL samples; 
one of the HSIL samples misclassified as negative whereas the rest were all considered 
HSIL. 
 
Table 7.2 Confusion matrix showing the result of the testing of the test set samples on the SIL PCA-LDA 
classification algorithm. 
Actual 
Classes 
Predicted Classes 
Negative LSIL HSIL 
Negative 0 27 0 
LSIL 0 9 0 
HSIL 1 3 7 
 
 
224 
 
These confusion matrices for both CIN and SIL algorithms remained unchanged when 
negative samples with previous disease were omitted from the PCA-LDA model set. 
 
The distribution of the test set samples according to age is shown in Figure 7.9. It can be 
observed that the majority of the samples in each category arise from patients aged 20 to 
29, which was expected given that the study was based on a screening population. 
Furthermore, neither negative nor CIN 1 categories were dominated by one single age 
group suggesting the misclassification of negative samples as CIN 1 might not be due to 
age bias.    
 
Figure 7.9 Test sample database according to patient’s age by decades; [20-29] years are represented in green, 
[30-39] in blue, [40-49] in red and [50-60+] in black. 
In addition, when negative samples from the test set were tested on the PCA-LDA 
algorithm which classifies negative samples according to their previous disease history, 
only one sample classified as “true” negative with no previous disease history (Table 
7.3). This was confirmed by the information made available by our clinical 
collaborators which showed all test set negative samples to have had previous disease. 
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The majority of samples had a previous history of moderate to severe dysplasia as 
shown in Table 7.4.   
Table 7.3 Confusion matrix of negative test set samples when tested on the PCA-LDA model to predict 
negative samples according to their previous disease history. 
 
 
 
 
 
 
 
 
Table 7.4 Negative test set database according to their previous disease history. 
Previous disease history No of samples 
Negative 0 
Borderline 0 
Low to mild dysplasia 8 
Moderate to severe dysplasia 19 
Total no. samples 27 
However when CIN 1 samples were also tested with a PCA-LDA classifier to 
distinguish between negative samples with and without previous history and CIN 1 
(Table 7.5), one sample was misclassified as negative without previous disease, two 
classified correctly as negative with previous disease and 25 misclassified as CIN 1. 
CIN 1 samples all classified correctly. 
  
Actual Classes 
Predicted Classes 
Negative  
Without previous 
history 
With previous 
history 
Negative test set 
samples 1 26 
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Table 7.5 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to 
predict negative samples according to their previous disease history as well as CIN 1 disease. 
 
The menstrual cycle data of the test set samples was also analysed. The sample database 
for this clinical feature was however very limited as shown in Table 7.6  where the 
sample numbers available for each day of the cycle are shown for each group  
Actual Classes 
Predicted Classes 
Negative 
CIN 1 Without previous 
history 
With previous 
history 
Negative test set 
samples 1 2 25 
CIN 1 test set 
samples 0 0 9 
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Table 7.6 Test set sample database, information regarding menstrual cycle day. 
Day of the Menstrual Cycle Number of samples Test Set Negative CIN 1 CIN 2 CIN 3 
1     
2     
3     
4     
5     
6     
7 2    
8     
9     
10 1 1   
11    1 
12 2  1  
13     
14 2   1 
15     
16     
17 1  1  
18     
19     
20 1  1  
21  1   
22     
23 1 1  1 
24     
25     
26     
27     
28 1    
TOTAL no samples 11 3 3 3 
 
The samples were then grouped according to their menstrual cycle phase, proliferative 
or secretory. Figure 7.10 shows the test sample database according to the menstrual 
cycle phase. Again, only small sample numbers were available, especially across the 
CIN sample groups which comprised fewer samples in total. 
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Figure 7.10 Test sample database according to menstrual cycle phases. Only samples with known menstrual 
date where considered. 
Negative test set samples were also tested in the PCA-LDA classification algorithm that 
separates negative samples according to their menstrual cycle phase. The confusion 
matrix in Table 7.7 shows that 6 of the 7 samples known to be in the secretory phase of 
the cycle, were correctly classified as such whilst one sample was misclassified as being 
in the proliferative phase. In addition, the 4 samples known to be in the secretory phase 
of the cycle were all correctly classified. The 16 negative test set samples with unknown 
menstrual cycle information were all deemed to be in the proliferative phase of the 
cycle. 
Table 7.7 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to 
predict negative samples according to their menstrual cycle phase. 
 
 
 
 
4 
1 2 1 
7 
2 1 2 
Negative
(n=11)
CIN 1
(n=3)
CIN 2
(n=3)
CIN 3
(n=3)
Proliferative Secretory
Actual Classes 
Predicted Classes 
Negative  
Proliferative phase Secretory phase 
Negative test set 
samples 21 6 
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However, similar to what was observed for previous disease history, when CIN 1 test 
set samples were included and tested on the PCA-LDA classification mode (Table 7.8) 
all negative samples misclassified as CIN 1. 
 
Table 7.8 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to 
predict negative samples according to their menstrual cycle phase as well as CIN 1 disease. 
 
Finally, negative and CIN 1 samples from the test set were tested on the PCA-LDA 
algorithm to classify between negative and HPV positive or negative CIN 1 samples. 
The confusion matrix in Table 7.9 revealed all CIN 1 samples classified correctly as 
CIN 1, including two as CIN 1 HPV negative and, all negative samples misclassified as 
CIN 1 HPV positive. Although the HPV status of the test set negative samples could not 
be confirmed as cytology negative samples are not routinely tested for HPV, two of the 
CIN 1 test set samples were confirmed to test negative for HPV (Appendix 4). 
 
Table 7.9 Confusion matrix of all test set samples when tested on the PCA-LDA disease classification model 
PCA-LDA which also stratifies CIN 1 samples into HPV positive or negative. 
Actual Classes 
Predicted Classes 
Negative CIN 1 HPV - HPV + 
Negative test set 
sample 0 0 27 
CIN 1 test set 
sample 0 2 7 
 
 
  
Actual Classes 
Predicted Classes 
Negative  CIN 1 Proliferative phase Secretory phase 
Negative test set 
samples 0 0 27 
CIN 1 test set 
samples 0 0 9 
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7.3 Discussion 
Thus far in this study cross validation has been used to evaluate the performance of the 
PCA-LDA models generated to achieve disease classification; cross validation methods 
have previously been reported to reduce the risk of overfitting when the number of 
samples available is too limited to subdivide into one training, and one independent 
validation set. However, much like a newly discovered biomarker, the potential to use 
spectral signatures to classify patient samples needs to be tested and confirmed in an 
independent, preferably large, cohort of samples to assess its true clinical viability 
(Baker et al. 2016).   
As part of the initial study design and, included in the ethical approval was the 
collection of an independent set of samples to be used for PCA-LDA model validation. 
Many of the received samples were however unsuitable for Raman spectroscopy (n= 
31) due to insufficient cellularity and/or masking effects of debris as a result of the 
ThinPrep® slide being prepared from residual material from the collection vial. The 
overall sample number of the test set (n=48) was much smaller than that of the model 
set (n=166). Nevertheless, this new database was used to test the PCA-LDA 
classification models obtained thus far. 
The general performance of both CIN and SIL PCA-LDA classification models for the 
test set was not as good as what was achieved in previous chapters for LOPOCV. 
Confusion matrices showed CIN 1 and CIN 3 detection to be satisfactory. The 
misclassification of CIN 2 samples as CIN 1 could be hypothesised to be either a 
misclassification in the reported cytology or perhaps due to sample regression 
(Moscicki et al. 2010b) with ICC profiling of the samples needed to confirm this. 
However, the fact that negative samples all misclassified as false positives posed a 
greater concern. Despite being expected from the mean Raman spectral analysis, this 
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misclassification could either mean (1) misclassification of the samples upon cytology 
screening, which seemed very unlikely that all the negative test set samples were false 
negatives; (2) complete inaccuracy of the PCA-LDA models obtained thus far; or (3) 
the need to account for all possible sources of normal patient variations (i.e. menstrual 
cycle, positive HPV infection)  which might be deeming normal negative samples as 
false positives. 
The mean spectral analysis (and) showed that the negative test set samples did not have 
the exact same fingerprint as the CIN 1 samples from the model set (Figure 8.7), despite 
showing a CIN 1 like profile (Figure 8.6).  This suggests that these samples are not true 
CIN 1 samples but rather a result of confounding factors, most probably due to normal 
patient variability. 
To further test this, PCA-LDA models from chapter 5 were used to evaluate how the 
negative samples of the test set would classify as regards previous disease history and 
menstrual cycle. Analysing negative samples alone, the PCA-LDA models were able to 
identify 99% of the negative test set samples as previously diseased, showing a similar 
high accuracy to classify with regard to menstrual cycle. However, when compared with 
CIN 1 samples, confusion matrices showed most negative samples were still 
misclassified as CIN 1 regardless of menstrual cycle or previous disease. For menstrual 
cycle, the limited sample numbers available may have prevented a more accurate 
classification and for previous disease history it should be noted that no “true negative” 
was included in the test set database. Furthermore, for the PCA-LDA classification 
model for negative samples in chapter 5 (Tables 5.18 – 5.20), only one sample had 
previous moderate to severe disease history. This could have undermined the model as 
more severe disease status might induce more marked spectral changes accounting for 
the observed misclassification.  
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PCA-LDA classification that would consider samples as negative, CIN 1 HPV positive 
or HPV negative was also analysed and results showed 100% of negative test set 
samples to classify as CIN 1 HPV positive. Unlike disease history and menstrual cycle 
phase, patient information was not available for the test set negative samples as regards 
HPV as negative cytology samples are not routinely tested. 
Nevertheless, our results seem to highlight the need to fully characterise the “normal” 
spectrum before disease classifiers can be applied. Even though possible variability was 
explored as discussed in Chapter 5, much of the information needed was not available in 
significant numbers to allow conclusive models. For example, data on normal 
menstruation cycle variation was limited and most importantly HPV testing of negative 
samples is not carried out routinely so this information was not available at all. When 
negative and CIN 1 test set samples were tested for negative versus CIN 1 HPV positive 
or negative classification, all negative samples were classified as CIN 1 HPV positive. 
The fact that two of the CIN 1 cases were classified as CIN 1 HPV negative, in 
agreement with their HPV test result, seems to suggest that the HPV status of the 
negative samples could be playing a key role in this misclassification.  Unfortunately, 
however, this could not be confirmed with a HPV test result. 
As discussed previously, a thorough investigation into the effects of different HPV 
infections, both high and low risk, on the Raman spectra needs to be undertaken across 
all sampling groups. Similarly, ICC panels such as p16/Ki-67 or others could aid in 
better understanding of the misclassifications occurring between sample groups 
(Ikenberg et al. 2013; Griffin et al. 2015). Similarly, biomarkers could help to better 
understand the importance of previous disease history as HPV infection could still be 
present and/or other biochemical changes which could confound disease classification 
algorithms. Indeed, HPV infection can persist after treatment for CIN with HPV and 
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cytology co-testing being currently recommended as follow-up test of cure for the 
CervicalCheck screening programme (CervicalCheck 2012; CervicalCheck 2015b).  
Our data also seems to suggest that despite being correctly inferred, menstrual cycle 
information from the patient samples does not improve the classification accuracy 
despite being reported to do so in in vivo studies (Kanter et al. 2009b). Similarly, 
menopausal status has also been reported to influence disease classification algorithms 
based on the sample Raman spectra (Kanter et al. 2009b). Our sample database did not 
comprise data with regard to this or hormonal therapy which therefore could not be 
investigated. However, a recent study by our group showed spectral variability could be 
observed based on hormonal variations but did not confound PCA separation between 
negative and abnormal samples (Traynor et al. 2016). Finally, increasing both 
modelling and test set numbers across all known clinical variables is the only way to 
improve classification algorithms and interpret/ understand misclassification.  
Lastly, the investigation of the samples p16 and Ki67 immunocytochemistry profiles 
and their correlation with the Raman spectral profiles is considered in the next chapter.  
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CHAPTER 8 INVESTIGATION OF P16 AND KI-67 STAINING 
PROFILES IN THINPREP® CERVICAL CYTOLOGY 
SAMPLES FOLLOWING RAMAN SPECTROSCOPIC 
ANALYSIS 
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In this chapter it is proposed to correlate the Raman spectroscopy profiles of the 
analysed samples with two of the molecular biomarkers described in chapter 1 (Section 
1.2): p16 and Ki-67. The simultaneous expression of both biomarkers is reported in the 
literature to relate to the underlying mechanism of cervical cancer progression and its 
most common detection method is the CINtec® PLUS kit (Roche). This 
immunocytochemistry polymer assay, already used in some clinics, is designed to 
provide a double stain of cytoplasmic p16 and nuclear Ki-67 proteins and is described 
in detail in section 3.4.1, chapter 4. The samples’ ICC profile is deemed positive if stain 
is observed for both p16 and Ki-67, or negative if only one or none of the biomarkers is 
observed. Additionally, all samples not stained with CINTec® PLUS kit will be stained 
with Pap stain. The complete sample set will then be subjected to confirmatory 
cytological screening at Altnagelvin Hospital.  
Possible correlation patterns between spectral data and ICC positivity/negativity are to 
be studied using PCA with PLS-LDA used to evaluate the ability to infer ICC profiles 
from Raman spectroscopy data. The ICC profiles of CIN 2 samples will be of particular 
interest as they might prove useful to distinguish between samples more like CIN 1 
(negative ICC) and samples more like CIN 3 (positive ICC).  Moreover, the re-
screening of all samples will be used to correct for any false positives or negatives in 
the sample database, and minimise bias for the PCA-LDA classifiers built in previous 
chapters.    
8.1 ICC Optimization  
Although the CINtec® PLUS kit (Ventana for Roche, Ireland) has been designed 
specifically for cervical cytology specimens and extensively described in the literature 
(Possati-Resende et al. 2015; Bergeron et al. 2015; White et al. 2016), it has never been 
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reported in cervical cytology samples subjected to Raman spectroscopy. Thus, it was 
necessary to establish if the H2O2 treatment and/or Raman recording had any influence 
on the quality of the staining obtained. For this purpose, ThinPrep® samples were used 
to assess the influence of H2O2 treatment and Raman recording on the 
immunocytochemistry result. 
ThinPrep® slides were prepared from one spare ThinPrep® vial of a known CIN3 case, 
obtained from The Coombe Women and Infants University Hospital, on the 
ThinPrep®2000 at the DIT School of Biological Sciences lab and subjected to both 
H2O2 treatment and Raman spectroscopy, firstly individually and then together. 
Negative controls in which H2O2 treatment and Raman spectroscopy were omitted were 
also included. 
ICC was performed as the manufacturer’s guidelines as described in section 3.4.1 of 
chapter 4. 
None of the procedures showed any influence on the quality of the immunostaining as 
shown in Figure 8.1.  
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Figure 8.1 CINtec® PLUS immunostain of CIN III ThinPrep® samples after H2O2 treatment and Raman 
spectroscopy.  In A-I) Red Ki-67 nuclear staining (arrows) and brown p16IKNK4a cytoplasmic staining 
(arrowheads) can be observed at x200 magnification under light microscopy, whereas no stain can be observed 
in the negative control slide A-II). B) is a positive control image of positive CINtec® PLUS immunostain from 
(Ventana® 2013).  
  
A-I 
A-II 
B 
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8.2 CINtec PLUSTM ICC staining of the samples included in this study 
ICC with CINtec PLUSTM was performed after all Raman spectroscopy recordings had 
been completed on all samples considered in the study, including the independent test 
set samples. ICC was however confined to a limited number of cases as each CINtec 
PLUSTM kit only provides enough reagents to immunostain approximately 50 samples 
and the limited consumable budget available for this project made it impossible to 
purchase more than one kit. 
Samples were randomly selected for ICC from across all sample groups, and one 
negative control in which the primary antibody was omitted was included in every 
staining batch, of 10 samples each. ICC was performed as per the manufacturer’s 
guidelines and optimisation protocol described in section 3.4.1 of chapter 3. 
All ICC stained samples were blindly evaluated by the author (Biomedical Scientist 
certified to practise by the Portuguese Health Service Administration) and Ms Alison 
Malkin (Fellow of the Academy of Clinical Science & Laboratory Medicine, Ireland 
and Fellow of the Institute of Biomedical Sciences, UK). Overall, the quality of the 
immunostain was found to be poor, with a brownish background colour throughout all 
samples (Figure 8.2, Figure 8.3 and Figure 8.4). Poorly preserved/defined nuclear 
structure (Figure 8.2C) of the cells made a definitive classification difficult, especially 
when trying to differentiate abnormality from metaplasia and inflammatory status; and 
to determine abnormality grade. In addition, differential diagnosis of cell aggregates 
was not possible in most samples as preservation of cell morphology was also found to 
be inadequate (Figure 8.4B). Dual staining of p16 and Ki-67 was only observed with 
confidence in one sample (Figure 8.5) classified as CIN 3 and in accordance with the 
sample’s cytological report.  Furthermore, the specificity of p16 stain to the cytoplasm 
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(Figure 8.2) and of Ki-67 to the nucleus (Figure 8.3) was in many circumstances 
dubious due to the poor detail evident upon microscopic evaluation. 
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x10
 
x200 x400 
A B C 
B 
Figure 8.2 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. Although brown stain, attributed to p16, can be observed (arrow heads) the morphological 
and nuclear detail is lost and the specificity of the stain to cytoplasm cannot be assessed. (A), (B) and (C) show the same sample at x100, x200 and x400 magnifications with 
arrow heads indicating the possible positive brown stain for p16. 
x200 x100 
A 
Figure 8.3 ThinPrep® cervical cytology sample stained with CINTecPLUSTM. (A) 
Shows the erratic single red stain, attributed to Ki-67, which can be observed in most 
samples. However, as no cytoplasm is present it is not possible to establish which type 
of cell it is or if the stain is specific. (B) is a x200 magnification of (A). 
 
241 
 
 
x10
 
B A 
x400 
Figure 8.4 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. (A) is a x100 magnification image showing inconsistent red stain indicated by the black 
arrows and attributed to Ki-67, on cells without cytoplasm.  Red stain, indicated by red arrow heads, can also be observed in some cells of cellular aggregate at x100 
magnification; however the morphological detail is lost and the specificity of the stain to the nucleus of the cells cannot be assessed. (B) Another sample with an 
aggregate of cells, at x400 magnification, where a brownish stain can be observed; in addition, red stain is also observed as indicated by the two black arrows. The 
morphological detail however does not allow establishing if both stains are specific for cytoplasm and nucleus respectively.  
  
B 
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The poor staining quality led both screeners to be unsure about the definitive ICC result 
of most samples and about the overall diagnosis classification; with some samples 
unsuitable for screening altogether. For this reason ICC staining patterns could not be 
correlated with the Raman spectroscopy profiles and the influence on the sample 
classification remains to be assessed. 
These results are thought to be a direct result from the long air-drying period to which 
the samples were subjected. Literature suggests that air-dried smears, even if previously 
alcohol-fixed before drying (like our ThinPrep® samples) could probably suffer from 
antigen deterioration and even when hydration is attempted results may not be reliable 
(Noorden 2015). Furthermore the ThinPrep® user’s manual does not recommend slides 
to be  air-dried at any time prior to staining (Hologic 2014). 
  
x200 x400 
B 
A 
Figure 8.5 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. Positive dual stain can be 
observed at x200 (A) and x400 magnification (B). The cell nucleus is stained red for Ki-67 whilst the cytoplasm 
stained brown for p16. 
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8.3 Pap staining of the samples included in this study 
All outstanding samples not randomly selected for p16 and Ki-67 ICC with the CINtec 
PLUS® kit were subjected to Pap stain (Sigma-Aldrich, UK) according to the method 
described in section 3.5, chapter 4. 
A dirty background was also observed throughout all Pap stained samples and, much 
like ICC, the quality of the stain seemed to have been compromised by the long air 
drying periods to which the samples were subjected. The ability to clearly see the detail 
of nuclear and cell clusters was lost as can be observed in Figure 8.6, leading once again 
to uncertainty with regards to final diagnosis of the samples as the degree of nuclear 
abnormality or chromatin pattern was deemed not assessable. The differentiation of 
metaplasia cell clusters from CIN aggregates was also often found difficult. The 
majority of the cells observed originated from the squamous cervical epithelia with 
superficial and intermediate cells being the most abundant types observed.  
 
Figure 8.6 Pap stained ThinPrep® cervical cytology sample showing a cellular aggregate with poor cellular 
morphology and nuclear detail to allow definitive classification of the sample. (A) and (B) show the cellular 
aggregate at x200 and x400 magnification respectively. Superficial cells can be observed in orange 
whileintermediate cells present a blue cytoplasm. 
B 
A 
x200 x400 
A 
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8.4  Discussion  
The ICC results are in clear contrast to those obtained upon optimisation of the 
technique therefore suggesting that the long periods of air drying to which the study 
samples had been subjected to before ICC had a significant negative impact on the 
quality of the ICC. Although the samples used to optimise the ICC were subjected to 
air-drying and the exact same Raman spectroscopic procedure as the study samples, 
they were prepared fresh from ThinPrep® vials whereas the samples included in this 
study were received as a ThinPrep® slide already air-dried for an unknown period of 
time. Furthermore, samples were received in several batches and ICC was only 
performed after all Raman spectroscopy was concluded in order to have an unbiased 
mix of all sample groups (from all received batches) being stained at the same time. 
This led to long periods of air drying, estimated to range from 1 to 3 years after the 
ThinPrep® slide was prepared.  
The ethical approval for this study only allowed the collection of one slide per case and 
therefore the biomarker part of the study was limited to a maximum of one ICC or 
conventional Pap stain. CINtec® PLUS was chosen because it was already fully 
optimised for cervical cytology samples and several reports have shown its clinical 
value for the diagnosis of CIN 2+ samples in triage of ASCUS and LSIL cytology 
(Bergeron et al. 2015; White et al. 2016).   
The kit allows the dual staining of p16 and Ki-67 proteins. The first is a cyclin 
dependent kinase inhibitor which is thought to slow down cell cycle by facilitating the 
re-binding of retinoblastoma protein (Rb) and E2F transcription factor.  However, when 
present, the HPV E7 protein, a product of HPV E7 oncogene, interrupts the linkage of 
Rb and E2F, disrupting this pathway and leading to the accumulation of p16 in the 
cell’s cytoplasm. Overexpression of p16 protein is therefore perceived as a product of 
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HPV induced transformation (Tsoumpou et al. 2009; Roelens et al. 2012). However, 
positive p16 stain has also been reported in non-dysplasic cells (Trunk et al. 2004). Ki-
67, on the other hand, is a nuclear protein expressed in all phases of the cell cycle 
except G0 and, under normal physiological conditions, limited to the basal layers of the 
cervical epithelium (Scholzen et al. 2000). A positive result is indicated by the co-
expression of both p16 and a Ki-67 protein in the same cell, a hallmark of the cell cycle 
deregulation. 
Approximately 90% of new HPV infections resolve within two years (Franco et al. 
1999; Ho et al. 1998). Furthermore 58% of CIN1 lesions are thought to regress without 
intervention (Ho et al. 1998; Holowaty et al. 1999)  within 24 months; and although 
CIN2 and 3 lesions are thought to be much more likely to persist than to regress, studies 
have also reported spontaneous regression (Moscicki et al. 2010a; Trimble et al. 2005). 
ICC panels are therefore used instead of or in conjunction with HPV testing, to achieve 
a better differential diagnosis and estimate the risk of progression. Several studies have 
further proposed this p16/Ki-67 dual staining to be used as a triage tool for equivocal or 
low-grade cervical cytology samples, reporting the ICC specificity to be higher than that 
of HPV testing for detection of CIN2+ in both ASCUS and LSIL populations (Bergeron 
et al. 2015; White et al. 2016). Nevertheless a systematic review have found the bias 
risk to the design of some preliminary studies to be high (Kisser et al. 2015). 
It was originally proposed to correlate the staining profiles with the Raman 
spectroscopy profile of the samples and evaluate if (1) it was possible to infer the 
staining pattern from the Raman signature and (2) if this information allowed 
refinement of the diagnosis algorithm for better differential diagnosis and reduction in 
the false positive rates, especially amongst CIN samples. In this study ICC and Pap 
stain were done manually so, in order to guarantee the processing of unbiased sample 
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groups (negative, CIN 1, 2 and 3), randomly selected samples from all groups were 
included in each staining batch. With samples being received at different time points, 
this delayed the staining procedures until after all samples were received and analysed 
by Raman spectroscopy which meant samples were air-dried for long and varied periods 
of time.  Despite being unable to fulfil this aim it is recommended that such a study be 
carried out in the future. Furthermore, changing the sample type acquired from the 
hospital from pre-prepared ThinPrep® slides to ThinPrep® vials would allow full 
control over the sample air-drying time and, at the same time, would allow multiple 
slides to be prepared from one single sample vial which could in turn be used to 
perform additional ICC panels like those proposed by several groups (Griffin et al. 
2015; Yemelyanova et al. 2013).  These groups argue that the assessment of the HPV 
lifecycle deregulation in cervical tissue may hold the key to improve disease 
stratification. Doorbar’s group propose complementary immunohistochemistry panels 
using HPV E4 protein reporting its ability to identify low-grade viral disease which due 
to abundant E4 expression can be distinguished from non-viral pathologies like 
metaplasia. Also reported was the combination of E4 and p16 proteins to sort CIN 2 
samples into subgroups of “CIN1-like productive infection” or “CIN3-like transforming 
infection” based on the extent of HPV deregulation and lifecycle completion present in 
the samples (Griffin et al. 2015). In a different study, Yemelyanova et al. reported L1 
and L2 (HPV capsid proteins) to be only expressed in LSIL/CIN1 lesions and rarely in 
HSIL/CIN2+ thus suggesting further examination of their ability to predict persistent 
infection and/or disease progression (Yemelyanova et al. 2013). 
Finally, both ICC and Pap stained samples were intended to be subjected to a re-screen 
in order to identify any discrepancies between the overall case classification obtained 
upon sample collection and the final classification obtainable from the actual sample 
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used for Raman spectroscopy. This was unfortunately not possible as although the 
recording coordinates allowed cell re-visiting, the vast majority of the cells displayed 
poor staining quality of both ICC and Pap stains after the Raman spectroscopy 
component of the project was completed. The re-screen of all recorded cells was 
intended to confirm if the cells recorded were indeed negative, CIN 1, 2 or 3, ensuring 
any discrepancies between Raman spectroscopy and cytology report did not arise from 
erroneous cell recording, particularly in CIN samples when multiple grades can be 
present in the same sample.  In addition, it would also validate if Raman spectroscopy 
allowed overall sample classification regardless if all Raman-screened cells were of the 
highest abnormality grade or not. Despite the re-screening of the overall samples and 
the individual Raman recorded cells not being possible, the fact that the PCA-LDA 
model results seem in accordance with the classification reported in the sample 
cytological reports, supports our hypothesis that Raman spectroscopy is able to allow a 
correct sample classification even if it cannot be guaranteed all recorded cells belong to 
that specific classification category.  Nevertheless it is recommended that future studies 
perform any ICC or structural stains such as Pap as soon as possible after Raman 
spectroscopy acquisition to avoid subjecting the samples to long air-drying periods 
which was found to compromise the quality of the staining which in turn prevents the 
visualization of the cellular and nuclear morphology needed to make an accurate 
diagnosis classification. Additionally, having access to ThinPrep® vials would on one 
hand, ensure a complete control over the sample preparation and air-drying times and, 
on the other hand allow further ICC markers to be evaluated as multiple slides could 
then be prepared.  
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CHAPTER 9 CONCLUSIONS AND FUTURE WORK 
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9.1 Conclusion 
In this study the aim was to evaluate the potential of Raman spectroscopy as a 
biomedical tool for the screening of routine cervical cytology samples from a screening 
population.  
Cervical cancer remains one of the most common cancers affecting women worldwide 
(IARC 2012b) and despite the success of the current screening programmes which are 
based on the cytological evaluation of cervical cells under light microscopy, new 
technologies are needed. The subjectivity of the grading characteristics and the constant 
intra and inter-laboratory validation necessary to achieve and maintain the highest 
reported sensitivity and specificity rates has led to the investigation of better diagnosis 
tools. 
The performance of automated screening systems is much debated and all current 
systems still require a highly trained pathologist or cytoscreener to sign-off the final 
diagnosis (Kitchener et al. 2011). After HPV was accepted as the underlying condition 
for cervical cancer, HPV testing has emerged, in recent years, as the ultimate diagnosis 
tool with several countries trialling it as a primary, and/or co-testing screening tool. In 
Ireland, HPV testing is currently used for triage of abnormal cytology samples 
(CervicalCheck 2015a) and has recently been recommended as a primary test tool for 
the UK (NHS Cervical Screening Programme 2016). However, HPV testing only 
provides information regarding the HPV infection status which in turn depends on the 
actual test used and its detection modality (for viral DNA or RNA); information 
regarding cellular abnormalities remain unknown. Although a HPV negative result is a 
good predictor of low risk of cervical cancer, a HPV positive result is unclear as most 
infections can resolve in a few months to a year.  Similarly, HPV testing is not 
recommended as a primary or co-testing tool in young women (up to 30 years of age) as 
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HPV infections are most common in these women (American Cancer Society 2016). 
Furthermore, the trial introduction of HPV testing as a screening tool has resulted in an 
increase in colposcopy referral rates by as much as 200% and these remain increased 
despite improved guidelines (Haldorsen et al. 2015).  
Raman spectroscopy of cervical cytology samples would, in theory, be able to provide a 
better alternative allowing a non-subjective result based on the underlying biochemical 
changes that lead to cervical cancer. Previous studies have shown it is possible to 
differentiate normal and abnormal samples based on Raman spectral signatures.  
Although ex vivo studies have clear potential for aiding histological diagnosic, they are 
not suitable for screening purposes due to the need for tissue excision/biopsy. In vivo 
Raman measurements are proposed as an alternative with protocols resembling a 
colposcopy-like procedure in the clinic.  Nevertheless, these measurements might be 
more prone to confounding factors such as blood and debris, infections and alterations 
in general tissue density due to menstrual cycle or aging for example. Cytology has 
been widely used for cervical cancer screening, however only two previous studies have 
reported in the literature to investigate the potential of Raman spectroscopy using this 
platform. Rubina et al. considered cellular pellets (Rubina et al. 2013a) rather than a cell 
monolayer as studied by Bonnier et al. (Bonnier et al. 2014). Both studies identified the 
need to eliminate the contribution of blood and debris to the sample spectra and 
proposed suitable sample preparation methods to do so.  Rubina et al. further reported 
PCA-LDA classifiers to achieve a classification efficiency of approximately 80% but 
both studies were limited in terms of sample numbers and did not study the influence of 
any clinical factors to the Raman spectra.  In this study cervical cytology samples from 
a screening population were investigated by Raman spectroscopy and multivariate 
analysis, namely PCA and PCA-LDA, to test the ability for disease diagnosis. 
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In order to be cost-effective Raman spectroscopy and indeed all cytology and 
histopathology analysis platforms, have to be performed using common glass slides as 
used routinely in cervical cytology, as opposed to Raman substrates like calcium 
fluoride slides which are too expensive  to be cost-effective.  
The use of glass as a substrate limited our recording to the nucleus of the cells as 
previous studies showed the glass contribution to the cytoplasm to be too high to allow 
useful spectra to be obtained (Ostrowska 2011). Nevertheless, the use of glass substrates 
remain a challenge to the study as although similar glass spectra were obtained across 
all slides, the glass contribution to the sample spectra differed between sample groups. 
This seemed to be related to nuclear and cellular morphology, with a higher 
contribution in CIN 1 samples where cells displayed bigger and flatter nuclei. Initial 
PCA analysis showed it was possible to separate between negative and CIN samples 
based on their Raman spectral profiles but glass features dominated the main PC 
loadings. It was therefore necessary to correct for the substrate contribution in order to 
avoid classification bias. From all the methods tested, NNLS seemed to provide the best 
results by minimizing the glass features observed whilst retaining enough spectral 
information to allow separation of the samples upon PCA. A new glass correction 
method based on EMSC has recently been published (Kerr et al. 2016) and although it 
would be interesting to test it on this dataset, the fact that only one single reference glass 
spectrum is used might not result in any improvement against the NNLS method, 
presented here, which used a matrix of glass recorded from all model set samples. 
PCA-LDA analysis was further employed to construct CIN classification models of the 
samples based on their spectral profile. LOPOCV was used to test the model 
performance and sensitivity and specificity results obtained were very encouraging, all 
above 95%, therefore better than what is reported for Pap screening and HPV testing 
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(Arbyn et al. 2006; Kitchener et al. 2011; Dudding et al. 2015). The SIL reporting 
system was also investigated with PCA-LDA classifiers with similarly high sensitivity 
and specificity results, all above 97%.  
However, patient specimens are heterogeneous; with both major advantages and 
disadvantages. If on one hand, they provide the ultimate sample, on the other hand, they 
do not allow for any control or testing of the variables that might affect them; making 
most of the work dependent on the information received from clinic, both quantitatively 
and qualitatively. The greatest limitation of the study was therefore the sample database. 
Although the number of samples used was higher than that used in many spectroscopy 
studies reported in the literature for cervical cancer (Ramos et al.,2015); they were 
unevenly distributed across all sample groups, a direct result from collecting from a 
screening population where fortunately the vast majority of the cases are negative. This 
however, could have a negative impact when trying to construct classification models 
like PCA-LDA as class unbalance could lead to bias (Varmuza et al. 2009; Beleites et 
al. 2013). A further limitation was the clinical information made available to this study. 
For example, it was not possible to control the numbers of 20, 30, 40 or 50 year old 
patients being screened at the time the study samples were being collected, or that a 
patient would remember the date of her last menstruation period allowing us to infer the 
menstrual cycle day and phase.  As a result the clinical information received was 
incomplete with some information available for only some samples. Nevertheless, 
having demonstrated that PCA and PCA-LDA of the Raman spectroscopy profiles of 
cervical cytology samples could be used to achieve accurate sample classification, the 
influence of several clinical factors on the sample spectra and the PCA-LDA algorithms 
was investigated. 
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The results suggested it is not feasible to infer patient age from the Raman spectral 
profile of the samples and it was postulated to have no impact on the disease 
classification models which is in agreement with other spectroscopy studies (Sahu et al. 
2012; Bhattacharjee et al. 2013) that reported age not to influence disease classification 
algorithms despite being inferred from the spectra. Nevertheless, the further evaluation 
of age would still be advised in future studies. The limited sample database did not 
allow CIN samples to be analysed according to age and also prevented the PCA-LDA 
classification models to be organised for age, making age-related performance still 
unknown.   
Menstrual cycle information was more limited as it was dependent on the patient being 
able to inform the clinic as to when her last menstruation period occurred. Nevertheless, 
the moderate performance of the PCA-LDA results suggests it might be feasible to infer 
such menstrual cycle phase from the patient Raman spectra but this information did not 
improve the CIN classification algorithms.   
Despite being mainly limited to CIN 1 samples, the correlation of HPV infection status 
with the Raman spectral profiles seems to suggest HPV infection to have a significant 
impact on the spectral profile of the sample; with PCA-LDA models showing 
encouraging performance to predict CIN 1 HPV positivity or negativity in addition to 
the other classification groups, particularly in the CIN PCA-LDA classifier. These 
results seem in line with reports that HPV infection can be detected by Raman 
spectroscopy of cervical pellets and cell lines (Jess et al. 2007; Ostroswka et al. 2010; 
Vargis et al. 2012) and more recently cervical fluids (Choi et al. 2015). However it was 
not possible to conclude on different HPV infection profiles (HPV typing) due to small 
sample numbers across all groups on the database. Negative samples should also be 
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investigated with the results obtained for the test set group (chapter 8) suggesting that it 
might play an important role.  
Finally, previous disease history was also considered as it has previously been reported 
that underlying disease might be inferred by Raman spectroscopy for both in vivo 
(Keller et al. 2008) and ex vivo studies (Rashid et al. 2014). Our results are suggestive 
that previous disease information could successfully be inferred from the spectral data 
of negative and CIN1 samples. However, this was only true for the presence or absence 
of previous disease as specific backgrounds could not be correctly inferred due to the 
small sample numbers available. Furthermore, no significant difference was found to 
the model performance after LOPOCV when previously diseased negative samples were 
removed from the PCA-LDA disease classification model which seems supportive that 
previous disease does not bear much influence to the overall disease classification 
algorithm. However, only one of the negative samples had previous history of moderate 
to severe dysplasia which might result in previous disease influence being 
underestimated in these models. Results for the test set sample database are supportive 
of this with all negative samples presenting with previous disease history and the 
majority (74.1 %) with moderate to severe dysplasia, it was reassuring the PCA-LDA 
model classified 96.3% of these samples correctly as having previous disease history.  
When an independent dataset to our PCA-LDA models was tested, confusion matrices 
show the CIN and SIL classification models to be 100% accurate to detect CIN1/LSIL, 
with one false negative case reported for CIN 3 samples (n=5), with all others correctly 
classified as either CIN3 or HSIL.  A mixed picture was obtained for the CIN 2 samples 
with only 50% classifying correctly, perhaps a result of disease regression or further 
suggesting the heterogeneity of this group with some samples being CIN1/LSIL-like 
(Griffin et al. 2015). Finally, 100% the cytology screened negative samples of the test 
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set were deemed as false positives by both CIN and SIL PCA-LDA models, 
misclassifying as CIN 1 and LSIL, respectively. The negative samples were then 
analysed according to their previous disease history with the PCA-LDA model 
classifying all but one (96.3%) as having had previous disease; a result in line with the 
information available for these samples all known to be positive for previous disease, 
74.1% moderate or severe.  These results seem to support the idea that previous disease 
history might in fact act as a confounding factor in the case of negative samples. It 
could be that the small sample numbers with previous disease (n=18) available in the 
model set (n=88) were underfit by the rest of the “true” negative samples or, that there 
is a specific timeframe since previous disease occurs in which effects can still be 
translated into spectral features. HPV results for the negative samples were not available 
so although dysplasia was not seen morphologically, HPV infection may still have been 
present.  
Both negative and CIN 1 test samples were further tested on the PCA-LDA 
classification model to distinguish negative from CIN 1 HPV positive or negative 
samples. In this model, all negative samples classified as CIN 1 HPV positive further 
suggesting that HPV infection might indeed still be present perhaps causing the CIN 1 
spectral phenotype. The fact that CIN 1 samples were all correctly classified including 
the only 2 HPV negatives included as part of the test dataset, strengthens these results. 
This study further attempted to analyse two of the most extensively studied biomarkers 
in cervical cancer research: p16 and Ki-67 (Bergeron et al. 2015; White et al. 2016). 
The dual ICC staining of both these biomarkers is accepted as a confirmation of 
persistent HPV infection and an indication of CIN 2+ (Roche Diagnostics 2016). The 
quality of cellular and particularly nuclear detail after ICC staining was however too 
poor to allow a definitive evaluation of most of the samples considered in this study. 
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Similar results were observed for the Pap stained samples and it was therefore decided 
the samples did not retain the necessary morphology detail to allow grading and 
differential diagnosis which could then be correlated with the Raman spectroscopy 
profiles. The poor morphology and nuclear detail is thought to be direct consequence of 
the long air drying periods to which the samples were subjected. 
It was therefore not possible to (a) correlate the samples ICC profiles with their Raman 
spectra or (b) confirm if each negative, CIN 1, 2 and 3 cell recorded was in fact of that 
specific category. However, the encouraging sensitivity and specificity results obtained 
for the PCA-LDA models using both CIN and SIL classifications seem supportive of 
the idea that it might not be necessary that all cells recorded from a CIN 1, 2 or 3 
sample need to be in fact CIN 1, 2 or 3 respectively. Although it was not possible to 
confirm, for example, that only CIN 1 cells were recorded from CIN 1 samples, the 
PCA-LDA classifiers showed high performance, parallel to the cytology diagnosis of 
CIN 1. This notion is further supported by reports that underlying pathology can be 
detected by Raman spectroscopy in normal appearing areas of a diseased sample (Keller 
et al. 2008; Rashid et al. 2014) indicating that the CIN spectral signature might be 
present even in normal appearing cells from a CIN sample (Schubert et al. 2010). 
Nevertheless it would be important that future studies are able to do this retrospective 
classification of the recorded samples as it will inform on numbers needed to achieve 
good classification.  
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9.2 Future directions 
The results of this study show Raman spectroscopy can successfully be used for the 
evaluation of cervical cytology samples collected from a screening population and 
prepared through the ThinPrep® LBC platform. Compared to other techniques, and in 
particular vibrational spectroscopies like scanning near-field optical microscopy in 
combination with free electron-laser (SNOM-IR-EL), ATR (Halliwell et al. 2016) and 
infrared micro-spectroscopy (Schubert et al. 2010) which have also been reported  to be 
promising diagnosis tools, the Raman methodology reported in this study has the 
advantages of requiring minimal sample preparation and the ability to use a cheaper and 
more common substrate, the ThinPrep® glass slide already used for cervical cancer 
screening. This means Raman spectroscopy could be more easily implemented in the 
current cervical cancer screening workflow process and also represents a more cost-
effective tool to increasingly pressured health care systems.  Compared with the manual 
or semi-automated screening of cytology samples, currently used for cervical cancer 
screening, Raman spectroscopy would allow for a non-subjective outcome, dependent 
only on the sample biochemical fingerprint rather than subjective grading characteristics 
which in turn would allow for improved reproducibility and maintenance of high 
sensitivity and specificity rates.  
The samples in this study were however not recorded blindly or at random, as abnormal 
looking cells were targeted when the samples were known to have an abnormal 
cytological diagnosis. Despite saving the coordinates of the recorded cells with the 
intention of revisiting and assessing them after ICC and Pap staining; the morphological 
detail needed to do so was not preserved due to long air-drying periods and it was 
therefore not possible to confirm the diagnosis/grade of each recorded cell. 
Nevertheless, good performance was achieved for PCA-LDA classifiers based on the 
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recorded Raman spectra, which had the cytology diagnosis as reference. As previously 
mentioned, this suggests that it might not be necessary that in CIN/SIL samples, all cells 
recorded from are in fact CIN or SIL (Schubert et al. 2010).  
Future studies would however need to address some of the limitations found by this 
study. Firstly, there is a need for long spanning sample collection to guarantee similar 
patient numbers across all diagnosis categories and clinical features. Even though 
Raman spectroscopy would still be recorded from cells prepared onto ThinPrep® slides, 
future studies should however aim for the collection of the ThinPrep® vials rather than 
a ready-made slide as collected for this study. The collection of vials would allow 
control over all steps of the slide preparation, guaranteeing similar air-drying periods 
amongst all samples, for example; whilst allowing multiple slides to be generated from 
the same sample which in turn would broaden the amount of research possible. For 
example, multiple biomarkers could be tested for the same sample. Future studies 
should be designed so that ThinPrep® vials would be collected, slides prepared and 
samples promptly subjected to Raman spectroscopy. The next step to take Raman cyto-
spectroscopy closer to the clinic is automation of both the recording process and the 
spectral analysis and classification algorithms. The ultimate system would have to be 
user-friendly and independent of subjective cell selection or user knowledge of Raman 
spectroscopy.  
In prospective studies the samples should be recorded blind (with unknown cytology 
outcome) and preferably by multiple users so that reproducibility could also be 
evaluated. Similarly, users would select cells at random and evaluate multipoint (when 
all cells are marked before recording starts) versus individual recording as this would 
enable a more automated recording step to be tested. The results of this study are 
suggestive that it might not be necessary for the correct classification of CIN and SIL 
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samples that all cells recorded from those samples are of that diagnosis category, 
however this still warrants further investigation.  
All samples collected would obviously be anonymised and, subject to ethical approval, 
all known clinical information would also be made available to the study(ies). It would 
be important to gather information with regards to age, LMP, menopausal status and 
any therapies undertaken, parity, previous disease history (if possible with dates), HPV 
vaccination and infection status, oral contraceptive use, all previously reported 
(Castellsagué et al. 2003; La Vecchia et al. 2014; Hestbech et al. 2015) to play a role in 
cervical cancer pathogenesis; so that the influence of these variables on the sample 
spectra and diagnosis algorithms can be thoroughly investigated. Biological samples are 
dynamic, and cervical cancer research is a rapidly changing field. HPV vaccination for 
example is thought to change the landscape of HPV infection and cervical 
abnormalities. So it is important that these are also monitored whilst developing this 
technology. Furthermore, despite much debate (Dudding et al. 2015) cervical cancer 
screening guidelines are likely to change to primary HPV testing, at least in the UK 
where that recommendation has been recently made (NHS Cervical Screening 
Programme 2016). Although the actual screening guidelines have not yet been made 
public, this will potentially mean that all cervical smears would be primary tested for 
the presence of HPV and only subjected to cytology screening if HPV positive. For 
development of a cytological screening tool, it would therefore be necessary to partner 
with a clinical-research team of pathologist and experienced screeners in order to obtain 
a cytological diagnosis of all the samples, even those which are HPV negative.  
In addition, partnering with one or more screening centres would also be necessary in 
order to access as many smear vials as possible, as they become ready to be discarded 
after diagnosis. Samples would then be Raman screened, Pap stained and finally 
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cytologically screened by 2 or more independent screeners. Results would be compared 
against HPV test results used for screening diagnosis and also against further HPV and 
biomarker research which would investigate low-risk types and the pattern of HPV 
infection and abnormality transformation (Yemelyanova et al. 2013; Griffin et al. 2015). 
If possible, spanning sample collection over at least 2 screening calls would also allow 
the investigation of regression/prognosis from the sample Raman spectra.  
Finally, this study only explored PCA-LDA algorithm for the sample classification; 
however more complex algorithms such as support vector machines should also be 
evaluated. If significant sample numbers can also be obtained across the clinical 
parameters these could also be input into the classifiers, to test if they would allow for 
an improved classification.  
In conclusion, this study is supportive that Raman spectroscopy could be used for the 
diagnosis of cervical cytology samples. It could also potentially allow for a more 
accurate diagnosis than HPV DNA testing as the underlying mechanisms of cervical 
cancer progression are potentially detectable through the Raman spectra. However, the 
need for automation and the necessity to investigate and fully understand how clinical 
features influence the spectral profiles will be key to take the technology closer to the 
clinic.  
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Appendix 2 The 2001 Bethesda Classification System adapted from (Apgar et al. 2003)  
I. SPECIMEN ADEQUACY 
Satisfactory for evaluation (note presence/absence of endocervical/transformation zone component) 
Unsatisfactory for evaluation . . . (specify reason) 
Specimen rejected/not processed (specify reason) 
Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality 
because of (specify reason) 
II. GENERAL CATEGORIZATION (Optional) 
Negative for intraepithelial lesion or malignancy 
Epithelial cell abnormality 
Other 
III. INTERPRETATION/RESULT 
Negative for Intraepithelial Lesion or Malignancy 
Organisms: 
Trichomonas vaginalis 
Fungal oganisms morphologically consistent with Candida species 
Shift in flora suggestive of bacterial vaginosis 
Bacteria morphologically consistent with Actinomyces species 
Cellular changes consistent with herpes simplex virus 
Other non-neoplastic findings (Optional to report; list not comprehensive): 
Reactive cellular changes associated with: 
inflammation (includes typical repair) 
radiation 
intrauterine contraceptive device 
Glandular cells status posthysterectomy 
Atrophy 
Epithelial Cell Abnormalities 
Squamous cell 
Atypical squamous cells (ASC): 
of undetermined significance (ASC-US) 
cannot exclude HSIL (ASC-H) 
Low-grade squamous intraepithelial lesion (LSIL) encompassing: human papillomavirus/mild 
dysplasia/cervical intraepithelial neoplasia (CIN) 1 
High-grade squamous intraepithelial lesion (HSIL) encompassing: moderate and severe 
dysplasia, carcinoma in situ; CIN 2 and CIN 3 
Squamous cell carcinoma 
Glandular cell 
Atypical glandular cells (AGC) (specify endocervical, endometrial, or not otherwise specified) 
Atypical glandular cells, favor neoplastic (specify endocervical or not otherwise specified) 
Endocervical adenocarcinoma in situ (AIS) 
Adenocarcinoma 
Other (List not comprehensive) 
Endometrial cells in a woman _40 years of age 
IV. AUTOMATED REVIEW AND ANCILLARY TESTING (Include as appropriate) 
V. EDUCATIONAL NOTES AND SUGGESTIONS (Optional) 
  
300 
 
Appendix 3 Modelling set sample database with relevant patient information  
Cytology sample model set database and respective clinical information. All samples received from Altnagelvin Hospital, Northern Ireland are listed with those considered unsuitable 
for Raman spectroscopy highlighted. 
HPV results are available for all samples with the exception of negative samples; hrHPV stands for high-risk HPV types.  Regarding to clinical history, samples are classified as no 
previous history, negative (NEG), borderline (BL), LSIL, HSIL or CIN 1, 2 or 3 history. Menstrual cycle day was obtained by subtracting the last menstruation period (LMP) date 
from the smear date. Samples from day 4 to 13 were classified as being in the proliferative phase of the menstrual cycle whereas samples in day 14 to 28 were considered to be in the 
secretory phase of the cycle. 
Model 
Sample 
ID 
Cytology 
diagnosis Smear Date LMP 
Menstrual 
cyle day 
Menstrual 
cycle phase HPV Result Age History  
1 Negative 14-03-2012 27-02-2012 16 Secretory n/a 37 
Mild, BL , 
NEG, CIN1, 
NEG 
2 Negative 14-03-2012 n/a n/a n/a n/a 56 NEG 
3 Negative 14-03-2012 n/a n/a n/a n/a 51 NEG 
4 Negative 14-03-2012 n/a n/a n/a n/a 52 NEG 
5 Negative 13-03-2012 n/a n/a n/a n/a 59 NEG 
6 Negative 13-03-2012 03-03-2012 10 Proliferative n/a 44 NEG 
7 Negative 13-03-2012 n/a n/a n/a n/a 28 BL, NEG 
8 Negative 14-03-2012 22-02-2012 21 Secretory n/a 37 NEG 
9 Negative 13-03-2012 n/a n/a n/a n/a 40 NEG 
10 Negative 13-03-2012 15-02-2012 27 Secretory n/a 42 NEG 
11 Negative 13-03-2012 06-03-2012 7 Proliferative n/a 30 NEG 
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12 Negative 13-03-2012 20-02-2012 22 Secretory n/a 46 NEG 
13 Negative 14-03-2012 n/a n/a n/a n/a 54 NEG 
14 Negative 13-03-2012 25-02-2012 17 Secretory n/a 27 NEG 
15 Negative 14-03-2012 23-02-2012 20 Secretory n/a 41 NEG 
16 Negative 13-03-2012 02-03-2012 11 Proliferative n/a 46 NEG 
17 Negative 15-03-2012 n/a n/a n/a n/a 62 MOD, NEG 
18 Negative 15-03-2012 05-03-2012 10 Proliferative n/a 25 NEG 
19 Negative 14-03-2012 n/a n/a n/a n/a 32 NEG 
20 Negative 14-03-2012 28-02-2012 15 Secretory n/a 42 NEG 
21 Negative 14-03-2012 n/a n/a n/a n/a 37 NEG 
22 Negative 15-03-2012 20-02-2012 24 Secretory n/a 41 NEG 
23 Negative 13-03-2012 n/a n/a n/a n/a 28 NEG 
24 Negative 15-03-2012 n/a n/a n/a n/a 33 NEG 
25 Negative 14-03-2012 n/a n/a n/a n/a 35 NEG 
26 Negative 15-03-2012 n/a n/a n/a n/a 49 NEG 
27 Negative 13-03-2012 n/a n/a n/a n/a 41 NEG 
28 Negative 13-03-2012 26-02-2012 16 Secretory n/a 39 NEG 
29 Negative 13-03-2012 n/a n/a n/a n/a 32 NEG 
30 Negative 12-03-2012 n/a n/a n/a n/a 45 NEG 
31 Negative 13-03-2012 n/a n/a n/a n/a 54 NEG 
32 Negative 13-03-2012 21-02-2012 21 Secretory n/a 46 MOD, NEG 
33 Negative 13-03-2012 08-03-2012 5 Proliferative n/a 31 1st Smear 
34 Negative 13-03-2012 26-02-2012 16 Secretory n/a 32 BL, NEG 
35 Negative n/a n/a n/a n/a n/a 48 NEG 
36 Negative 13-03-2012 n/a n/a n/a n/a 64 NEG 
37 Negative 14-03-2012 09-03-2012 5 Proliferative n/a 38 BL, NEG, Mild, NEG 
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38 Negative 14-03-2012 n/a n/a n/a n/a 26 NEG 
39 Negative 14-03-2012 n/a n/a n/a n/a 34 NEG 
40 Negative 14-03-2012 06-03-2012 8 Proliferative n/a 27 NEG 
41 Negative 14-03-2012 n/a n/a n/a n/a 27 NEG 
42 Negative 14-03-2012 24-02-2012 19 Secretory n/a 40 
NEG, BL, 
Mild, CIN1, 
NEG 
43 Negative 14-03-2012 n/a n/a n/a n/a 57 Mild, NEG, BL, NEG 
44 Negative 14-03-2012 01-03-2012 13 Proliferative n/a 47 NEG 
45 Negative 14-03-2012 06-03-2012 8 Proliferative n/a 32 NEG, BL, NEG 
46 Negative 14-03-2012 23-02-2012 20 Secretory n/a 36 NEG 
47 Negative 14-03-2012 n/a n/a n/a n/a 45 NEG 
48 Negative 12-03-2012 20-02-2012 21 Secretory n/a 48 NEG 
49 Negative 14-03-2012 n/a n/a n/a n/a 30 NEG 
50 Negative 13-03-2012 n/a n/a n/a n/a 32 NEG 
51 Negative 13-03-2012 n/a n/a n/a n/a 42 NEG 
52 Negative 13-03-2012 n/a n/a n/a n/a 52 NEG, BL, NEG 
53 Negative 13-03-2012 n/a n/a n/a n/a 62 NEG 
54 Negative 13-03-2012 n/a n/a n/a n/a 33 NEG 
55 Negative 13-03-2012 18-02-2012 24 Secretory n/a 35 NEG 
56 Negative 13-03-2012 15-02-2012 27 Secretory n/a 53 NEG 
57 Negative 13-03-2012 n/a n/a n/a n/a 62 NEG 
58 Negative 12-03-2012 03-03-2012 9 Proliferative n/a 55 NEG 
59 Negative 14-03-2012 n/a n/a n/a n/a 29 NEG 
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60 Negative 14-03-2012 n/a n/a n/a n/a 53 NEG 
61 Negative 13-03-2012 n/a n/a n/a n/a 56 
Mild, CIN3, 
NEG, Mild, 
NEG 
62 Negative 14-03-2012 06-03-2012 8 Proliferative n/a 50 NEG 
63 Negative 14-03-2012 n/a n/a n/a n/a 27 1st Smear 
64 Negative 15-03-2012 10-03-2012 5 Proliferative n/a 23 NEG 
65 Negative 15-03-2012 05-03-2012 10 Proliferative n/a 38 NEG 
66 Negative 15-03-2012 24-02-2012 20 Secretory n/a 29 NEG 
67 Negative 12-03-2012 n/a n/a n/a n/a 50 NEG, BL, NEG 
68 Negative 15-03-2012 17-02-2012 27 Secretory n/a 32 NEG 
69 Negative 15-03-2012 08-03-2012 7 Proliferative n/a 47 NEG 
70 Negative 15-03-2012 01-03-2012 14 Secretory n/a 48 NEG 
71 Negative 14-03-2012 21-02-2012 22 Secretory n/a 48 NEG 
72 Negative 15-03-2012 n/a n/a n/a n/a 51 MOD, NEG 
73 Negative 15-03-2012 n/a n/a n/a n/a 58 NEG 
74 Negative 14-03-2012 n/a n/a n/a n/a 31 NEG 
75 Negative 15-03-2012 n/a n/a n/a n/a 55 Mild, Mild, NEG 
76 Negative 14-03-2012 23-02-2012 20 Secretory n/a 38 Mild, NEG 
77 Negative 14-03-2012 07-03-2012 7 Proliferative n/a 48 NEG 
78 Negative 14-03-2012 n/a n/a n/a n/a 54 NEG 
79 Negative 14-03-2012 07-03-2012 7 Proliferative n/a 39 NEG 
80 Negative 14-03-2012 n/a n/a n/a n/a 56 
NEG, BL, 
NEG, Mild, 
NEG, BL, 
NEG 
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81 Negative 14-03-2012 n/a n/a n/a n/a 43 NEG 
82 Negative 14-03-2012 n/a n/a n/a n/a 49 NEG 
83 Negative 14-03-2012 n/a n/a n/a n/a 31 NEG 
84 Negative 15-03-2012 23-02-2012 21 Secretory n/a 42 NEG 
85 Negative 16-03-2012 n/a n/a n/a n/a 47 BL, Mild, NEG 
86 Negative n/a n/a n/a n/a n/a 38 NEG 
87 Negative 14-03-2012 01-03-2012 13 Proliferative n/a 32 1st Smear 
88 Negative 14-03-2012 01-03-2012 13 Proliferative n/a 41 NEG 
89 Negative 14-03-2012 27-02-2012 16 Secretory n/a 49 NEG 
90 Negative 14-03-2012 n/a n/a n/a n/a 63 1st Smear 
91 Negative 14-03-2012 n/a n/a n/a n/a 38 NEG, Mild, NEG 
92 Negative 15-03-2012 26-02-2012 n/a n/a n/a 47 
Mild, NEG, 
BL, NEG, 
BL, NEG 
93 Negative 14-03-2012 02-03-2012 12 Proliferative n/a 36 BL, NEG 
94 Negative 12-03-2012 n/a n/a n/a n/a 57 NEG, BL, NEG 
95 Negative 14-03-2012 n/a n/a n/a n/a 26 1st Smear 
96 Negative 14-03-2012 n/a n/a n/a n/a 50 NEG 
97 Negative 14-03-2012 n/a n/a n/a n/a 57 NEG 
98 Negative 14-03-2012 05-03-2012 9 Proliferative n/a 31 NEG 
99 CIN 1 06-01-2014 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 + 
HPV18 
26 
MILD, CIN 
1, MILD, 
CIN 1, BL 
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100 CIN 1 15-01-2014 n/a n/a n/a HPV18 33 NEG, MID,  CIN 1 
101 CIN 1 17-01-2014 n/a n/a n/a 12 other hr HPV types 27 MILD, CIN 1  
102 CIN 1 29-01-2014 n/a n/a n/a 12 other hr HPV types 23 
NEG, MILD, 
CIN 1  
103 CIN 1 07-02-2014 20-01-2014 18 Secretory 12 other hr HPV types 33 
NEG, MILD, 
CIN 1  
104 CIN 1 14-02-2014 n/a n/a n/a HPV 16 + 18 25 MILD, CIN 1  
105 CIN 1 20-02-2014 n/a n/a n/a 12 other hr HPV types 45 
CIN 1, NEG, 
MILD, CIN 1  
106 CIN 1 20-02-2014 06-02-2014 14 Secretory 12 other hr HPV types 28 
NEG, MILD, 
CIN 1, 
MILD, CIN 1 
107 CIN 1 21-02-2014 n/a n/a n/a 12 other hr HPV types 33 
NEG, MILD, 
CIN 1 
108 CIN 1 21-03-2014 07-03-2014 14 Secretory 12 other hr HPV types 31 
BL, MILD, 
CIN 1, 
MILD, CIN 1  
109 CIN 1 04-04-2014 n/a n/a n/a Negative 47 NEG, MILD  
110 CIN 1 07-04-2014 n/a n/a n/a Negative 66 CIN 1, BL, NEG, MILD 
111 CIN 1 07-04-2014 26-03-2014 12 Proliferative Negative 34 NEG, MILD 
112 CIN 1 09-04-2014 20-03-2014 20 Secretory Negative 32 NEG, MILD 
113 CIN 1 23-05-2014 15-05-2014 8 Proliferative Negative 46 NEG, MILD 
114 CIN 1 10-04-2014 n/a n/a n/a Negative 36 BL, NEG, MILD  
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115 CIN 1 29-05-2015 n/a n/a n/a Negative 46 
CIN 1, CIN 1 
, MILD, 
MILD, NEG, 
MOD , CON 
1, MOD, BL, 
MILD  
116 CIN 1 14-04-2014 06-04-2014 8 Proliferative Negative 45 NEG, BL, BL, MILD 
117 CIN 1 14-04-2014 n/a n/a n/a Negative 26 MILD 
118 CIN 1 17-04-2014 n/a n/a n/a Negative 24 MILD, CIN 1, MILD 
119 CIN 1 23-04-2014 n/a n/a n/a Negative 57 
NEG, BL, 
MILD, CIN 
1, BL, MILD 
120 CIN 1 29-04-2014 01-04-2014 28 Secretory Negative 25 NEG, MILD 
121 CIN 1 06-05-2014 n/a n/a n/a Negative 46 NEG, BL, MILD 
122 CIN 1 09-05-2014 12-04-2014 27 Secretory Negative 28 
NEG, MILD, 
CIN 1, 
MILD, CIN 
1, BL, CIN 3, 
MILD 
123 CIN 1 12-05-2014 n/a n/a n/a Negative 45 NEG, MILD 
124 CIN 1 15-05-2014 26-04-2014 19 Secretory Negative 32 NEG, MOD, BL, MILD 
125 CIN 1 16-05-2014 n/a n/a n/a Negative 49 BL, NEG, MILD 
126 CIN 1 16-05-2014 n/a n/a n/a Negative 27 BL, NEG, MILD 
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127 CIN 1 20-05-2014 01-05-2014 19 Secretory Negative 49 NEG, MILD 
128 CIN 1 n/a n/a n/a n/a Negative 47 NEG, MILD 
129 CIN 1 07-01-2014 n/a n/a n/a 12 other hr HPV types 24 
MILD, NEG, 
MILD 
130 CIN 1 08-01-2014 n/a n/a n/a 12 other hr HPV types 44 
MILD, NEG, 
MILD 
131 CIN 1 08-01-2014 24-12-2013 15 Secretory 12 other hr HPV types 43 
BL, NEG, 
BL, MILD 
132 CIN 1 21-01-2014 n/a n/a n/a 12 other hr HPV types 25 MILD 
133 CIN 1 22-01-2014 n/a n/a n/a HPV18 26 NEG, MILD 
134 CIN 1 22-01-2014 n/a n/a n/a 12 other hr HPV types 29 MILD  
135 CIN 1 02-02-2014 14-01-2014 19 Secretory 12 other hr HPV types 26 BL, MILD 
136 CIN 1 05-02-2014 17-01-2014 19 Secretory HPV 16 24 BL, NEG, MILD 
137 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 31 
NEG, MOD, 
BL, NEG,  
MILD,  BL, 
MILD  
138 CIN 1 07-03-2014 01-03-2014 6 Proliferative 12 other hr HPV types 42 NEG, MILD  
139 CIN 1 19-03-2014 11-03-2014 8 Proliferative 12 other hr HPV types 37 MILD 
140 CIN 1 27-03-2014 06-03-2014 21 Secretory 12 other hr HPV types 31 
NEG, BL, 
MILD 
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141 CIN 1 10-01-2014 02-01-2014 8 Proliferative 12 other hr HPV types 26 MILD 
142 CIN 2 28-07-2011 n/a n/a n/a HPV16 23 No previous history 
143 CIN 2 10-08-2011 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 + 
HPV18 
27 
NEG 
144 CIN 2 21-09-2011 n/a n/a n/a 12 other hr HPV types 31 
NEG 
145 CIN 2 07-09-2011 n/a n/a n/a POS W9 24 No previous history 
146 CIN 2 06-07-2011 29-06-2011 7 Proliferative 12 other hr HPV types 25 
No previous 
history 
147 CIN 2 24-08-2011 n/a n/a n/a POS W9 29 NEG 
148 CIN 2 07-07-2011 10-06-2011 27 Secretory 12 other hr HPV types 40 
NEG 
149 CIN 2 09-08-2011 21-07-2011 19 Secretory 12 other hr HPV types 24 
No previous 
history 
150 CIN 2 30-08-2011 n/a n/a n/a 12 other hr HPV types 24 
NEG 
151 CIN 2 26-08-2011 n/a n/a n/a 12 other hr HPV types 47 
NEG 
152 CIN 2 10-10-2011 n/a n/a n/a HPV16 25 No previous history 
153 CIN 2 n/a n/a n/a n/a HPV16 32 LSIL  
309 
 
154 CIN 2 17-10-2011 n/a n/a n/a 12 other hr HPV types 38 LSIL  
155 CIN 2 11-10-2011 n/a n/a n/a HPV16 29 NEG 
156 CIN 2 17-08-2011 08-08-2011 9 Proliferative 12 other hr HPV types 28 HSIL 
157 CIN 2 03-08-2011 20-07-2011 14 Secretory 
12 other hr 
HPV types + 
HPV16 
22 HSIL 
158 CIN 2 02-08-2011 18-07-2011 15 Secretory Negative 35 LSIL 
159 CIN 2 19-07-2011 n/a n/a n/a HPV16 25 LSIL 
160 CIN 2 02-11-2011 21-10-2011 12 Proliferative 
12 other hr 
HPV types + 
HPV16 
27 LSIL  
161 CIN 2 07-12-2011 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 
27 No previous history 
162 CIN 2 06-12-2011 n/a n/a n/a 12 other hr HPV types 27 HSIL 
163 CIN 2 13-12-2011 23-11-2011 20 Secretory HPV16 24 LSIL  
165 CIN 3 15-07-2011 n/a n/a n/a 12 other hr HPV types 25 
No previous 
history 
166 CIN 3 19-07-2011 n/a n/a n/a HPV16 31 No previous history 
167 CIN 3 26-07-2011 06-07-2011 20 Secretory 12 other hr HPV types 41 
No previous 
history 
168 CIN 3 27-07-2011 22-07-2011 5 Proliferative 12 other hr HPV types 20 HSIL 
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169 CIN 3 26-07-2011 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 
21 LSIL 
170 CIN 3 09-08-2011 29-07-2011 11 Proliferative HPV16 34 NEG 
171 CIN 3 10-08-2011 n/a n/a n/a HPV16 31 No previous history 
172 CIN 3 19-08-2011 15-08-2011 4 Proliferative 
12 other hr 
HPV types + 
HPV16 
28 No previous history 
173 CIN 3 22-08-2011 n/a n/a n/a 12 other hr HPV types 50 HSIL 
174 CIN 3 23-08-2011 01-08-2011 20 Secretory HPV16 29 No previous history 
175 CIN 3 25-08-2011 n/a n/a n/a HPV 18 36 No previous history 
176 CIN 3 24-08-2011 04-08-2011 20 Secretory 12 other hr HPV types 30 NEG 
177 CIN 3 26-08-2011 18-08-2011 8 Proliferative HPV16 28 No previous history 
178 CIN 3 05-10-2011 30-09-2011 5 Proliferative HPV16 26 LSIL 
179 CIN 3 n/a n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 
29 No previous history 
180 CIN 3 12-10-2011 n/a n/a n/a 12 other hr HPV types 31 NEG 
181 CIN 3 05-09-2011 n/a n/a n/a FAILED 25 LSIL 
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182 CIN 3 05-09-2011 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 
25 HSIL 
183 CIN 3 15-09-2011 01-09-2011 14 Secretory HPV16 21 No previous history 
184 CIN 3 n/a n/a n/a n/a 12 other hr HPV types 26 
No previous 
history 
185 CIN 3 28-09-2011 n/a n/a n/a 
12 other hr 
HPV types + 
HPV16 
54 LSIL 
186 CIN 3 03-10-2011 n/a n/a n/a 12 other hr HPV types 25 
No previous 
history 
187 CIN 3 30-09-2011 n/a n/a n/a 12 other hr HPV types 44 LSIL 
188 CIN 3 04-10-2011 17-09-2011 17 Secretory HPV 18 31 No previous history 
189 CIN 3 11-10-2011 n/a n/a n/a HPV16 32 LSIL 
190 CIN 3 11-10-2011 n/a n/a n/a HPV16 25 NEG 
191 CIN 3 11-10-2011 26-09-2011 15 Secretory HPV16 39 LSIL 
192 CIN 3 21-10-2011 13-10-2011 8 Proliferative 
12 other hr 
HPV types + 
HPV16 
35 No previous history 
193 CIN 3 25-10-2011 05-10-2011 20 Secretory 12 other hr HPV types 38 
No previous 
history 
194 CIN 3 11-11-2011 20-10-2011 22 Secretory 
12 other hr 
HPV types + 
HPV16 
20 
NEG 
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195 CIN 3 11-11-2011 04-11-2011 7 Proliferative 
12 other hr 
HPV types + 
HPV16 
32 
NEG 
196 CIN 3 15-11-2011 n/a n/a n/a HPV16 26 HSIL 
197 CIN 3 22-11-2011 n/a n/a n/a 12 other hr HPV types 39 
No previous 
history 
198 CIN 3 09-12-2011 n/a n/a n/a 12 other hr HPV types 27 
No previous 
history 
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Appendix 4 Test set sample database with relevant patient information  
Cytology sample test set database and respective clinical information. All samples received from Altnagelvin Hospital, Northern Ireland are listed with those considered unsuitable for 
Raman spectroscopy highlighted. 
HPV results are available for all samples with exception of negative samples; hrHPV stands for high-risk HPV types.  Regarding to clinical history, samples are classified as no 
previous history, negative (NEG), borderline (BL), LSIL, HSIL or CIN 1, 2 or 3 history. Menstrual cycle day was obtained by subtracting the last menstruation period date from the 
smear date. Samples from day 4 to 13 were classified as being in the proliferative phase of the menstrual cycle whereas samples in day 14 to 28 were considered to be in the secretory 
phase of the cycle. 
 
Test 
Sample 
ID  
Cytology 
diagnosis 
Smear 
date  LMP date 
Menstruation 
cycle day 
Menstruation 
cycle phase HPV result Age 
Previous 
disease 
history 
1 CIN 1 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV16 
27 HSIL 
2 CIN 1 n/a n/a n/a n/a HPV16 29 NEG  
3 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 29 HSIL 
4 CIN 1 n/a n/a n/a n/a Negative 36 NEG 
5 CIN 1 21/07/2014 28/06/2014 23 Secretory Negative 41 NEG 
6 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 21 HSIL  
7 CIN 1 17/07/2014 07/07/2014 10 Proliferative 
12 other hr 
HPV types 
+ HPV18 
27 LSIL 
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8 CIN 1 21/07/2014 13/07/2014 8 Proliferative 12 other hr HPV types 28 HSIL 
9 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 39 LSIL 
10 CIN 1 n/a n/a n/a n/a n/a 41 No Previous History 
11 Negative n/a n/a n/a n/a n/a 53 LSIL 
12 Negative 23/07/2015 25/06/2015 28 Secretory n/a 30 HSIL 
13 Negative 22/07/2015 12/07/2015 10 Proliferative n/a 29 HSIL 
14 Negative n/a n/a n/a n/a n/a 53 HSIL 
15 Negative n/a n/a n/a n/a n/a 27 HSIL 
16 Negative 20/07/2015 06/07/2015 14 Proliferative n/a 33 LSIL 
17 Negative 16/07/2015 13/07/2015 3 Proliferative n/a 32 HSIL 
18 Negative 17/07/2015 18/06/2015 29 Secretory n/a 31 HSIL 
19 Negative n/a n/a n/a n/a n/a 30 HSIL 
20 Negative n/a n/a n/a n/a n/a 35 HSIL 
21 Negative n/a n/a n/a n/a n/a 28 LSIL 
22 Negative n/a n/a n/a n/a n/a 46 HSIL 
23 Negative 20/07/2015 13/07/2015 7 Proliferative n/a 29 HSIL 
24 Negative 23/07/2015 11/07/2015 12 Proliferative n/a 35 HSIL 
25 Negative n/a n/a n/a n/a n/a 25 LSIL 
26 Negative 24/07/2015 01/07/2015 23 Secretory n/a 37 LSIL 
27 Negative 27/07/2015 29/06/2015 28 Secretory n/a 29 HSIL 
28 Negative n/a n/a n/a n/a n/a 49 HSIL 
29 Negative 17/07/2015 10/07/2015 7 Proliferative n/a 25 HSIL 
30 CIN 3 09/09/2014 18/08/2014 22 Secretory HPV16 40 LSIL 
315 
 
31 CIN 2 29/03/2013 11/03/2013 18 Secretory 12 other hr HPV types 28 NEG 
32 CIN 3 26/03/2013 02/03/2013 24 Secretory W2 32 NEG 
33 CIN 3 31/03/2013 24/03/2013 7 Proliferative HPV16 31 LSIL 
34 CIN 3 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV16 
27 NEG 
35 CIN 3 n/a n/a n/a n/a HPV16 25 No Previous History 
36 CIN 2 n/a n/a n/a n/a 12 other hr HPV types 25 HSIL 
37 CIN 2 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV18 
25 LSIL 
38 CIN 2 19/12/2014 07/12/2014 12 Proliferative 
12 other hr 
HPV types 
+ HPV16 
27 No Previous History 
39 Negative 30/09/2015 22/09/2015 8 Proliferative n/a 23 HSIL 
40 Negative n/a n/a n/a n/a n/a 43 HSIL 
41 Negative 30/09/2015 16/09/2015 14 Proliferative n/a 29 HSIL 
42 Negative n/a n/a n/a n/a n/a 42 LSIL 
43 Negative 05/10/2015 18/09/2015 17 Secretory n/a 49 LSIL 
44 Negative n/a n/a n/a n/a n/a 37 HSIL 
45 Negative 02/10/2015 23/09/2015 9 Proliferative n/a 26 LSIL 
46 Negative 05/10/2015 15/09/2015 20 Secretory n/a 41 HSIL 
47 Negative 02/10/2015 20/09/2015 12 Proliferative n/a 35 HSIL 
48 Negative n/a n/a n/a n/a n/a 27 HSIL 
49 Negative n/a n/a n/a n/a n/a 23 HSIL 
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50 Negative n/a n/a n/a n/a n/a 35 HSIL 
51 Negative 02/10/2015 01/10/2015 1 Proliferative n/a 27 HSIL 
52 Negative n/a n/a n/a n/a n/a 34 LSIL 
53 Negative n/a n/a n/a n/a n/a 35 LSIL 
54 Negative 25/09/2015 27/08/2015 29 Secretory n/a 27 HSIL 
55 Negative n/a n/a n/a n/a n/a 31 HSIL 
56 Negative n/a n/a n/a n/a n/a 52 HSIL 
57 Negative 30/09/2015 16/09/2015 14 Proliferative n/a 32 LSIL 
58 Negative 28/09/2015 02/09/2015 26 Secretory n/a 26 HSIL  
59 CIN 1 n/a n/a n/a n/a Negative 30 NEG 
60 CIN 1 23/09/2015 28/08/2015 26 Secretory Negative 27 NEG 
61 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 37 
LSIL 
62 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 51 
LSIL 
63 CIN 1 n/a n/a n/a n/a HPV16 40 LSIL 
64 CIN 1 n/a n/a n/a n/a 12 other hr HPV types 33 
LSIL 
65 CIN 1 22/10/2015 01/10/2015 21 Secretory 12 other hr HPV types 49 HSIL 
66 CIN 1 n/a n/a n/a n/a HPV16 54 NEG 
67 CIN 1 25/10/2015 03/10/2015 22 n/a 12 other hr HPV types 42 HSIL 
68 CIN 1 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV16 
45 NEG 
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69 CIN 2 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV16 
28 LSIL 
70 CIN 3 08/07/2015 27/06/2015 11 Proliferative HPV16 27 HSIL 
71 CIN 2 n/a n/a n/a n/a 12 other hr HPV types 35 NEG 
72 CIN 3 10/07/2015 17/06/2015 23 Secretory HPV16 26 No Previous History 
73 CIN 2 04/06/2015 15/05/2015 20 Secretory 12 other hr HPV types 21 LSIL 
74 CIN 2 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV18 
34 NEG 
75 CIN 3 03/07/2015 19/06/2015 14 Proliferative HPV16 47 No Previous History 
76 CIN 2 n/a n/a n/a n/a HPV16 28 LSIL 
77 CIN 3 26/06/2015 09/06/2015 17 Secretory HPV16 39 NEG 
78 CIN 3 n/a n/a n/a n/a 
12 other hr 
HPV types 
+ HPV16 
25 No Previous History 
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Appendix 5 SOP for XploRATM Raman spectrometer calibration for 
cervical cytology by Fiona Lyng and Franck Bonnier, 2012  
 
The XploRA™ Confocal Raman Microscope is a spectroscopy instrument which 
collects scattered light and generates a spectrum containing a biochemical 
fingerprint of cervical cells. 
 
This SOP is an instruction guide to; 
1.1: Start up  
 
1.2: Calibration procedures  
1.2.1 Manual calibration of the grating 
1.2.2 Laser Check 
1.2.3 Dark Current measurement 
1.2.4 NIST 2242  Standard 
1.2.5 Recording of the optics signal 
 
 
Note: Please fill in the logging book when relevant. The calibrations have to be 
done once a day by the first person using the Raman spectrometer during the 
day. 
 
1.3: recording of a reference spectrum 
1.4: Obtaining and saving spectra from cervical cells 
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PROCEDURE: 
1.1 : Start up 
1.1.1 Switch on laser by turning key in power box to the right, 
blue light comes on 
1.1.2 Leave for 20 mins 
1.1.3 Enter Password 
1.1.4 Double click Labspec 5 
1.1.5 Wait for initialization to complete and check detector is at -
70deg on bottom task bar 
1.1.6 Click video on top task bar 
 
1.2: Calibration procedures 
1.2.1  MANUAL CALIBRATION 
• Place the silicon slide on the XploRA™ stage, and close 
instrument doors. 
• Click on video camera icon on top task bar. Instrument will instruct 
user to: 
  
 
 
 
• Manually turn illuminator wheel to video position 2 
• Use the joystick to move the silicon into the field of view 
Please set illuminator to video position 2 and 
focus on the sample 
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• Focus on white section of the Silicon with the 10x objective, then 
moving on and focus at 50x objective and finally focus on silicon 
using the 100x objective. 
• Center the grating on the silica peak. For this, enter 520 in the text 
box associated to the grating. This text box can be found at the 
bottom of the screen where is indicating spectrometer. The first 
line correspond to the grating used. For this study the 1200T 
should be in place. Below is the grating position, where 520 
should be written. Press enter key to validate the value and move 
the grating to this position.    
• For consistency make sure the acquisition time is set to 1s with 
only 1 accumulation. The laser power should be at 50%. To start 
the recording click on the Spectrum RTD icon (top of the screen). 
The system will record a spectrum every second and displays it on 
the screen. The recording won’t stop until the operator click on the 
STOP icon (top right of the screen) 
 
 RTD Exposure Time (s): 1 
 Exposure Time (s): 20  
 Accumulation: 2  
 
• A peak corresponding to the silica should be easily identifiable 
around 520 cm-1. Using the joystick adjust the Z position to have 
the maximum intensity = the max counts per second. Indicate the 
max value found in the logging book. 
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• Find the peak position, either manually or using the peak search 
function in the software by click of the peak search icon on the top 
right of the screen. The silica peak should be at 520.7 cm-1 but 
due to the spectral resolution using the 1200T grating a value 
between 520.5 and 521 cm-1 will be considered acceptable. By 
clicking on “approx” followed by “fit” a more exact estimation of the 
peak position can be achieved. 
• In order to adjust the peak position, open the Setup window 
(command list of the top right of the screen) then the instrument 
calibration window. To calibrate the grating positions please 
modify ONLY the zero position value. Increase the value to shift 
the spectrum to left and decrease it to shift the spectrum toward 
the right. Click on apply to save the new grating position, close the 
instrument calibration window and the window displaying the 
spectrum. Restart the recording using the spectrum RTD icon. 
Check the peak position, if it is not in the range 520.5 – 521 cm-1 
restart this step. 
• Re-enter 520 cm-1 in the text box corresponding to the grating 
before starting  
 
           1.2.2. Laser intensity – laser check 
• When the calibration is done, check the laser intensity at the 
objective using the laser check. Place the laser check under the 
100x objective and record the intensity for at least 3-5 seconds. 
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Read the value and restart the recording 3 times. Write done the 
average value found in the logging book. 
 
         1.2.3. Dark current 
• The black current is obtained by turn off the laser and recording a 
spectrum in the spectral range 400 – 1800 cm-1. 
 
 RTD Exposure Time (s): 1 
 Exposure Time (s): 20 
 Accumulation: 2  
 
• Repeat three times using relevant parameters  
• Create a sub-folder with the date inside the folder 2012 and save 
the files as follow: 
o Dark current 1 
o Dark current 2 
o Dark current 3 
 
        1.2.4. NIST 2242 STANDARD (1/month) 
• Place NIST 2242 reference standard on the XploRA™ stage, and 
close instrument doors. 
•  Focus a smooth dark section of the reference standard with the 10x 
objective, then moving on and focus at 50x objective and finally focus 
on standard using the 100x objective. 
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• At the bottom of the screen, change the parameter settings as 
follows; 
 
 RTD Exposure Time (s): 1 
 Exposure Time (s): 20    
 Accumulation: 2     
 
• Click on “laser on” icon followed by “pink pig” acquisition icon. 
• Repeat three times and save the spectra as 
o Y STD 1 
o Y STD 2 
o Y STD 3 
 
        1.2.5. Optics signal 
• The recording of the signal corresponding to the optics is really 
important for the data correction before preprocessing and 
analysis. This is included in the calibration but could be 
considered as part of the data recording. This step as to be 
completed for every single sample recorded. This will help to 
adjust the correction of the data with the appropriate signal. 
 
• Position the glass slide with the sample to be analyzed on the 
stage. For the data correction a spectrum from the background is 
required. It corresponds to the signal of the substrate, is this case 
the glass slide, and the internal signal of the optics (mirrors, 
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objectives, filters). Before recording spectra from the cells move 
out of the area containing the cell deposition and record a 
spectrum from the blank glass. The steps are the same as used 
previously for the petridish, first focus using the 10x then the 50x 
and finally the 100x. The spectrum has to be recorded with the 
same parameters as the cells, thus use 3 x 10s in the spectral 
range 400-1800 cm-1 with a laser power at 50%. Repeat the 
recording 3 times and save the spectra in a folder named 
accordingly to the sample to be recorded.  
• Reminder: the signal corresponding to the optics has to be 
recorded for each sample.   
• Create de folder named with the sample number and save the 
spectra as follow: spectrum_glass_sample_number 
 
1.3: Reference spectrum acquisition 
• Place the lid of a petri dish on the stage. As for the silica, first focus using 
the 10x objective and then switch to the 50x and finally the 100x. This 
step consists in recording a reference spectrum in the spectral range of 
interest to make sure the calibrations are made identically day after day. 
Click on the spectral range icon (top right of the screen) and make sure it 
is set up for the spectral range 400-1800 cm-1 with relevant parameter 
acquisitions.  
o RTD Exposure Time (s): 1 
o Exposure Time (s): 20 
o Accumulation: 2  
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• Click on “laser on” icon followed by “pink pig” acquisition icon. 
 
• Save the spectrum with the date of day. (this is considered as the 
reference spectrum day 0) 
 
• Compare the spectrum recoding corresponding to the plastic with the 
one from the previous day (day -1). The peaks should all overlap 
between the 2 spectra. If not, use the instrument calibration step to 
readjust the peaks positions. This step is crucial to have a good 
reproducibility in the data recorded over time but also between operators. 
When the spectra collected from the plastic (at day 0 and day -1) are 
found with identical peaks positions the calibration is finished and the 
system is ready for recording of data from cells. 
 
• Save the spectrum recorded as follow: reference_spectrum_date 
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